<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3‐5D - Hara, T - 2021 | Cochrane Library</title> <meta content="Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3‐5D - Hara, T - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013424.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3‐5D - Hara, T - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013424.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013424.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3‐5D" name="citation_title"/> <meta content="Takashi Hara" name="citation_author"/> <meta content="Kyoto University Graduate School of Medicine/School of Public Health" name="citation_author_institution"/> <meta content="hara.takashi.74x@kyoto-u.jp" name="citation_author_email"/> <meta content="Yasukazu Hijikata" name="citation_author"/> <meta content="Kyoto University Graduate School of Medicine/School of Public Health" name="citation_author_institution"/> <meta content="Yukiko Matsubara" name="citation_author"/> <meta content="Hiroshima University Hospital" name="citation_author_institution"/> <meta content="Norio Watanabe" name="citation_author"/> <meta content="Soseikai General Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD013424.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/07/07" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013424.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013424.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013424.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antibodies, Monoclonal [adverse effects, therapeutic use]; Bias; Bone Density [drug effects]; Bone Density Conservation Agents [adverse effects, *therapeutic use]; Denosumab [adverse effects, therapeutic use]; Femur Neck [drug effects]; Fractures, Spontaneous [epidemiology, prevention &amp; control]; Hip; Indoles [adverse effects, therapeutic use]; Lumbar Vertebrae [drug effects]; Osteoporosis, Postmenopausal [drug therapy, mortality, *therapy]; Parathyroid Hormone-Related Protein [adverse effects, therapeutic use]; Raloxifene Hydrochloride [adverse effects, therapeutic use]; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic [*complications, therapy]; Spinal Fractures [diagnostic imaging, prevention &amp; control]; Teriparatide [adverse effects, therapeutic use]; Thiophenes [adverse effects, therapeutic use]; *Watchful Waiting" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013424.pub2&amp;doi=10.1002/14651858.CD013424.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013424.pub2&amp;doi=10.1002/14651858.CD013424.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013424.pub2&amp;doi=10.1002/14651858.CD013424.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013424.pub2&amp;doi=10.1002/14651858.CD013424.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013424.pub2&amp;doi=10.1002/14651858.CD013424.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013424.pub2&amp;doi=10.1002/14651858.CD013424.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013424.pub2&amp;doi=10.1002/14651858.CD013424.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013424.pub2&amp;doi=10.1002/14651858.CD013424.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013424.pub2&amp;doi=10.1002/14651858.CD013424.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013424.pub2&amp;doi=10.1002/14651858.CD013424.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013424.pub2&amp;doi=10.1002/14651858.CD013424.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013424.pub2&amp;doi=10.1002/14651858.CD013424.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013424.pub2&amp;doi=10.1002/14651858.CD013424.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013424.pub2&amp;doi=10.1002/14651858.CD013424.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013424.pub2&amp;doi=10.1002/14651858.CD013424.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013424.pub2&amp;doi=10.1002/14651858.CD013424.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013424.pub2&amp;doi=10.1002/14651858.CD013424.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013424.pub2&amp;doi=10.1002/14651858.CD013424.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013424.pub2&amp;doi=10.1002/14651858.CD013424.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013424.pub2&amp;doi=10.1002/14651858.CD013424.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013424.pub2&amp;doi=10.1002/14651858.CD013424.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013424.pub2&amp;doi=10.1002/14651858.CD013424.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013424.pub2&amp;doi=10.1002/14651858.CD013424.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="uYcNEb5O";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013424\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013424\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013424\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013424\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ms","hr","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013424.pub2",title:"Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3\\u20105D",firstPublishedDate:"Jul 7, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uYcNEb5O&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013424.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013424.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013424.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013424.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013424.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013424.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013424.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013424.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013424.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013424.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3364 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013424.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013424.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013424.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013424.pub2/full#CD013424-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013424.pub2/full#CD013424-sec-0110"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013424.pub2/full#CD013424-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013424.pub2/full#CD013424-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013424.pub2/full#CD013424-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013424.pub2/full#CD013424-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013424.pub2/full#CD013424-sec-0046"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013424.pub2/full#CD013424-sec-0104"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013424.pub2/appendices#CD013424-sec-0115"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/table_n/CD013424StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/table_n/CD013424StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013424.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013424.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013424.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013424.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013424.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013424.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3‐5D </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013424.pub2/information#CD013424-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Takashi Hara</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013424.pub2/information#CD013424-cr-0005">Yasukazu Hijikata</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013424.pub2/information#CD013424-cr-0006">Yukiko Matsubara</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013424.pub2/information#CD013424-cr-0007">Norio Watanabe</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/information/en#CD013424-sec-0120">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 07 July 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013424.pub2">https://doi.org/10.1002/14651858.CD013424.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013424-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013424-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013424-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013424-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013424-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013424-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013424-abs-0001" lang="en"> <section id="CD013424-sec-0001"> <h3 class="title" id="CD013424-sec-0001">Background</h3> <p>Chronic kidney disease (CKD) is an independent risk factor for osteoporosis and is more prevalent among people with CKD than among people who do not have CKD. Although several drugs have been used to effectively treat osteoporosis in the general population, it is unclear whether they are also effective and safe for people with CKD, who have altered systemic mineral and bone metabolism. </p> </section> <section id="CD013424-sec-0002"> <h3 class="title" id="CD013424-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of pharmacological interventions for osteoporosis in patients with CKD stages 3‐5, and those undergoing dialysis (5D). </p> </section> <section id="CD013424-sec-0003"> <h3 class="title" id="CD013424-sec-0003">Search methods</h3> <p>We searched the Cochrane Kidney and Transplant Register of Studies up to 25 January 2021 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov. </p> </section> <section id="CD013424-sec-0004"> <h3 class="title" id="CD013424-sec-0004">Selection criteria</h3> <p>Randomised controlled trials comparing any anti‐osteoporotic drugs with a placebo, no treatment or usual care in patients with osteoporosis and CKD stages 3 to 5D were included. </p> </section> <section id="CD013424-sec-0005"> <h3 class="title" id="CD013424-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected studies, assessed their quality using the risk of bias tool, and extracted data. The main outcomes were the incidence of fracture at any sites; mean change in the bone mineral density (BMD; measured using dual‐energy radiographic absorptiometry (DXA)) of the femoral neck, total hip, lumbar spine, and distal radius; death from all causes; incidence of adverse events; and quality of life (QoL). Summary estimates of effect were obtained using a random‐effects model, and results were expressed as risk ratios (RR) and their 95% confidence intervals (CI) for dichotomous outcomes, and mean difference (MD) for continuous outcomes. Confidence in the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. </p> </section> <section id="CD013424-sec-0006"> <h3 class="title" id="CD013424-sec-0006">Main results</h3> <p>Seven studies involving 9164 randomised participants with osteoporosis and CKD stages 3 to 5D met the inclusion criteria; all participants were postmenopausal women. Five studies included patients with CKD stages 3‐4, and two studies included patients with CKD stages 5 or 5D. Five pharmacological interventions were identified (abaloparatide, alendronate, denosumab, raloxifene, and teriparatide). All studies were judged to be at an overall high risk of bias. </p> <p>Among patients with CKD stages 3‐4, anti‐osteoporotic drugs may reduce the risk of vertebral fracture (RR 0.52, 95% CI 0.39 to 0.69; low certainty evidence). Anti‐osteoporotic drugs probably makes little or no difference to the risk of clinical fracture (RR 0.91, 95% CI 0.79 to 1.05; moderate certainty evidence) and adverse events (RR 0.99, 95% CI 0.98 to 1.00; moderate certainty evidence). We were unable to incorporate studies into the meta‐analyses for BMD at the femoral neck, lumbar spine and total hip as they only reported the percentage change in the BMD in the intervention group. </p> <p>Among patients with severe CKD stages 5 or 5D, it is uncertain whether anti‐osteoporotic drug reduces the risk of clinical fracture (RR 0.33, 95% CI 0.01 to 7.87; very low certainty evidence). It is uncertain whether anti‐osteoporotic drug improves the BMD at the femoral neck because the certainty of this evidence is very low (MD 0.01, 95% CI 0.00 to 0.02). Anti‐osteoporotic drug may slightly improve the BMD at the lumbar spine (MD 0.03, 95% CI 0.03 to 0.04, low certainty evidence). No adverse events were reported in the included studies. It is uncertain whether anti‐osteoporotic drug reduces the risk of death (RR 1.00, 95% CI 0.22 to 4.56; very low certainty evidence). </p> </section> <section id="CD013424-sec-0007"> <h3 class="title" id="CD013424-sec-0007">Authors' conclusions</h3> <p>Among patients with CKD stages 3‐4, anti‐osteoporotic drugs may reduce the risk of vertebral fracture in low certainty evidence. Anti‐osteoporotic drugs make little or no difference to the risk of clinical fracture and adverse events in moderate certainty evidence. Among patients with CKD stages 5 and 5D, it is uncertain whether anti‐osteoporotic drug reduces the risk of clinical fracture and death because the certainty of this evidence is very low. Anti‐osteoporotic drug may slightly improve the BMD at the lumbar spine in low certainty evidence. It is uncertain whether anti‐osteoporotic drug improves the BMD at the femoral neck because the certainty of this evidence is very low. Larger studies including men, paediatric patients or individuals with unstable CKD‐mineral and bone disorder are required to assess the effect of each anti‐osteoporotic drug at each stage of CKD. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013424-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013424-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013424-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013424-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013424-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013424-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013424-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD013424-abs-0013">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD013424-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013424-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013424-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013424-abs-0002" lang="en"> <h3>Pharmacological treatments for osteoporosis in patients with chronic kidney disease</h3> <p><b>What is the issue?</b><br/>Patients with chronic kidney disease (CKD) have an increased risk of osteoporosis (weakened bone strength), which can often lead to bone fracture. Several drugs are available for the treatment of osteoporosis; however, it is unknown whether these drugs are equally effective and safe in patients with CKD because bone strength impairment in these patients occurs via a different mechanism. </p> <p><b>What did we do?</b><br/>Data were collected from studies including patients with osteoporosis and CKD stages 3‐5, and those undergoing dialysis (stage 5D) with data available on fracture, change in the bone mineral density (BMD; a bone strength index), and adverse events. We included seven studies with available evidence up to 25 January 2021, comparing anti‐osteoporotic drugs (abaloparatide, alendronate, denosumab, raloxifene, and teriparatide) with placebo (a dummy drug), in 9,164 postmenopausal women. We performed a meta‐analysis to assess the effects of these anti‐osteoporotic drugs. </p> <p><b>What did we find?</b><br/>In postmenopausal women with CKD stages 3‐4, anti‐osteoporotic drugs may reduce vertebral fracture in low certainty evidence. Anti‐osteoporotic drugs probably make little or no difference to clinical fracture and adverse events in moderate certainty evidence. In postmenopausal with CKD stages 5 or 5D, it is uncertain whether anti‐osteoporotic drug reduces the risk of clinical fracture and death, and anti‐osteoporotic drug may slightly improve BMD at the lumbar spine in low certainty evidence. It is uncertain whether anti‐osteoporotic drug improve BMD at the femoral neck. </p> <p><b>Conclusions</b><br/>Among postmenopausal women with CKD stages 3‐4, anti‐osteoporotic drugs may reduce the risk of vertebral fracture. Among patients with CKD stages 5 and 5D, anti‐osteoporotic drug may slightly improve bone strength. However, these conclusions are based on limited data and therefore uncertain. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013424-sec-0110" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013424-sec-0110"></div> <h3 class="title" id="CD013424-sec-0111">Implications for practice</h3> <section id="CD013424-sec-0111"> <p>Among patients with CKD stages 3‐4, anti‐osteoporotic drugs may reduce the risk of vertebral fracture in low certainty evidence. Anti‐osteoporotic drugs probably make little or no difference to the risk of clinical fracture and adverse events in moderate certainty evidence. </p> <p>In low certainty evidence, patients with CKD stages 5 and 5D, it is uncertain whether anti‐osteoporotic drug reduces the risk of clinical fracture and death because the certainty of this evidence is very low. Anti‐osteoporotic drug may slightly improve the BMD at the lumbar spine in low certainty evidence. It is uncertain whether anti‐osteoporotic drug improves the BMD at the femoral neck because the certainty of this evidence was very low. </p> </section> <h3 class="title" id="CD013424-sec-0112">Implications for research</h3> <section id="CD013424-sec-0112"> <p>Several concerns remain, and future studies should address the following points.</p> <p> <ol id="CD013424-list-0022"> <li> <p>This review could not assess the effectiveness or safety of anti‐osteoporotic drugs in patients with unstable CKD‐MBD; it is important to establish the recommendations for these patients. </p> </li> <li> <p>This review could not assess the effectiveness or safety of anti‐osteoporotic drugs in men or paediatric patients; it is also important to establish the recommendations for these patients. </p> </li> <li> <p>We could not sufficiently assess the effectiveness or safety of anti‐osteoporotic drugs in patients with each CKD stage. Therefore, these analyses should be repeated when more data become available. </p> </li> <li> <p>We could not sufficiently assess the effect of each anti‐osteoporotic drug. Therefore, these analyses should be repeated after the publication of more data. </p> </li> <li> <p>Future studies should compare the subtypes of anti‐osteoporotic drugs in order to provide clinicians with information on the comparative effectiveness of available therapies. </p> </li> </ol> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013424-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013424-sec-0008"></div> <div class="table" id="CD013424-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Any anti‐osteoporotic drugs versus placebo in postmenopausal women with osteoporosis and CKD stages 3‐4</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Any anti‐osteoporotic drugs versus placebo in</b> postmenopausal women<b>with osteoporosis and CKD stages 3‐4</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> postmenopausal women with osteoporosis and CKD stages 3‐4 </p> <p><b>Settings:</b> multinational; outpatients </p> <p><b>Intervention:</b> any anti‐osteoporotic drugs (abaloparatide, alendronate, denosumab, raloxifene, teriparatide) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Any anti‐osteoporotic drugs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vertebral fracture by radiography</b> </p> <p>Follow up: range 19 to 54 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> <p>(28 to 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.52</p> <p>(0.39 to 0.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9,054 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical fracture</b> </p> <p>Follow up: range 24 to 54 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 1000</p> <p>(43 to 57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.91</p> <p>(0.79 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5,827 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in BMD of the femoral neck</b> </p> <p>Follow up: range 19 to 54 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Included studies only reported the percentage change in the BMD in the intervention group. In the three studies the mean change in BMD of the femoral neck was reported to improve by approximately 0.5% to 5% in the intervention group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6,081 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in BMD of the lumbar spine</b> </p> <p>Follow up: range 19 to 54 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Included studies only reported the percentage change in the BMD in the intervention group. In the five studies the mean change in BMD of the lumbar spine was reported to improve by approximately 1% to 15% in the intervention group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9,054 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in BMD of the total hip</b> </p> <p>Follow up: range 19 to 54 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Included studies only reported the percentage change in the BMD in the intervention group. In the three studies the mean change in BMD of the total hip was reported to improve by approximately 5% to 6% in the intervention group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3,998 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in BMD of the distal radius</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow up: range 19 to 54 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>946 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>937 per 1000</p> <p>(927 to 946)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.99</p> <p>(0.98 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9,054 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b> </p> <p>Follow up: range 36 to 54 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Included studies only reported total death. Death ranged from 0.7% to 1.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4,973 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1, 3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CKD:</b> chronic kidney disease; <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; <b>BMD:</b> bone mineral density; <b>QoL</b>: quality of life </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/><b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to a serious risk of bias: all studies had a high overall risk of bias<br/><sup>2</sup> Downgraded one level due to inconsistency: there was substantial heterogeneity </p> <p><sup>3</sup>Downgraded one level due to a publication bias: there were high risk of reporting bias </p> <p><sup>4</sup>Downgraded one level due to indirectness: surrogate endpoint was evaluated </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013424-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Raloxifene versus placebo for postmenopausal women with osteoporosis and CKD stages 5 and 5D</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Raloxifene versus placebo for postmenopausal women with osteoporosis and CKD stages 5 and 5D</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> postmenopausal women with osteoporosis and CKD stages 5 and 5D </p> <p><b>Settings:</b> Iran, Venezuela; in‐ and outpatients </p> <p><b>Intervention:</b> any anti‐osteoporotic drugs (raloxifene) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Raloxifene</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vertebral fracture by radiography</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical fracture</b> </p> <p>Follow up: 8 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> <p>(0 to 260)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.33</p> <p>(0.01 to 7.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in BMD of the femoral neck</b><br/>Follow up: range 8 to 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean change in BMD of the femoral neck was 0.01 g/cm² higher with raloxifene than placebo (95% CI 0.00 to 0.02) </p> <p>(mean change in BMD of the femoral neck in placebo group was ‐0.009 to ‐0.002 g/cm²)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.01</p> <p>(0.00 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1, 3, 4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in BMD of the lumbar spine</b><br/>Follow up: range 8 to 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean change in BMD of the lumbar spine was 0.03 g/cm² higher with raloxifene than placebo (95% CI 0.03 to 0.04) </p> <p>(mean change BMD of the lumbar in placebo group was ‐0.019 to ‐0.003 g/cm²)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.03</p> <p>(0.03 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1, 4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in BMD of the total hip</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in BMD of the distal radius</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow up: range 8 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No adverse events were observed in the included studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b> </p> <p>Follow up: range 8 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> <p>(11 to 228)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00</p> <p>(0.22 ‐ 4.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CKD:</b> chronic kidney disease; <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; <b>MD:</b> Mean Difference; <b>BMD:</b> bone mineral density; <b>QoL:</b> quality of life </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level due to a serious risk of bias: all studies had a high overall risk of bias<br/><sup>2</sup>Downgraded two levels due to serious imprecision: there were very few/no events and the CIs encompass both considerable benefit and considerable harm<br/><sup>3</sup>Downgraded one level due to inconsistency: there was considerable heterogeneity<br/><sup>4</sup>Downgraded one level due to indirectness: surrogate endpoint was evaluated </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013424-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013424-sec-0009"></div> <section id="CD013424-sec-0010"> <h3 class="title" id="CD013424-sec-0010">Description of the condition</h3> <p>The World Health Organization (WHO) defines osteoporosis as ‘a disease characterised by low bone mass and microarchitectural deterioration of bone tissue, leading to enhanced bone fragility and a consequent increase in fracture risk’ (<a href="./references#CD013424-bbs2-0102" title="World Health Organization. Assessment of fracture risk and its implication to screening for postmenopausal osteoporosis: Technical report series 843. apps.who.int/iris/handle/10665/39142 (accessed 27 May 2021).">WHO 1994</a>). Thereafter, the National Institutes of Health (NIH) defines osteoporosis mechanistically as ‘a skeletal disorder characterised by compromised bone strength predisposing to a higher risk of fracture. Bone strength reflects the integration of two main features: bone quantity and bone quality’ (<a href="./references#CD013424-bbs2-0083" title="NIH Consensus Development Panel. NIH Consensus Development Panel on Osteoporosis Prevention. Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference. Southern Medical Journal2001;94(6):569–73. [MEDLINE: 11440324]">NIH 2001</a>). The clinical diagnosis of osteoporosis is broadly based on bone mineral density (BMD) measurements. BMD is converted into a T‐score, which indicates the number of standard deviations (SDs) above or below the mean BMD for young adults. Osteoporosis is diagnosed when the T‐scores are &lt; ‐2.5 SD (<a href="./references#CD013424-bbs2-0102" title="World Health Organization. Assessment of fracture risk and its implication to screening for postmenopausal osteoporosis: Technical report series 843. apps.who.int/iris/handle/10665/39142 (accessed 27 May 2021).">WHO 1994</a>). Osteoporosis dose not manifest clinically manifestations until a fracture develops. These osteoporotic fractures are a global healthcare burden. An estimated 9.0 million osteoporotic fractures were reported worldwide in 2000 (<a href="./references#CD013424-bbs2-0062" title="JohnellO , KanisJA . An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporosis International2006;17(12):1726-33. [MEDLINE: 16983459]">Johnell 2006</a>), with an estimated annual cost of 19 billion USD in the USA (<a href="./references#CD013424-bbs2-0044" title="BurgeR , Dawson-HughesB , SolomonDH , WongJB , KingA , TostesonA . Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. Journal of Bone &amp; Mineral Research2007;22(3):465-75. [MEDLINE: 17144789]">Burge 2007</a>) and 1.8 billion GBP in the UK (<a href="./references#CD013424-bbs2-0043" title="BurgeRT , WorleyD , JohansenA , BhattacharyyaS , BoseU . The cost of osteoporotic fractures in the UK: Projections for 2000-2020. Journal of Medical Economics2001;4:51–62. [EMBASE: 32537253]">Burge 2001</a>). The ability to perform activities of daily living deteriorates after a fracture, along with the quality of life (QoL). Furthermore, morbidity and death are markedly increased in patients following a major bone fracture (<a href="./references#CD013424-bbs2-0042" title="BrownerWS , PressmanAR , NevittMC , CummingsSR . Mortality following fractures in older women: the study of osteoporotic fractures. Archives of Internal Medicine1996;156(14):1521-5. [MEDLINE: 8687260]">Browner 1996</a>; <a href="./references#CD013424-bbs2-0067" title="KeeneGS , ParkerMJ , PryorGA . Mortality and morbidity after hip fractures. BMJ1993;307(6914):1248-50. [MEDLINE: 8166806]">Keene 1993</a>). Therefore, preventive interventions are therefore needed to reduce or prevent fractures in patients with osteoporosis. Current national osteoporosis guidelines recommend pharmacological interventions with anti‐osteoporotic drugs in addition to non‐pharmacological interventions that include modifying nutrition, ceasing smoking, performing weight‐bearing exercises, and moderating alcohol intake (<a href="./references#CD013424-bbs2-0051" title="EastellR , RosenCJ , BlackDM , CheungAM , MuradMH , ShobackD . Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* clinical practice guideline. Journal of Clinical Endocrinology &amp; Metabolism2019;104(5):1595-622. [MEDLINE: 30907953]">Eastell 2019</a>; <a href="./references#CD013424-bbs2-0064" title="KanisJA , CooperC , RizzoliR , ReginsterJY , Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women [Erratum in: Osteoporos Int. 2020 Jan;31(1):209; PMID: 31673731] [Erratum in: Osteoporos Int. 2020 Apr;31(4):801; PMID: 32072205]. Osteoporosis International2019;30(1):3-44. [MEDLINE: 30324412]">Kanis 2019</a>; <a href="./references#CD013424-bbs2-0080" title="Naranjo HernándezA , Díaz Del Campo FontechaP , Aguado AcínMP , Arboleya RodríguezL , Casado BurgosE , CastañedaS , et al. Recommendations by the Spanish Society of Rheumatology on Osteoporosis [Recomendaciones de la Sociedad Espanola de Reumatologia sobre osteoporosis]. Reumatología Clínica2019;15(4):188-210. [MEDLINE: 30470636]">Naranjo Hernandez 2018</a>; <a href="./references#CD013424-bbs2-0085" title="National Osteoporosis Guideline Group. NOGG 2017: Clinical guideline for the prevention and treatment of osteoporosis. www.sheffield.ac.uk/NOGG/NOGG%20Guideline%202017.pdf (accessed 27 May 2021).">NOGG 2017</a>; <a href="./references#CD013424-bbs2-0090" title="QaseemA , ForcieaMA , McLeanRM , DenbergTD , Clinical Guidelines Committee of the American College of Physicians. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians [Erratum in: Ann Intern Med. 2017 Sep 19;167(6):448; PMID: 28975328]. Annals of Internal Medicine2017;166(11):818-39. [MEDLINE: 28492856]">Qaseem 2017</a>). </p> <p>The number of patients with chronic kidney disease (CKD) is increasing. In 2015, CKD was ranked the 10th most common cause of death globally, with an age‐standardised annual death rate of 19.2 per 100,000 of the population (<a href="./references#CD013424-bbs2-0054" title="GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015 [Erratum in: Lancet. 2017 Jan 7;389(10064):e1; PMID: 28091379]. Lancet2016;388(10053):1459-544. [PMID: 27733281]">GBD 2016</a>). Thus, CKD is a major healthcare problem. Osteoporosis is an important comorbidity in patients with CKD. The National Health and Nutrition Examination Survey indicated that osteoporosis is two times more common in patients with moderate‐to‐severe CKD than in the general population (<a href="./references#CD013424-bbs2-0082" title="NickolasTL , McMahonDJ , ShaneE . Relationship between moderate to severe kidney disease and hip fracture in the United States. Journal of the American Society of Nephrology2006;17(11):3223-32. [MEDLINE: 17005938]">Nickolas 2006</a>). Furthermore, the prevalence of osteopenia in patients undergoing dialysis is up to 20% in skeletal structures clinically associated with fracture (<a href="./references#CD013424-bbs2-0099" title="SteinMS , PackhamDK , EbelingPR , WarkJD , BeckerGJ . Prevalence and risk factors for osteopenia in dialysis patients. American Journal of Kidney Diseases1996;28(4):515-22. [MEDLINE: 8840940]">Stein 1996</a>). Fractures have been reported to occur 2 to 100 times more frequently in patients with CKD than in age‐matched individuals without CKD (<a href="./references#CD013424-bbs2-0036" title="AlemAM , SherrardDJ , GillenDL , WeissNS , BeresfordSA , HeckbertSR , et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney International2000;58(1):396-9. [MEDLINE: 10886587]">Alem 2000</a>; <a href="./references#CD013424-bbs2-0082" title="NickolasTL , McMahonDJ , ShaneE . Relationship between moderate to severe kidney disease and hip fracture in the United States. Journal of the American Society of Nephrology2006;17(11):3223-32. [MEDLINE: 17005938]">Nickolas 2006</a>). Patients with CKD who have fractures also develop other serious problems. Major bone fractures are associated with high rates of hospitalisation and death (<a href="./references#CD013424-bbs2-0070" title="KimSM , LongJ , Montez-RathM , LeonardM , ChertowGM . Hip fracture in patients with non-dialysis-requiring chronic kidney disease. Journal of Bone &amp; Mineral Research2016;31(10):1803-9. [MEDLINE: 27145189]">Kim 2016</a>; <a href="./references#CD013424-bbs2-0100" title="TentoriF , McCulloughK , KilpatrickRD , BradburyBD , RobinsonBM , KerrPG , et al. High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney International2013;85(1):166-73. [MEDLINE: 23903367]">Tentori 2013</a>). Healthcare–associated costs after fractures exceeded $600 million in 2010 in the USA (<a href="./references#CD013424-bbs2-0070" title="KimSM , LongJ , Montez-RathM , LeonardM , ChertowGM . Hip fracture in patients with non-dialysis-requiring chronic kidney disease. Journal of Bone &amp; Mineral Research2016;31(10):1803-9. [MEDLINE: 27145189]">Kim 2016</a>). </p> <p>Conditions associated with CKD make the diagnosis and treatment of osteoporosis difficult (<a href="./references#CD013424-bbs2-0047" title="CunninghamJ , SpragueSM , Cannata-AndiaJ , CocoM , Cohen-SolalM , FitzpatrickL , et al. Osteoporosis in chronic kidney disease. American Journal of Kidney Diseases2004;43(3):566-71. [MEDLINE: 14981616]">Cunningham 2004</a>). Impairment of skeletal strength in patients with CKD occurs via a different mechanism. Kidney Disease: Improving Global Outcomes (KDIGO) defines CKD‐mineral and bone disorder (MBD) as a systemic condition of mineral and bone metabolism resulting from CKD (<a href="./references#CD013424-bbs2-0065" title="Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney International - Supplement2009;Aug(113):S1-130. [MEDLINE: 19644521]">KDIGO 2009</a>). The disorder is characterised by the following: 1) abnormalities in calcium, phosphorus, parathyroid hormone (PTH), or vitamin D metabolism; 2) bone turnover, mineralization, volume linear growth, or strength abnormalities; or 3) vascular or another soft‐tissue calcification (<a href="./references#CD013424-bbs2-0065" title="Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney International - Supplement2009;Aug(113):S1-130. [MEDLINE: 19644521]">KDIGO 2009</a>). The initial onset of CKD‐MBD occurs in early‐stage CKD (<a href="./references#CD013424-bbs2-0073" title="LevinA , BakrisGL , MolitchM , SmuldersM , TianJ , WilliamsLA , et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease [Erratum in: Kidney Int. 2009 Jun 1;75(11):1237; PMID: 30036915]. Kidney International2007;71(1):31-8. [MEDLINE: 17091124]">Levin 2007</a>). Bone disorder caused by CKD‐MBD is termed renal osteodystrophy (ROD); it is a form of osteoporosis and a complex heterogeneous disorder of bone quality and density. ROD is traditionally classified as follows: hyperparathyroid bone disease, mild hyperparathyroid bone disease, mixed osteodystrophy, low turnover/adynamic bone disease, and osteomalacia (<a href="./references#CD013424-bbs2-0074" title="LlachF , Bover, J. Brenner and Rector's The Kidney. 6th edition. Vol. 2. Philadelphia: WB Saunders Company, 2000. [ISBN: 978-0721679983]">Llach 2000</a>). Although bone biopsy is the gold standard diagnostic tool of ROD, access is limited, and it is not suitable for repeated evaluations. Alternatively, bone turnover markers such as intact PTH and alkaline phosphatase, are used clinically by nephrologists; however, their predictive values for bone turnover is limited (<a href="./references#CD013424-bbs2-0068" title="KhairallahP , NickolasTL . Updates in CKD-associated osteoporosis. Current Osteoporosis Reports2018;16(6):712-23. [MEDLINE: 30353319]">Khairallah 2018a</a>; <a href="./references#CD013424-bbs2-0098" title="SpragueSM , Bellorin-FontE , JorgettiV , CarvalhoAB , MallucheHH , FerreiraA , et al. Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. American Journal of Kidney Diseases2016;67(4):559-66. [MEDLINE: 26321176]">Sprague 2016</a>). The state of bone turnover should be evaluated when an anti‐osteoporotic drug is used, because drug use may lead to adynamic bone disease in patients with CKD (<a href="./references#CD013424-bbs2-0038" title="AmerlingR , HarbordNB , PullmanJ , FeinfeldDA . Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series. Blood Purification2010;29(3):293-9. [MEDLINE: 20090316]">Amerling 2010</a>). A single cross‐sectional study of 13 patients with CKD stages 2‐4 suggested that the use of bisphosphonates was associated with adynamic bone disease in these patients (<a href="./references#CD013424-bbs2-0038" title="AmerlingR , HarbordNB , PullmanJ , FeinfeldDA . Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series. Blood Purification2010;29(3):293-9. [MEDLINE: 20090316]">Amerling 2010</a>). Although that study did not demonstrate that bisphosphonates caused adynamic bone disease, no large‐scale clinical safety data are available for patients with moderate‐to‐severe CKD treated with bisphosphonates. In addition, the key drug used in patients with osteoporosis is contraindicated for those with severe CKD (<a href="./references#CD013424-bbs2-0084" title="NittaK , YajimaA , TsuchiyaK . Management of osteoporosis in chronic kidney disease. Internal Medicine2017;56(24):3271-6. [MEDLINE: 29021477]">Nitta 2017</a>). Based on this, the CKD‐MBD KDIGO guidelines were revised in 2017 to recommend the use of BMD measurements to assess fracture risk. In addition, they emphasised the importance of managing CKD‐MBD by controlling of vitamin D deficiency, hyperphosphataemia, and hyperparathyroidism before initiating anti‐osteoporotic drugs for CKD‐associated osteoporosis (<a href="./references#CD013424-bbs2-0066" title="Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) [Erratum in: Kidney Int Suppl (2011). 2017 Dec;7(3):e1; PMID: 30681074]. Kidney International Supplements2017;7(1):1-59. [MEDLINE: 30675420]">KDIGO 2017</a>). </p> </section> <section id="CD013424-sec-0011"> <h3 class="title" id="CD013424-sec-0011">Description of the intervention</h3> <p>A number of agents are effective for the treatment of osteoporosis in the general population, including bisphosphonates, denosumab, selective oestrogen receptor modulators (SERMs), and teriparatide (<a href="./references#CD013424-bbs2-0046" title="CrandallCJ , NewberrySJ , DiamantA , LimYW , GelladWF , BoothMJ , et al. Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Annals of Internal Medicine2014;161(10):711-23. [MEDLINE: 25199883]">Crandall 2014</a>). In addition, abaloparatide and romosozumab, which have been recently introduced, and strontium ranelate are used to treat osteoporosis (<a href="./references#CD013424-bbs2-0091" title="ReginsterJY , BianicF , CampbellR , MartinM , WilliamsSA , FitzpatrickLA . Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Osteoporosis International2019;30(7):1465-73. [MEDLINE: 30953114]">Reginster 2019</a>). </p> <section id="CD013424-sec-0012"> <h4 class="title">Bisphosphonates</h4> <p>Bisphosphonates are analogues of inorganic pyrophosphates that inhibit osteoclast function. They are typically administered orally in pill form, although intravenous (IV) bisphosphonates are also available. Oral regimes involve daily or weekly administration, whereas IV bisphosphonates are administered monthly or yearly. The first‐line treatment for osteoporosis is usually bisphosphonates when pharmacological intervention is recommended. However, the use of bisphosphonates may lead to bisphosphonate‐related osteonecrosis of the jaw (<a href="./references#CD013424-bbs2-0092" title="RuggieroSL , MehrotraB , RosenbergTJ , EngroffSL . Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. Journal of Oral &amp; Maxillofacial Surgery2004;62(5):527-34. [MEDLINE: 15122554]">Ruggiero 2004</a>) and atypical femoral fracture (<a href="./references#CD013424-bbs2-0050" title="DonnellyE , SalehA , UnnanuntanaA , LaneJM . Atypical femoral fractures: epidemiology, etiology, and patient management. Current Opinion in Supportive &amp; Palliative Care2012;6(3):348-54. [MEDLINE: 22643705]">Donnelly 2012</a>). In addition, oral bisphosphonates may cause erosive oesophagitis when patients fail to maintain an upright posture for approximately 30 minutes after taking the medicine with a glass of water (<a href="./references#CD013424-bbs2-0049" title="De GroenPC , LubbeDF , HirschLJ , DaifotisA , StephensonW , FreedholmD , et al. Esophagitis associated with the use of alendronate. New England Journal of Medicine1996;335(14):1016-21. [MEDLINE: 8793925]">De Groen 1996</a>). </p> </section> <section id="CD013424-sec-0013"> <h4 class="title">Denosumab</h4> <p>Denosumab is a fully humanised monoclonal antibody specific to the receptor activator of nuclear factor kappa B ligand (RANKL), which mainly regulates osteoclasts. The recommended dosage of denosumab is 60 mg administered by subcutaneous(SC) injection by every 6 months (<a href="./references#CD013424-bbs2-0041" title="BoneHG , BologneseMA , YuenCK , KendlerDL , WangH , LiuY , et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. Journal of Clinical Endocrinology &amp; Metabolism2008;93(6):2149-57. [MEDLINE: 18381571]">Bone 2008</a>). The discontinuation of denosumab may lead to a rebound in bone turnover and rapid BMD loss and increased risk of fracture (<a href="./references#CD013424-bbs2-0076" title="MillerPD , BologneseMA , LewieckiEM , McClungMR , DingB , AustinM , et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone2008;43(2):222-9. [MEDLINE: 18539106]">Miller 2008</a>). This is an important difference from bisphosphonates. Conversely, treatment adherence and patient preferences may be better with denosumab than with bisphosphonates (<a href="./references#CD013424-bbs2-0053" title="EliasafA , AmitaiA , Maram EdryM , Yosselson SuperstineS , Rotman PikielnyP . Compliance, persistence, and preferences regarding osteoporosis treatment during active therapy or drug holiday. Journal of Clinical Pharmacology2016;56(11):1416-22. [MEDLINE: 26999526]">Eliasaf 2016</a>; <a href="./references#CD013424-bbs2-0079" title="MorizioP , BurkhartJI , OzawaS . Denosumab: a unique perspective on adherence and cost-effectiveness compared with oral bisphosphonates in osteoporosis patients. Annals of Pharmacotherapy2018;52(10):1031-41. [MEDLINE: 29616561]">Morizio 2018</a>). Major adverse effects associated with denosumab include cellulitis, urinary tract infections, hypocalcaemia, osteonecrosis of the jaw, and atypical femoral fracture. Denosumab does not depend on kidney clearance for its metabolism and excretion. However, the low kidney function is associated with more frequent hypocalcaemia (<a href="./references#CD013424-bbs2-0040" title="BlockGA , BoneHG , FangL , LeeE , PadhiD . A single-dose study of denosumab in patients with various degrees of renal impairment. Journal of Bone &amp; Mineral Research2012;27(7):1471-9. [MEDLINE: 22461041]">Block 2012</a>; <a href="./references#CD013424-bbs2-0048" title="DaveV , ChiangCY , BoothJ , MountPF . Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5. American Journal of Nephrology2015;41(2):129-37. [MEDLINE: 25790847]">Dave 2015</a>). </p> </section> <section id="CD013424-sec-0014"> <h4 class="title">selective oestrogen receptor modulators (SERMs)</h4> <p>SERMs (bazedoxifene, raloxifene) are synthetic non‐steroidal compounds that interact with oestrogen receptors. Differing from oestrogen, these medicines act as either receptor agonists or antagonists in the target sites. They are associated with a lower cancer risk than oestrogen, and they have beneficial effects on the bone. SERMs have been shown to reduce the risk of only vertebral fractures (<a href="./references#CD013424-bbs2-0046" title="CrandallCJ , NewberrySJ , DiamantA , LimYW , GelladWF , BoothMJ , et al. Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Annals of Internal Medicine2014;161(10):711-23. [MEDLINE: 25199883]">Crandall 2014</a>). They are typically administered orally in pill form once a day. Serious adverse effects associated with SERMs include deep venous thrombosis (DVT), pulmonary embolism, and stroke (<a href="./references#CD013424-bbs2-0035" title="AdomaityteJ , FarooqM , QayyumR . Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis. Thrombosis &amp; Haemostasis2008;99(2):338-42. [MEDLINE: 18278183]">Adomaityte 2008</a>; <a href="./references#CD013424-bbs2-0039" title="Barrett-ConnorE , MoscaL , CollinsP , GeigerMJ , GradyD , KornitzerM , et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. New England Journal of Medicine2006;355(2):125-37. [PMID: 16837676]">Barrett‐Connor 2006</a>). </p> </section> <section id="CD013424-sec-0015"> <h4 class="title">Teriparatide</h4> <p>Teriparatide is a recombinant human PTH (1‐34). It is administered by SC injection, either daily or weekly. PTH generally stimulates osteoclast activity to release more ionic calcium into the blood, subsequently elevating the serum calcium levels. Teriparatide has anabolic effects on the skeleton, with the most pronounced effects on cancellous bone. The adverse effects include temporary elevation of the serum calcium levels, postural hypotension, dizziness, headache, and nausea (<a href="./references#CD013424-bbs2-0081" title="NeerRM , ArnaudCD , ZanchettaJR , PrinceR , GaichGA , ReginsterJY , et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal of Medicine2001;344(9):1434-41. [MEDLINE: 11346808]">Neer 2001</a>). </p> </section> <section id="CD013424-sec-0016"> <h4 class="title">Abaloparatide</h4> <p>Abaloparatide is an analogue of a PTH; it was approved by the United States Food and Drug Administration (US FDA) to treat osteoporosis in 2017. It has a relatively greater affinity for PTH/PTHrP receptor type 1 (or PTHR1) in the transient state and is an anabolic agent. The recommended dose of abaloparatide is 80 μg, administered via SC injection once a day. Adverse effects include hypercalciuria, dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain, and vertigo (<a href="./references#CD013424-bbs2-0077" title="MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of Abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]">Miller 2016</a>). </p> </section> <section id="CD013424-sec-0017"> <h4 class="title">Romosozumab</h4> <p>Romosozumab is a humanised monoclonal antibody that binds and inhibits the activity of the protein sclerostin. It has a dual effects on the bone; it increases bone formation and decreases bone breakdown. The recommended dose of romosozumab is 210 mg, administered via SC injection once a month; it should be limited to 12 doses. Serious adverse effects are cardiac death, heart attack, and stroke (<a href="./references#CD013424-bbs2-0094" title="SaagKG , PetersenJ , BrandiML , KaraplisAC , LorentzonM , ThomasT , et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. New England Journal of Medicine2017;377(15):1417-27. [MEDLINE: 28892457]">Saag 2017</a>). Other adverse effects include headache, joint pain, and pain at the injection site (<a href="./references#CD013424-bbs2-0045" title="CosmanF , CrittendenDB , AdachiJD , BinkleyN , CzerwinskiE , FerrariS , et al. Romosozumab treatment in postmenopausal women with osteoporosis. New England Journal of Medicine2016;375(16):1532-43. [MEDLINE: 27641143]">Cosman 2016</a>). The approval of romosozumab was on hold owing to its serious adverse effects, but it was finally approved by the US FDA for the treatment of osteoporosis in 2019 with a black box warning. </p> </section> <section id="CD013424-sec-0018"> <h4 class="title">Strontium ranelate</h4> <p>Strontium ranelate consists of two divalent cation atoms. Strontium has pharmacological actions and its structure is closely related to calcium, an active component of the bone. This agent has been suggested to decrease bone resorption and stimulate bone formation. The recommended oral daily dose of strontium ranelate is 2 g (<a href="./references#CD013424-bbs2-0075" title="MeunierPJ , RouxC , SeemanE , OrtolaniS , BadurskiJE , SpectorTD , et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. New England Journal of Medicine2004;350(5):459-68. [MEDLINE: 14749454]">Meunier 2004</a>). Adverse effects include nausea and diarrhoea. The use of this agent may lead to DVT, heart attack, and severe allergic reaction (<a href="./references#CD013424-bbs2-0034" title="AbrahamsenB , GroveEL , VestergaardP . Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate. Osteoporosis International2014;25(2):757-62. [MEDLINE: 24322475]">Abrahamsen 2014</a>; <a href="./references#CD013424-bbs2-0086" title="OsborneV , LaytonD , PerrioM , WiltonL , ShakirSA . Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England. Drug Safety2010;33(7):579-91. [MEDLINE: 20553059]">Osborne 2010</a>). </p> </section> </section> <section id="CD013424-sec-0019"> <h3 class="title" id="CD013424-sec-0019">How the intervention might work</h3> <p>Available anti‐osteoporotic drugs are antiresorptive and/or anabolic agents. In the general population, these drugs improve the BMD and reduce the risk of some fractures. A systematic review reported that bisphosphonates, denosumab, and teriparatide reduced the risk of fractures compared with the placebo in postmenopausal women with osteoporosis. These interventions were found to reduce vertebral fractures (relative risk (RR) reduction range: 0.40 to 0.60) and nonvertebral fractures (RR reduction range: 0.60 to 0.80). Raloxifene, which is a SERMs, reduced the risks of only vertebral fractures (<a href="./references#CD013424-bbs2-0046" title="CrandallCJ , NewberrySJ , DiamantA , LimYW , GelladWF , BoothMJ , et al. Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Annals of Internal Medicine2014;161(10):711-23. [MEDLINE: 25199883]">Crandall 2014</a>). A more recent systematic review indicated that abaloparatide, romosozumab, and strontium ranelate also reduce the incidence of fractures compared with placebo in postmenopausal women with osteoporosis. This review showed that abaloparatide, romosozumab, and strontium ranelate reduces the incidence of vertebral fractures (RR: 0.13 (95% credible interval (CrI) 0.04 to 0.34); 0.31 (95% CrI 0.2 to 0.37); and 0.71 (95% CrI 0.63 to 0.80), respectively) and nonvertebral fractures (RR: 0.50 (95% CrI 0.28 to 0.85); 0.64 (95% CrI 0.49 to 0.81); and 0.87 (95% CrI 0.76 to 0.99), respectively) (<a href="./references#CD013424-bbs2-0091" title="ReginsterJY , BianicF , CampbellR , MartinM , WilliamsSA , FitzpatrickLA . Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Osteoporosis International2019;30(7):1465-73. [MEDLINE: 30953114]">Reginster 2019</a>). Anti‐osteoporotic drugs may also be indicated for patients with CKD who have a stable CKD‐MBD and undergoing bone turnover assessment. </p> </section> <section id="CD013424-sec-0020"> <h3 class="title" id="CD013424-sec-0020">Why it is important to do this review</h3> <p>According to the WHO, the elderly population is continuing to grow globally at an unprecedented rate (<a href="./references#CD013424-bbs2-0058" title="HeW , GoodkindD , KowalP . An Aging World: 2015. www.census.gov/content/dam/Census/library/publications/2016/demo/p95-16-1.pdf (accessed 27 May 2021).">He 2016</a>). Clinical and epidemiological evidence indicates that ageing is a major factor associated with the incidence of CKD and osteoporosis (<a href="./references#CD013424-bbs2-0055" title="GlassockRJ , RuleAD . The implications of anatomical and functional changes of the aging kidney: with an emphasis on the glomeruli. Kidney International2012;82(3):270-7. [MEDLINE: 22437416]">Glassock 2012</a>; <a href="./references#CD013424-bbs2-0063" title="KanisJA , BorgstromF , De LaetC , JohanssonH , JohnellO , JonssonB , et al. Assessment of fracture risk. Osteoporosis International2005;16(6):581-9. [MEDLINE: 15616758]">Kanis 2005</a>). Osteoporotic fractures are highly co‐prevalent with CKD in the elderly population (<a href="./references#CD013424-bbs2-0071" title="KlawanskyS , KomaroffE , Cavanaugh PF Jr, MitchellDY , GordonMJ , ConnellyJE , et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporosis International2003;14(7):570-6. [MEDLINE: 12844211]">Klawansky 2003</a>). Treatment for osteoporosis in patients with CKD is therefore an area of high unmet need. The publication of the CKD‐MBD KDIGO guidelines in 2017 represented a dramatic change in the previous paradigm regarding the diagnosis and treatment of osteoporosis in patients with CKD. These guidelines have changed the view of the nephrologists in terms of the management of osteoporosis and its treatment in patients with CKD. However, it remains unclear how nephrologists should manage their patients (<a href="./references#CD013424-bbs2-0068" title="KhairallahP , NickolasTL . Updates in CKD-associated osteoporosis. Current Osteoporosis Reports2018;16(6):712-23. [MEDLINE: 30353319]">Khairallah 2018a</a>; <a href="./references#CD013424-bbs2-0069" title="KhairallahP , NickolasTL . Management of osteoporosis in CKD. Clinical Journal of The American Society of Nephrology: CJASN2018;13(6):962-9. [MEDLINE: 29487093]">Khairallah 2018b</a>). Cochrane systematic review has evaluated interventions for bone disease in only kidney transplant recipients (<a href="./references#CD013424-bbs2-0089" title="PalmerSC , ChungEY , McGregorDO , BachmannF , StrippoliGF . Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database of Systematic Reviews2019, Issue 10. Art. No: CD005015. [DOI: 10.1002/14651858.CD005015.pub4]">Palmer 2019</a>). Only one other systematic review has evaluated interventions for osteoporosis in patients with CKD, and this study was not comprehensive (<a href="./references#CD013424-bbs2-0103" title="WilsonLM , RebholzCM , JirruE , LiuMC , ZhangA , GayleardJ , et al. Benefits and harms of osteoporosis medications in patients with chronic kidney disease. Annals of Internal Medicine2017;166(9):649-58. [PMID: 28395318]">Wilson 2017</a>). <a href="./references#CD013424-bbs2-0103" title="WilsonLM , RebholzCM , JirruE , LiuMC , ZhangA , GayleardJ , et al. Benefits and harms of osteoporosis medications in patients with chronic kidney disease. Annals of Internal Medicine2017;166(9):649-58. [PMID: 28395318]">Wilson 2017</a> searched only published studies in PubMed and the Cochrane Central Register of Controlled Studies (CENTRAL). Meta‐analyses that exclude unpublished studies and outcomes are likely to overestimate the effects of the evaluated interventions or miss important adverse events, as reflected in Chapters 8.14.1 and 10.2.1 of the Cochrane Handbook (<a href="./references#CD013424-bbs2-0060" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). Additionally, limiting the review to only English‐language articles may introduce a bias. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013424-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013424-sec-0021"></div> <p>To assess the efficacy and safety of pharmacological interventions for osteoporosis in patients with CKD stages 3‐5, and those undergoing dialysis (5D). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013424-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013424-sec-0022"></div> <section id="CD013424-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013424-sec-0024"> <h4 class="title">Types of studies</h4> <p>We included all published, unpublished, and ongoing randomised controlled trials (RCTs) and quasi‐RCTs (RCTs in which treatment allocation was determined by alternation, use of alternate medical records, date of birth, or other predictable methods). </p> </section> <section id="CD013424-sec-0025"> <h4 class="title">Types of participants</h4> <p>Participants of any age with CKD stages 3–5D as defined by the K/DOQI (<a href="./references#CD013424-bbs2-0072" title="LeveyAS , CoreshJ , BalkE , KauszAT , LevinA , SteffesMW , et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification [Erratum in: Ann Intern Med. 2003 Oct 7;139(7):605]. Annals of Internal Medicine2003;139(2):137-47. [PMID: 12859163]">Levey 2003</a>) or the KDIGO guidelines (<a href="./references#CD013424-bbs2-0052" title="EknoyanG , LameireN , EckardtKU , KasiskeBL , WheelerDC , et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD: summary of recommendation statements. Kidney International Supplements2013;3(1):5-14. [DOI: 10.1053/j.ajkd.2014.01.416]">Eknoyan 2013</a>) were considered for inclusion. The review excluded patients who had a functioning kidney transplant or were those treated with corticosteroids, because corticosteroids strongly contribute to the progression of osteoporosis. Additionally, two Cochrane reviews have already evaluated these populations (<a href="./references#CD013424-bbs2-0037" title="AllenCS , YeungJH , VandermeerB , HomikJ . Bisphosphonates for steroid-induced osteoporosis. Cochrane Database of Systematic Reviews2016, Issue 10. Art. No: CD001347. [DOI: 10.1002/14651858.CD001347.pub2]">Allen 2016</a>; <a href="./references#CD013424-bbs2-0089" title="PalmerSC , ChungEY , McGregorDO , BachmannF , StrippoliGF . Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database of Systematic Reviews2019, Issue 10. Art. No: CD005015. [DOI: 10.1002/14651858.CD005015.pub4]">Palmer 2019</a>). The target population included patients with evidence of severe osteopenia or osteoporosis according to WHO criteria (T score &lt; −2.0 SD). The International Society for Clinical Densitometry suggests that the diagnosis of osteoporosis in children and adolescents should not be made based on densitometric criteria alone (<a href="./references#CD013424-bbs2-0061" title="International Society for Clinical Densitometry (ISCD). Skeletal health assessment In children from infancy to adolescence. https://iscd.org/learn/official-positions/pediatric-positions (last accessed 5 July 2021).">ISCD 2019</a>). Thus, based on a previous study (<a href="./references#CD013424-bbs2-0101" title="WardL , TriccoAC , PhuongP , CranneyA , BarrowmanN , GabouryI , et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database of Systematic Reviews2007, Issue 4. Art. No: CD005324. [DOI: 10.1002/14651858.CD005324.pub2]">Ward 2007</a>), children who had at least one low‐trauma fracture and/or reduced BMD were included. </p> </section> <section id="CD013424-sec-0026"> <h4 class="title">Types of interventions</h4> <p>Patients receiving anti‐osteoporotic drugs were compared with individuals receiving a placebo, no treatment, or usual care. The primary intervention was treatment with anti‐osteoporotic drugs, including the following: </p> <p> <ol id="CD013424-list-0001"> <li> <p>Bisphosphonates (etidronate, clodronate, tiludronate, alendronate, risedronate, ibandronate, pamidronate, zoledronate) </p> </li> <li> <p>Denosumab</p> </li> <li> <p>SERMs (bazedoxifene, raloxifene)</p> </li> <li> <p>Teriparatide</p> </li> <li> <p>Abaloparatide</p> </li> <li> <p>Romosozumab</p> </li> <li> <p>Strontium ranelate</p> </li> </ol> </p> <p>Other treatments (e.g., vitamin D, phosphate binders, calcium supplements, calcimimetics, dialysate calcium adjustment, and dietary calcium or phosphate manipulation) were excluded from primary comparisons but were listed as co‐interventions. This approach was used as these interventions were included in three previous Cochrane reviews (<a href="./references#CD013424-bbs2-0087" title="PalmerSC , McGregorDO , CraigJC , ElderG , MacaskillP , StrippoliGFM . Vitamin D compounds for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews2007, Issue 4. Art. No: CD008175. [DOI: 10.1002/14651858.CD008175]">Palmer 2007b</a>; <a href="./references#CD013424-bbs2-0088" title="PalmerSC , McGregorDO , CraigJC , ElderG , MacaskillP , StrippoliGF . Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database of Systematic Reviews2007, Issue 4. Art. No: CD005633. [DOI: 10.1002/14651858.CD005633.pub2]">Palmer 2009</a>; <a href="./references#CD013424-bbs2-0093" title="RuospoM , PalmerSC , NataleP , CraigJC , VecchioM , ElderGJ , et al. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD006023. [DOI: 10.1002/14651858.CD006023.pub3]">Ruospo 2018</a>). We did not place any restrictions on the doses of therapy. All studies had a follow‐up period of at least six months. </p> </section> <section id="CD013424-sec-0027"> <h4 class="title">Types of outcome measures</h4> <section id="CD013424-sec-0028"> <h5 class="title">Primary outcomes</h5> <p>The primary outcomes at final follow‐up were as follows.</p> <p> <ul id="CD013424-list-0002"> <li> <p>Incidence of fracture at any sites (clinical or radiographic)</p> </li> <li> <p>Mean change in the BMD measured using dual‐energy radiographic absorptiometry (DXA) at the femoral neck, total hip, lumbar spine, or distal radius. </p> </li> <li> <p>Adverse events: osteonecrosis of the jaw that delays dental healing, atypical femoral fracture, any gastroesophageal disorder (oesophagitis, oesophageal ulcer, oesophageal stricture, oesophageal erosions, dysphagia, gastric bleeding, duodenitis, or ulceration), nausea, diarrhoea, any musculoskeletal disorders (bone pain, arthralgia, myalgia, and muscle cramps), fever, hypersensitivity reactions, cellulitis, venous thromboembolism, stroke, oedema, hot flushes, acute kidney injury (AKI), histological osteomalacia or low‐bone turnover renal osteodystrophy, urinary tract infections (UTI), sepsis, and any other complication that may occur. </p> </li> </ul> </p> </section> <section id="CD013424-sec-0029"> <h5 class="title">Secondary outcomes</h5> <p>The secondary outcomes at maximal follow‐up were as follows:</p> <p> <ul id="CD013424-list-0003"> <li> <p>SONG core outcomes: the <a href="http://songinitiative.org/" target="_blank">SONG core outcomes</a>, as specified by the Standardised Outcomes in Nephrology initiative (<a href="./references#CD013424-bbs2-0097" title="SONG Initiative. The SONG Handbook Version 1.0. www.songinitiative.org/reports-and-publications/2017.">SONG 2017</a>). We evaluated the following: </p> <ul id="CD013424-list-0004"> <li> <p>Death (any cause, including cardiovascular)</p> </li> <li> <p>Cardiovascular and cerebrovascular morbidity</p> </li> <li> <p>Life participation (only in participants undergoing peritoneal dialysis (PD))</p> </li> <li> <p>Fatigue score (only in participants undergoing haemodialysis (HD))</p> </li> <li> <p>Vascular access failure (only in participants undergoing HD)</p> </li> <li> <p>PD‐related infections (only in participants undergoing PD)</p> </li> <li> <p>PD failure (only in participants undergoing PD)</p> </li> </ul> </li> <li> <p>QoL as reported in individual studies</p> </li> <li> <p>Serum levels of intact PTH, calcium, phosphorus, and alkaline phosphatase (total or bone‐specific). </p> </li> </ul> </p> </section> </section> </section> <section id="CD013424-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013424-sec-0031"> <h4 class="title">Electronic searches</h4> <p>We searched the <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant Register of Studies</a> up to 25 January 2021 through contact with the Information Specialist using search terms relevant to this review. The Register contains studies identified from the following sources: </p> <p> <ol id="CD013424-list-0005"> <li> <p>Monthly searches of CENTRAL</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Handsearching of kidney‐related journals and the proceedings of major kidney conferences</p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected kidney and transplant journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Register were identified through searches of CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of search strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available on the Cochrane Kidney and Transplant website under <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">CKT Register of Studies</a>. </p> <p>See <a href="./appendices#CD013424-sec-0116">Appendix 1</a> for search terms used in strategies for this review. </p> </section> <section id="CD013424-sec-0032"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD013424-list-0006"> <li> <p>Reference lists of review articles, relevant studies, and clinical practice guidelines</p> </li> <li> <p>Experts/organisations in the field seeking information about unpublished or incomplete studies </p> </li> <li> <p>Grey literature sources (e.g., abstracts, dissertations, and theses), in addition to those already included in the Cochrane Kidney and Transplant Register of Studies </p> </li> </ol> </p> </section> </section> <section id="CD013424-sec-0033"> <h3 class="title" id="CD013424-sec-0033">Data collection and analysis</h3> <section id="CD013424-sec-0034"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently screened the titles and abstracts from search results and coded them as ‘retrieve’ (eligible or potentially eligible/unclear) or ‘do not retrieve’. We retrieved the full text of study reports or publications, which were then independently assessed by two review authors for inclusion. The reason for excluding ineligible studies was recorded. We resolved any disagreement through discussion or, if required, by consultation with a third author. We identified and excluded duplicates studies and collated multiple reports of the same study; this enabled each study rather than each report, to act as a unit of interest in the review. The selection process was recorded in sufficient detail to the enable completion of the PRISMA flow diagram and to generate a table detailing the ‘Characteristics of excluded studies’ (<a href="./references#CD013424-bbs2-0078" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of Internal Medicine2009;151(4):264-9. [MEDLINE: 19622511]">Moher 2009</a>). </p> </section> <section id="CD013424-sec-0035"> <h4 class="title">Data extraction and management</h4> <p>A data collection form for was used to document study characteristics and outcome data; this form was piloted on at least one study included in the review. The data extraction form included the following items. </p> <p> <ul id="CD013424-list-0007"> <li> <p>Methods: study design, total duration of study, number of study centres and location, study setting, withdrawals, and date of study </p> </li> <li> <p>Participants: number (N), mean age, age range, sex, baseline CKD stage, diagnostic criteria, follow‐up duration, inclusion criteria, and exclusion criteria </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications, and intervention dosage </p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported </p> </li> <li> <p>Notes: funding for studies and notable conflicts of interest reported by study authors, and any other necessary information </p> </li> </ul> </p> <p>Two review authors independently extracted outcome data from the included studies. In the ‘<a href="./references#CD013424-sec-0126" title="">Characteristics of included studies</a>’, we noted if the study authors did not report outcome data in a usable way. We resolved disagreements by consensus or by involving a third author. One review author transferred data into Review Manager. Double data entry was used to confirm that the data were entered correctly data were entered correctly. A second review author spot‐checked study characteristics for accuracy against study reports. </p> </section> <section id="CD013424-sec-0036"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were independently assessed by two authors using the risk of bias assessment tool (<a href="./references#CD013424-bbs2-0060" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>) (see <a href="./appendices#CD013424-sec-0117">Appendix 2</a>). </p> <p> <ul id="CD013424-list-0008"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study?</p> <ul id="CD013424-list-0009"> <li> <p>Participants and personnel (performance bias)</p> </li> <li> <p>Outcome assessors (detection bias)</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Were reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias?</p> </li> </ul> </p> <p>We judged each potential source of bias as high, low, or unclear, and included text from the study report and justification for our judgement in the risk of bias table. We summarised the risk of bias judgements across studies for each of the domains listed. Blinding was considered for different key outcomes where necessary (e.g., for unblinded outcome assessment, the risk of bias for death (any cause) may be differ from that for a participant‐reported health‐related QoL scale). We contacted study authors for additional information to clarify any risk of bias when the study reports did not provide enough detail to allow for a clear judgement. We considered the risk of bias for studies that contribute to a particular outcome when considering treatment effects. </p> <p>We assessed the overall risk of bias based on the following bias domains: allocation concealment, blinding of outcome assessors, and incomplete outcome data. </p> <p> <ul id="CD013424-list-0010"> <li> <p>Low risk of bias: all the above domains are at a low risk of bias</p> </li> <li> <p>High risk of bias: one or more of the above domains are at a high or unclear risk of bias </p> </li> </ul> </p> </section> <section id="CD013424-sec-0037"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous outcomes as risk ratio (RR) with 95% confidence intervals (CI). Where continuous scales of measurement were used to assess the effects of treatment, the mean difference (MD) or the standardised mean difference (SMD) were used if different scales were used. For outcomes provided as rates, the results were expressed as rate ratios with 95% CIs. If studies included a mixture of change‐from‐baseline and final value scores, we used the (unstandardised) MD method in RevMan according to Chapter 9.4.5.2 of the Cochrane handbook (<a href="./references#CD013424-bbs2-0060" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). However, the change‐from‐baseline and final value scores were not combined as the SMD, as the SD would reflect the differences in the reliability of the measurements rather than the differences in the measurement scale (<a href="./references#CD013424-bbs2-0060" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). If a study reported outcomes at multiple time points, we used the last time point recorded. We performed meta‐analyses only when this approach was meaningful; that is, if treatments, participants, and the underlying clinical questions were sufficiently similar to allow for pooling. Skewed data were to be presented descriptively (for example, as medians and interquartile ranges for each group). </p> </section> <section id="CD013424-sec-0038"> <h4 class="title">Unit of analysis issues</h4> <p>We did not anticipate the inclusion of studies with non‐standard designs, such as cross‐over studies and cluster‐RCTs, in the review. However, studies with multiple arms could be identified and included. In such cases, all intervention groups that were relevant to the review were included. To avoid double counting of the comparator, the number of patients in the comparator group was divided across the number of eligible intervention arms. </p> </section> <section id="CD013424-sec-0039"> <h4 class="title">Dealing with missing data</h4> <p>Any further information required from the original author was requested in writing by (e.g. emailing the corresponding author), and any relevant information obtained in this manner was included in the review. Important numerical data, such as the number of screened and randomised patients, as well as the intention‐to‐treat (ITT), as‐treated, and per‐protocol populations, were carefully evaluated. Attrition rates, including dropouts, losses to follow‐up, and withdrawals were investigated. Issues of missing data and imputation methods (for example, last‐observation‐carried‐forward) were critically appraised (<a href="./references#CD013424-bbs2-0060" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). </p> </section> <section id="CD013424-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was initially assessed by the visual inspection of the forest plots. Thereafter, statistical heterogeneity was quantified using the I² statistic, which described the percentage of total variation across studies that was due to heterogeneity rather than sampling error (<a href="./references#CD013424-bbs2-0059" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [MEDLINE: 12958120]">Higgins 2003</a>). I² values can be interpreted as follows: </p> <p> <ul id="CD013424-list-0011"> <li> <p>0% to 40%: might not be important</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>The importance of the observed I² value depended on the magnitude and direction of treatment effects and the strength of evidence for heterogeneity (e.g. P‐value from the Chi² test, or a CI for I²) (<a href="./references#CD013424-bbs2-0060" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). </p> </section> <section id="CD013424-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <p>If possible, funnel plots were used to assess for the potential existence of small study bias (<a href="./references#CD013424-bbs2-0060" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). </p> </section> <section id="CD013424-sec-0042"> <h4 class="title">Data synthesis</h4> <p>Different CKD patient populations (patients with CKD stage 3‐5, and patients undergoing dialysis (5D)) were analysed separately. When the selected relevant studies were sufficiently similar, a meta‐analysis was performed. Considering substantial heterogeneity between studies, we used the random‐effects model. If substantial or considerable heterogeneity (I²&gt; 60%) was present, we did not perform a meta‐analysis (see <a href="#CD013424-sec-0040">Assessment of heterogeneity</a>). </p> </section> <section id="CD013424-sec-0043"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If sufficient data were available, we conducted the following subgroup analyses for the primary outcomes. </p> <p> <ul id="CD013424-list-0012"> <li> <p>Age (&lt; 18 years and ≥ 18 years)</p> </li> <li> <p>Sex</p> </li> <li> <p>Types of interventions</p> </li> <li> <p>intact PTH (&lt; 50, 50 to 300, and &gt; 300 pg/mL)</p> </li> <li> <p>Concomitant use of vitamin D</p> </li> </ul> </p> </section> <section id="CD013424-sec-0044"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analyses, defined a priori, were performed to assess the robustness of our conclusions. We performed the following sensitivity analyses for the primary outcomes. </p> <p> <ul id="CD013424-list-0013"> <li> <p>Excluding studies judged to be at a high overall risk of bias</p> </li> <li> <p>Excluding studies judged to be at a high or unclear risk of bias for at least one of the overall risk of bias domains. </p> </li> </ul> </p> </section> <section id="CD013424-sec-0045"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>The main results of the review are presented in the ‘Summary of findings’ tables. These tables presented key information related to the quality of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (<a href="./references#CD013424-bbs2-0095" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Schunemann 2011a</a>). The ‘Summary of findings’ tables also included an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach (<a href="./references#CD013424-bbs2-0056" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6. [MEDLINE: 18436948]">GRADE 2008</a>; <a href="./references#CD013424-bbs2-0057" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94. [MEDLINE: 21195583]">GRADE 2011</a>). This approach defined the quality of a body of evidence as the extent to which one could be confident that an estimate of effect or association was close to the true quantity of specific interest. The quality of a body of evidence involved consideration of the within‐trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates, and risk of publication bias (<a href="./references#CD013424-bbs2-0096" title="SchünemannHJ , OxmanAD , HigginsJP , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Schunemann 2011b</a>). We planned to present the following outcomes in the ‘Summary of findings’ tables. </p> <p> <ul id="CD013424-list-0014"> <li> <p>Incidence of fracture at any sites</p> </li> <li> <p>Mean change in the BMD measured using DXA at the femoral neck, total hip, lumbar spine, and distal radius </p> </li> <li> <p>Death (any cause)</p> </li> <li> <p>Incidence of adverse events</p> </li> <li> <p>QoL.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013424-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013424-sec-0046"></div> <section id="CD013424-sec-0047"> <h3 class="title">Description of studies</h3> <p>Detailed descriptions of the studies covered in this review are provided in the following tables: <a href="./references#CD013424-sec-0126" title="">Characteristics of included studies</a>; <a href="./references#CD013424-sec-0127" title="">Characteristics of excluded studies</a>; <a href="./references#CD013424-sec-0128" title="">Characteristics of ongoing studies</a>. </p> <section id="CD013424-sec-0048"> <h4 class="title">Results of the search</h4> <p>After searching the Specialised Register, contacting pharmaceutical companies, an additional web search, and removing duplicates, a total of 84 records were identified. After title and abstract screening and full‐text review, seven studies (48 records) were included (<a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a>; <a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>; <a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a>; <a href="./references#CD013424-bbs2-0004" title="BoonenS , MarinF , MellstromD , XieL , DesaiahD , KregeJH , et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Journal of the American Geriatrics Society2006;54(5):782-9. [MEDLINE: 16696744]ChenP , MillerPD , DelmasPD , MisurskiDA , KregeJH . Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. Journal of Bone &amp; Mineral Research2006;21(11):1785-90. [MEDLINE: 17002571]CransGG , SilvermanSL , GenantHK , GlassEV , KregeJH . Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. Arthritis &amp; Rheumatism2004;50(12):4028-34. [MEDLINE: 15593198]Dawson-HughesB , ChenP , KregeJH . Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. Journal of Clinical Endocrinology &amp; Metabolism2007;92(12):4630-6. [MEDLINE: 17911178]DelmasPD , LicataAA , ReginsterJY , CransGG , ChenP , MisurskiDA , et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone2006;39(2):237-43. [MEDLINE: 16563890]GallagherJC , GenantHK , CransGG , VargasSJ , KregeJH . Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1583-7. [MEDLINE: 15613428]GenantHK , HalseJ , BrineyWG , XieL , GlassEV , KregeJH . The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Current Medical Research &amp; Opinion2005;21(7):1027-34. [MEDLINE: 16004669]GenantHK , SirisE , CransGG , DesaiahD , KregeJH . Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone2005;37(2):170-4. [MEDLINE: 15961357]JiangY , ZhaoJJ , MitlakBH , WangO , GenantHK , EriksenEF . Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. Journal of Bone &amp; Mineral Research2003;18(11):1932-41. [MEDLINE: 14606504]KregeJH , WanX . Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone2012;50(1):161-4. [MEDLINE: 22036910]MillerPD , SchwartzEN , ChenP , MisurskiDA , KregeJH . Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis International2007;18(1):59-68. [MEDLINE: 17013567]NeerRM , ArnaudCD , ZanchettaJR , PrinceR , GaichGA , ReginsterJY , et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal Medicine2001;344(19):1434-41. [MEDLINE: 11346808]PaschalisEP , GlassEV , DonleyDW , EriksenEF . Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial. Journal of Clinical Endocrinology &amp; Metabolism2005;90(8):4644-9. [MEDLINE: 15914535]SatterwhiteJ , HeathmanM , MillerPD , MarinF , GlassEV , DobnigH . Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcified Tissue International2010;87(6):485-92. [MEDLINE: 20953593]SilvermanSL , PiziakVK , ChenP , MisurskiDA , WagmanRB . Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. Journal of Rheumatology2005;32(12):2405-9. [MEDLINE: 16331772]Uusi-RasiK , SemanickLM , ZanchettaJR , BogadoCE , EriksenEF , SatoM , et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone2005;36(6):948-58. [MEDLINE: 15878318]WattsNB , MillerPD , KohlmeierLA , SebbaA , ChenP , WongM , et al. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. Journal of Bone &amp; Mineral Research2009;24(6):1125-31. [MEDLINE: 19113918]">FTP 2001</a>; <a href="./references#CD013424-bbs2-0005" title="HaghverdiF , FarbodaraT , MortajiS , SoltaniP , SaidiN . Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5 [Erratum in: Iran J Kidney Dis. 2015 Jan;9(1):76; PMID: 25599744]. Iranian Journal of Kidney Diseases2014;8(6):461-6. [MEDLINE: 25362221]">Haghverdi 2014</a>; <a href="./references#CD013424-bbs2-0006" title="HeilbergIP , HernandezE , AlonzoE , ValeraR , FerreiraLG , GomesSA , et al. Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. Renal Failure2005;27(2):155-61. [MEDLINE: 15807179]HernandezE , ValeraR , AlonzoE , Bajares-LilueM , CarliniR , CaprilesF , et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney International2003;63(6):2269-74. [MEDLINE: 12753317]HernandezE , ValeraR , TeranJ , Bajares-LilueM , CapriilesF , AlonzoE , et al. The effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone resorption markers and serum lipids in postmenopausal women on chronic hemodialysis (HD) [abstract no: A2974]. Journal of the American Society of Nephrology2000;11(Sept):563-4A. [CENTRAL: CN-00550530] HernandezE , ValeraR , TeranJ , Bajares-LilueM , CaprilesF , AlonzoE , et al. One year controlled study on the effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone metabolism and serum lipids on postmenopausal women on chronic hemodialysis (HD) [abstract no: A3879]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):743A. [CENTRAL: CN-00550533] Weisinger, JR, HeilbergIP , HernandezE , CarliniR , Bellorin-FontE . Selective estrogen receptor modulators in chronic renal failure. Kidney International - Supplement2003;63(85):S62-5. [MEDLINE: 12753268]">Hernandez 2003</a>; <a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a>), and 23 studies (33 records) were excluded. Three ongoing studies were identified (<a href="./references#CD013424-bbs2-0033" title="CristolJP . Study evaluating denosumab on bone and vascular metabolism in osteoporotic chronic kidney disease (HDENO) [Randomized controlled study evaluating the effect of a biotherapy treatment (anti-RANKL ligand antibody: denosumab) on bone and vascular metabolism in osteoporotic chronic kidney disease]. www.clinicaltrials.gov/show/NCT02792413 (first received 7 June 2016). ">NCT02792413</a>; <a href="./references#CD013424-bbs2-0031" title="MasmouB . Effect of alendronate in patents with osteoporosis and chronic kidney disease [Effect of alendronate on bone densitometry in osteoporetic chronic kidney disease stage 3a-3b]. en.irct.ir/trial/33312 (first received 22 October 2018). ">IRCT20180506039549N1</a>; <a href="./references#CD013424-bbs2-0032" title="MallucheH . Renal osteodystrophy: an individual management approach [Renal osteodystrophy: a fresh approach]. www.clinicaltrials.gov/show/NCT02440581 (first received 12 May 2015). ">NCT02440581</a>) and these will be assessed in a future update of this review (<a href="#CD013424-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD013424-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram." data-id="CD013424-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram.</p> </div> </div> </div> </section> <section id="CD013424-sec-0049"> <h4 class="title">Included studies</h4> <p>The seven studies (48 records) included in this systematic review are summarised in the <a href="./references#CD013424-sec-0126" title="">Characteristics of included studies</a>. </p> <section id="CD013424-sec-0050"> <h5 class="title">Study design</h5> <p>All studies were parallel RCTs.</p> </section> <section id="CD013424-sec-0051"> <h5 class="title">Sample size</h5> <p>A total of 9,164 randomised participants were included in this review. The sample sizes ranged from 50 to 4,973. Five studies were included in the subgroup of large studies (<a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a>; <a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>; <a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a>; <a href="./references#CD013424-bbs2-0004" title="BoonenS , MarinF , MellstromD , XieL , DesaiahD , KregeJH , et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Journal of the American Geriatrics Society2006;54(5):782-9. [MEDLINE: 16696744]ChenP , MillerPD , DelmasPD , MisurskiDA , KregeJH . Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. Journal of Bone &amp; Mineral Research2006;21(11):1785-90. [MEDLINE: 17002571]CransGG , SilvermanSL , GenantHK , GlassEV , KregeJH . Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. Arthritis &amp; Rheumatism2004;50(12):4028-34. [MEDLINE: 15593198]Dawson-HughesB , ChenP , KregeJH . Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. Journal of Clinical Endocrinology &amp; Metabolism2007;92(12):4630-6. [MEDLINE: 17911178]DelmasPD , LicataAA , ReginsterJY , CransGG , ChenP , MisurskiDA , et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone2006;39(2):237-43. [MEDLINE: 16563890]GallagherJC , GenantHK , CransGG , VargasSJ , KregeJH . Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1583-7. [MEDLINE: 15613428]GenantHK , HalseJ , BrineyWG , XieL , GlassEV , KregeJH . The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Current Medical Research &amp; Opinion2005;21(7):1027-34. [MEDLINE: 16004669]GenantHK , SirisE , CransGG , DesaiahD , KregeJH . Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone2005;37(2):170-4. [MEDLINE: 15961357]JiangY , ZhaoJJ , MitlakBH , WangO , GenantHK , EriksenEF . Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. Journal of Bone &amp; Mineral Research2003;18(11):1932-41. [MEDLINE: 14606504]KregeJH , WanX . Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone2012;50(1):161-4. [MEDLINE: 22036910]MillerPD , SchwartzEN , ChenP , MisurskiDA , KregeJH . Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis International2007;18(1):59-68. [MEDLINE: 17013567]NeerRM , ArnaudCD , ZanchettaJR , PrinceR , GaichGA , ReginsterJY , et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal Medicine2001;344(19):1434-41. [MEDLINE: 11346808]PaschalisEP , GlassEV , DonleyDW , EriksenEF . Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial. Journal of Clinical Endocrinology &amp; Metabolism2005;90(8):4644-9. [MEDLINE: 15914535]SatterwhiteJ , HeathmanM , MillerPD , MarinF , GlassEV , DobnigH . Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcified Tissue International2010;87(6):485-92. [MEDLINE: 20953593]SilvermanSL , PiziakVK , ChenP , MisurskiDA , WagmanRB . Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. Journal of Rheumatology2005;32(12):2405-9. [MEDLINE: 16331772]Uusi-RasiK , SemanickLM , ZanchettaJR , BogadoCE , EriksenEF , SatoM , et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone2005;36(6):948-58. [MEDLINE: 15878318]WattsNB , MillerPD , KohlmeierLA , SebbaA , ChenP , WongM , et al. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. Journal of Bone &amp; Mineral Research2009;24(6):1125-31. [MEDLINE: 19113918]">FTP 2001</a>; <a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a>). </p> </section> <section id="CD013424-sec-0052"> <h5 class="title">Setting</h5> <p>We included four multinational studies (<a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a>; <a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a>; <a href="./references#CD013424-bbs2-0004" title="BoonenS , MarinF , MellstromD , XieL , DesaiahD , KregeJH , et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Journal of the American Geriatrics Society2006;54(5):782-9. [MEDLINE: 16696744]ChenP , MillerPD , DelmasPD , MisurskiDA , KregeJH . Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. Journal of Bone &amp; Mineral Research2006;21(11):1785-90. [MEDLINE: 17002571]CransGG , SilvermanSL , GenantHK , GlassEV , KregeJH . Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. Arthritis &amp; Rheumatism2004;50(12):4028-34. [MEDLINE: 15593198]Dawson-HughesB , ChenP , KregeJH . Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. Journal of Clinical Endocrinology &amp; Metabolism2007;92(12):4630-6. [MEDLINE: 17911178]DelmasPD , LicataAA , ReginsterJY , CransGG , ChenP , MisurskiDA , et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone2006;39(2):237-43. [MEDLINE: 16563890]GallagherJC , GenantHK , CransGG , VargasSJ , KregeJH . Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1583-7. [MEDLINE: 15613428]GenantHK , HalseJ , BrineyWG , XieL , GlassEV , KregeJH . The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Current Medical Research &amp; Opinion2005;21(7):1027-34. [MEDLINE: 16004669]GenantHK , SirisE , CransGG , DesaiahD , KregeJH . Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone2005;37(2):170-4. [MEDLINE: 15961357]JiangY , ZhaoJJ , MitlakBH , WangO , GenantHK , EriksenEF . Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. Journal of Bone &amp; Mineral Research2003;18(11):1932-41. [MEDLINE: 14606504]KregeJH , WanX . Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone2012;50(1):161-4. [MEDLINE: 22036910]MillerPD , SchwartzEN , ChenP , MisurskiDA , KregeJH . Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis International2007;18(1):59-68. [MEDLINE: 17013567]NeerRM , ArnaudCD , ZanchettaJR , PrinceR , GaichGA , ReginsterJY , et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal Medicine2001;344(19):1434-41. [MEDLINE: 11346808]PaschalisEP , GlassEV , DonleyDW , EriksenEF . Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial. Journal of Clinical Endocrinology &amp; Metabolism2005;90(8):4644-9. [MEDLINE: 15914535]SatterwhiteJ , HeathmanM , MillerPD , MarinF , GlassEV , DobnigH . Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcified Tissue International2010;87(6):485-92. [MEDLINE: 20953593]SilvermanSL , PiziakVK , ChenP , MisurskiDA , WagmanRB . Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. Journal of Rheumatology2005;32(12):2405-9. [MEDLINE: 16331772]Uusi-RasiK , SemanickLM , ZanchettaJR , BogadoCE , EriksenEF , SatoM , et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone2005;36(6):948-58. [MEDLINE: 15878318]WattsNB , MillerPD , KohlmeierLA , SebbaA , ChenP , WongM , et al. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. Journal of Bone &amp; Mineral Research2009;24(6):1125-31. [MEDLINE: 19113918]">FTP 2001</a>; <a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a>), two single‐country multicentre studies (<a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>; <a href="./references#CD013424-bbs2-0006" title="HeilbergIP , HernandezE , AlonzoE , ValeraR , FerreiraLG , GomesSA , et al. Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. Renal Failure2005;27(2):155-61. [MEDLINE: 15807179]HernandezE , ValeraR , AlonzoE , Bajares-LilueM , CarliniR , CaprilesF , et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney International2003;63(6):2269-74. [MEDLINE: 12753317]HernandezE , ValeraR , TeranJ , Bajares-LilueM , CapriilesF , AlonzoE , et al. The effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone resorption markers and serum lipids in postmenopausal women on chronic hemodialysis (HD) [abstract no: A2974]. Journal of the American Society of Nephrology2000;11(Sept):563-4A. [CENTRAL: CN-00550530] HernandezE , ValeraR , TeranJ , Bajares-LilueM , CaprilesF , AlonzoE , et al. One year controlled study on the effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone metabolism and serum lipids on postmenopausal women on chronic hemodialysis (HD) [abstract no: A3879]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):743A. [CENTRAL: CN-00550533] Weisinger, JR, HeilbergIP , HernandezE , CarliniR , Bellorin-FontE . Selective estrogen receptor modulators in chronic renal failure. Kidney International - Supplement2003;63(85):S62-5. [MEDLINE: 12753268]">Hernandez 2003</a>), and one single‐centre study (<a href="./references#CD013424-bbs2-0005" title="HaghverdiF , FarbodaraT , MortajiS , SoltaniP , SaidiN . Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5 [Erratum in: Iran J Kidney Dis. 2015 Jan;9(1):76; PMID: 25599744]. Iranian Journal of Kidney Diseases2014;8(6):461-6. [MEDLINE: 25362221]">Haghverdi 2014</a>). </p> </section> <section id="CD013424-sec-0053"> <h5 class="title">Participants</h5> <p>All studies were conducted in postmenopausal women. The mean age ranged from 62.5 to 77.6 years. Five studies (<a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a>; <a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>; <a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a>; <a href="./references#CD013424-bbs2-0004" title="BoonenS , MarinF , MellstromD , XieL , DesaiahD , KregeJH , et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Journal of the American Geriatrics Society2006;54(5):782-9. [MEDLINE: 16696744]ChenP , MillerPD , DelmasPD , MisurskiDA , KregeJH . Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. Journal of Bone &amp; Mineral Research2006;21(11):1785-90. [MEDLINE: 17002571]CransGG , SilvermanSL , GenantHK , GlassEV , KregeJH . Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. Arthritis &amp; Rheumatism2004;50(12):4028-34. [MEDLINE: 15593198]Dawson-HughesB , ChenP , KregeJH . Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. Journal of Clinical Endocrinology &amp; Metabolism2007;92(12):4630-6. [MEDLINE: 17911178]DelmasPD , LicataAA , ReginsterJY , CransGG , ChenP , MisurskiDA , et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone2006;39(2):237-43. [MEDLINE: 16563890]GallagherJC , GenantHK , CransGG , VargasSJ , KregeJH . Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1583-7. [MEDLINE: 15613428]GenantHK , HalseJ , BrineyWG , XieL , GlassEV , KregeJH . The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Current Medical Research &amp; Opinion2005;21(7):1027-34. [MEDLINE: 16004669]GenantHK , SirisE , CransGG , DesaiahD , KregeJH . Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone2005;37(2):170-4. [MEDLINE: 15961357]JiangY , ZhaoJJ , MitlakBH , WangO , GenantHK , EriksenEF . Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. Journal of Bone &amp; Mineral Research2003;18(11):1932-41. [MEDLINE: 14606504]KregeJH , WanX . Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone2012;50(1):161-4. [MEDLINE: 22036910]MillerPD , SchwartzEN , ChenP , MisurskiDA , KregeJH . Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis International2007;18(1):59-68. [MEDLINE: 17013567]NeerRM , ArnaudCD , ZanchettaJR , PrinceR , GaichGA , ReginsterJY , et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal Medicine2001;344(19):1434-41. [MEDLINE: 11346808]PaschalisEP , GlassEV , DonleyDW , EriksenEF . Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial. Journal of Clinical Endocrinology &amp; Metabolism2005;90(8):4644-9. [MEDLINE: 15914535]SatterwhiteJ , HeathmanM , MillerPD , MarinF , GlassEV , DobnigH . Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcified Tissue International2010;87(6):485-92. [MEDLINE: 20953593]SilvermanSL , PiziakVK , ChenP , MisurskiDA , WagmanRB . Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. Journal of Rheumatology2005;32(12):2405-9. [MEDLINE: 16331772]Uusi-RasiK , SemanickLM , ZanchettaJR , BogadoCE , EriksenEF , SatoM , et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone2005;36(6):948-58. [MEDLINE: 15878318]WattsNB , MillerPD , KohlmeierLA , SebbaA , ChenP , WongM , et al. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. Journal of Bone &amp; Mineral Research2009;24(6):1125-31. [MEDLINE: 19113918]">FTP 2001</a>; <a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a>) included patients with CKD stages 3a‐4. Two studies (<a href="./references#CD013424-bbs2-0005" title="HaghverdiF , FarbodaraT , MortajiS , SoltaniP , SaidiN . Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5 [Erratum in: Iran J Kidney Dis. 2015 Jan;9(1):76; PMID: 25599744]. Iranian Journal of Kidney Diseases2014;8(6):461-6. [MEDLINE: 25362221]">Haghverdi 2014</a>; <a href="./references#CD013424-bbs2-0006" title="HeilbergIP , HernandezE , AlonzoE , ValeraR , FerreiraLG , GomesSA , et al. Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. Renal Failure2005;27(2):155-61. [MEDLINE: 15807179]HernandezE , ValeraR , AlonzoE , Bajares-LilueM , CarliniR , CaprilesF , et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney International2003;63(6):2269-74. [MEDLINE: 12753317]HernandezE , ValeraR , TeranJ , Bajares-LilueM , CapriilesF , AlonzoE , et al. The effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone resorption markers and serum lipids in postmenopausal women on chronic hemodialysis (HD) [abstract no: A2974]. Journal of the American Society of Nephrology2000;11(Sept):563-4A. [CENTRAL: CN-00550530] HernandezE , ValeraR , TeranJ , Bajares-LilueM , CaprilesF , AlonzoE , et al. One year controlled study on the effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone metabolism and serum lipids on postmenopausal women on chronic hemodialysis (HD) [abstract no: A3879]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):743A. [CENTRAL: CN-00550533] Weisinger, JR, HeilbergIP , HernandezE , CarliniR , Bellorin-FontE . Selective estrogen receptor modulators in chronic renal failure. Kidney International - Supplement2003;63(85):S62-5. [MEDLINE: 12753268]">Hernandez 2003</a>) included patients undergoing HD or with CKD stage 5 not yet receiving dialysis. Patients receiving PD were not included. <a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a> reported data separately for CKD stages 3 and 4, and <a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a> reported data for stages 3a and 3b‐4. </p> </section> <section id="CD013424-sec-0054"> <h5 class="title">Interventions</h5> <p>Five agents were identified: abaloparatide, alendronate, denosumab, raloxifene, and teriparatide. One study compared abaloparatide with placebo and the active control teriparatide (<a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a>); one study compared alendronate with placebo (<a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>); one study compared denosumab with placebo (<a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a>); one study compared teriparatide with placebo (<a href="./references#CD013424-bbs2-0004" title="BoonenS , MarinF , MellstromD , XieL , DesaiahD , KregeJH , et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Journal of the American Geriatrics Society2006;54(5):782-9. [MEDLINE: 16696744]ChenP , MillerPD , DelmasPD , MisurskiDA , KregeJH . Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. Journal of Bone &amp; Mineral Research2006;21(11):1785-90. [MEDLINE: 17002571]CransGG , SilvermanSL , GenantHK , GlassEV , KregeJH . Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. Arthritis &amp; Rheumatism2004;50(12):4028-34. [MEDLINE: 15593198]Dawson-HughesB , ChenP , KregeJH . Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. Journal of Clinical Endocrinology &amp; Metabolism2007;92(12):4630-6. [MEDLINE: 17911178]DelmasPD , LicataAA , ReginsterJY , CransGG , ChenP , MisurskiDA , et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone2006;39(2):237-43. [MEDLINE: 16563890]GallagherJC , GenantHK , CransGG , VargasSJ , KregeJH . Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1583-7. [MEDLINE: 15613428]GenantHK , HalseJ , BrineyWG , XieL , GlassEV , KregeJH . The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Current Medical Research &amp; Opinion2005;21(7):1027-34. [MEDLINE: 16004669]GenantHK , SirisE , CransGG , DesaiahD , KregeJH . Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone2005;37(2):170-4. [MEDLINE: 15961357]JiangY , ZhaoJJ , MitlakBH , WangO , GenantHK , EriksenEF . Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. Journal of Bone &amp; Mineral Research2003;18(11):1932-41. [MEDLINE: 14606504]KregeJH , WanX . Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone2012;50(1):161-4. [MEDLINE: 22036910]MillerPD , SchwartzEN , ChenP , MisurskiDA , KregeJH . Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis International2007;18(1):59-68. [MEDLINE: 17013567]NeerRM , ArnaudCD , ZanchettaJR , PrinceR , GaichGA , ReginsterJY , et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal Medicine2001;344(19):1434-41. [MEDLINE: 11346808]PaschalisEP , GlassEV , DonleyDW , EriksenEF . Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial. Journal of Clinical Endocrinology &amp; Metabolism2005;90(8):4644-9. [MEDLINE: 15914535]SatterwhiteJ , HeathmanM , MillerPD , MarinF , GlassEV , DobnigH . Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcified Tissue International2010;87(6):485-92. [MEDLINE: 20953593]SilvermanSL , PiziakVK , ChenP , MisurskiDA , WagmanRB . Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. Journal of Rheumatology2005;32(12):2405-9. [MEDLINE: 16331772]Uusi-RasiK , SemanickLM , ZanchettaJR , BogadoCE , EriksenEF , SatoM , et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone2005;36(6):948-58. [MEDLINE: 15878318]WattsNB , MillerPD , KohlmeierLA , SebbaA , ChenP , WongM , et al. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. Journal of Bone &amp; Mineral Research2009;24(6):1125-31. [MEDLINE: 19113918]">FTP 2001</a>); and three studies compared raloxifene with placebo (<a href="./references#CD013424-bbs2-0005" title="HaghverdiF , FarbodaraT , MortajiS , SoltaniP , SaidiN . Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5 [Erratum in: Iran J Kidney Dis. 2015 Jan;9(1):76; PMID: 25599744]. Iranian Journal of Kidney Diseases2014;8(6):461-6. [MEDLINE: 25362221]">Haghverdi 2014</a>; <a href="./references#CD013424-bbs2-0006" title="HeilbergIP , HernandezE , AlonzoE , ValeraR , FerreiraLG , GomesSA , et al. Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. Renal Failure2005;27(2):155-61. [MEDLINE: 15807179]HernandezE , ValeraR , AlonzoE , Bajares-LilueM , CarliniR , CaprilesF , et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney International2003;63(6):2269-74. [MEDLINE: 12753317]HernandezE , ValeraR , TeranJ , Bajares-LilueM , CapriilesF , AlonzoE , et al. The effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone resorption markers and serum lipids in postmenopausal women on chronic hemodialysis (HD) [abstract no: A2974]. Journal of the American Society of Nephrology2000;11(Sept):563-4A. [CENTRAL: CN-00550530] HernandezE , ValeraR , TeranJ , Bajares-LilueM , CaprilesF , AlonzoE , et al. One year controlled study on the effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone metabolism and serum lipids on postmenopausal women on chronic hemodialysis (HD) [abstract no: A3879]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):743A. [CENTRAL: CN-00550533] Weisinger, JR, HeilbergIP , HernandezE , CarliniR , Bellorin-FontE . Selective estrogen receptor modulators in chronic renal failure. Kidney International - Supplement2003;63(85):S62-5. [MEDLINE: 12753268]">Hernandez 2003</a>; <a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a>). </p> </section> <section id="CD013424-sec-0055"> <h5 class="title">Outcomes</h5> <p>The duration of follow‐up ranged from 8 to 54 months. The following reported outcomes included data based on paired comparisons. </p> <p> <ul id="CD013424-list-0015"> <li> <p>Fracture was reported in six studies (9,114 participants) (<a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a>; <a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>; <a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a>; <a href="./references#CD013424-bbs2-0004" title="BoonenS , MarinF , MellstromD , XieL , DesaiahD , KregeJH , et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Journal of the American Geriatrics Society2006;54(5):782-9. [MEDLINE: 16696744]ChenP , MillerPD , DelmasPD , MisurskiDA , KregeJH . Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. Journal of Bone &amp; Mineral Research2006;21(11):1785-90. [MEDLINE: 17002571]CransGG , SilvermanSL , GenantHK , GlassEV , KregeJH . Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. Arthritis &amp; Rheumatism2004;50(12):4028-34. [MEDLINE: 15593198]Dawson-HughesB , ChenP , KregeJH . Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. Journal of Clinical Endocrinology &amp; Metabolism2007;92(12):4630-6. [MEDLINE: 17911178]DelmasPD , LicataAA , ReginsterJY , CransGG , ChenP , MisurskiDA , et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone2006;39(2):237-43. [MEDLINE: 16563890]GallagherJC , GenantHK , CransGG , VargasSJ , KregeJH . Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1583-7. [MEDLINE: 15613428]GenantHK , HalseJ , BrineyWG , XieL , GlassEV , KregeJH . The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Current Medical Research &amp; Opinion2005;21(7):1027-34. [MEDLINE: 16004669]GenantHK , SirisE , CransGG , DesaiahD , KregeJH . Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone2005;37(2):170-4. [MEDLINE: 15961357]JiangY , ZhaoJJ , MitlakBH , WangO , GenantHK , EriksenEF . Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. Journal of Bone &amp; Mineral Research2003;18(11):1932-41. [MEDLINE: 14606504]KregeJH , WanX . Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone2012;50(1):161-4. [MEDLINE: 22036910]MillerPD , SchwartzEN , ChenP , MisurskiDA , KregeJH . Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis International2007;18(1):59-68. [MEDLINE: 17013567]NeerRM , ArnaudCD , ZanchettaJR , PrinceR , GaichGA , ReginsterJY , et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal Medicine2001;344(19):1434-41. [MEDLINE: 11346808]PaschalisEP , GlassEV , DonleyDW , EriksenEF . Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial. Journal of Clinical Endocrinology &amp; Metabolism2005;90(8):4644-9. [MEDLINE: 15914535]SatterwhiteJ , HeathmanM , MillerPD , MarinF , GlassEV , DobnigH . Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcified Tissue International2010;87(6):485-92. [MEDLINE: 20953593]SilvermanSL , PiziakVK , ChenP , MisurskiDA , WagmanRB . Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. Journal of Rheumatology2005;32(12):2405-9. [MEDLINE: 16331772]Uusi-RasiK , SemanickLM , ZanchettaJR , BogadoCE , EriksenEF , SatoM , et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone2005;36(6):948-58. [MEDLINE: 15878318]WattsNB , MillerPD , KohlmeierLA , SebbaA , ChenP , WongM , et al. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. Journal of Bone &amp; Mineral Research2009;24(6):1125-31. [MEDLINE: 19113918]">FTP 2001</a>; <a href="./references#CD013424-bbs2-0005" title="HaghverdiF , FarbodaraT , MortajiS , SoltaniP , SaidiN . Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5 [Erratum in: Iran J Kidney Dis. 2015 Jan;9(1):76; PMID: 25599744]. Iranian Journal of Kidney Diseases2014;8(6):461-6. [MEDLINE: 25362221]">Haghverdi 2014</a>; <a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a>). Five studies assessed radiographic vertebral fracture assessed by a blinded, independent assessor (<a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a>; <a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>; <a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a>; <a href="./references#CD013424-bbs2-0004" title="BoonenS , MarinF , MellstromD , XieL , DesaiahD , KregeJH , et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Journal of the American Geriatrics Society2006;54(5):782-9. [MEDLINE: 16696744]ChenP , MillerPD , DelmasPD , MisurskiDA , KregeJH . Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. Journal of Bone &amp; Mineral Research2006;21(11):1785-90. [MEDLINE: 17002571]CransGG , SilvermanSL , GenantHK , GlassEV , KregeJH . Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. Arthritis &amp; Rheumatism2004;50(12):4028-34. [MEDLINE: 15593198]Dawson-HughesB , ChenP , KregeJH . Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. Journal of Clinical Endocrinology &amp; Metabolism2007;92(12):4630-6. [MEDLINE: 17911178]DelmasPD , LicataAA , ReginsterJY , CransGG , ChenP , MisurskiDA , et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone2006;39(2):237-43. [MEDLINE: 16563890]GallagherJC , GenantHK , CransGG , VargasSJ , KregeJH . Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1583-7. [MEDLINE: 15613428]GenantHK , HalseJ , BrineyWG , XieL , GlassEV , KregeJH . The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Current Medical Research &amp; Opinion2005;21(7):1027-34. [MEDLINE: 16004669]GenantHK , SirisE , CransGG , DesaiahD , KregeJH . Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone2005;37(2):170-4. [MEDLINE: 15961357]JiangY , ZhaoJJ , MitlakBH , WangO , GenantHK , EriksenEF . Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. Journal of Bone &amp; Mineral Research2003;18(11):1932-41. [MEDLINE: 14606504]KregeJH , WanX . Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone2012;50(1):161-4. [MEDLINE: 22036910]MillerPD , SchwartzEN , ChenP , MisurskiDA , KregeJH . Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis International2007;18(1):59-68. [MEDLINE: 17013567]NeerRM , ArnaudCD , ZanchettaJR , PrinceR , GaichGA , ReginsterJY , et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal Medicine2001;344(19):1434-41. [MEDLINE: 11346808]PaschalisEP , GlassEV , DonleyDW , EriksenEF . Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial. Journal of Clinical Endocrinology &amp; Metabolism2005;90(8):4644-9. [MEDLINE: 15914535]SatterwhiteJ , HeathmanM , MillerPD , MarinF , GlassEV , DobnigH . Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcified Tissue International2010;87(6):485-92. [MEDLINE: 20953593]SilvermanSL , PiziakVK , ChenP , MisurskiDA , WagmanRB . Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. Journal of Rheumatology2005;32(12):2405-9. [MEDLINE: 16331772]Uusi-RasiK , SemanickLM , ZanchettaJR , BogadoCE , EriksenEF , SatoM , et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone2005;36(6):948-58. [MEDLINE: 15878318]WattsNB , MillerPD , KohlmeierLA , SebbaA , ChenP , WongM , et al. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. Journal of Bone &amp; Mineral Research2009;24(6):1125-31. [MEDLINE: 19113918]">FTP 2001</a>; <a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a>). Five studies assessed non‐vertebral or clinical fracture (<a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>; <a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a>; <a href="./references#CD013424-bbs2-0004" title="BoonenS , MarinF , MellstromD , XieL , DesaiahD , KregeJH , et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Journal of the American Geriatrics Society2006;54(5):782-9. [MEDLINE: 16696744]ChenP , MillerPD , DelmasPD , MisurskiDA , KregeJH . Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. Journal of Bone &amp; Mineral Research2006;21(11):1785-90. [MEDLINE: 17002571]CransGG , SilvermanSL , GenantHK , GlassEV , KregeJH . Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. Arthritis &amp; Rheumatism2004;50(12):4028-34. [MEDLINE: 15593198]Dawson-HughesB , ChenP , KregeJH . Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. Journal of Clinical Endocrinology &amp; Metabolism2007;92(12):4630-6. [MEDLINE: 17911178]DelmasPD , LicataAA , ReginsterJY , CransGG , ChenP , MisurskiDA , et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone2006;39(2):237-43. [MEDLINE: 16563890]GallagherJC , GenantHK , CransGG , VargasSJ , KregeJH . Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1583-7. [MEDLINE: 15613428]GenantHK , HalseJ , BrineyWG , XieL , GlassEV , KregeJH . The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Current Medical Research &amp; Opinion2005;21(7):1027-34. [MEDLINE: 16004669]GenantHK , SirisE , CransGG , DesaiahD , KregeJH . Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone2005;37(2):170-4. [MEDLINE: 15961357]JiangY , ZhaoJJ , MitlakBH , WangO , GenantHK , EriksenEF . Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. Journal of Bone &amp; Mineral Research2003;18(11):1932-41. [MEDLINE: 14606504]KregeJH , WanX . Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone2012;50(1):161-4. [MEDLINE: 22036910]MillerPD , SchwartzEN , ChenP , MisurskiDA , KregeJH . Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis International2007;18(1):59-68. [MEDLINE: 17013567]NeerRM , ArnaudCD , ZanchettaJR , PrinceR , GaichGA , ReginsterJY , et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal Medicine2001;344(19):1434-41. [MEDLINE: 11346808]PaschalisEP , GlassEV , DonleyDW , EriksenEF . Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial. Journal of Clinical Endocrinology &amp; Metabolism2005;90(8):4644-9. [MEDLINE: 15914535]SatterwhiteJ , HeathmanM , MillerPD , MarinF , GlassEV , DobnigH . Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcified Tissue International2010;87(6):485-92. [MEDLINE: 20953593]SilvermanSL , PiziakVK , ChenP , MisurskiDA , WagmanRB . Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. Journal of Rheumatology2005;32(12):2405-9. [MEDLINE: 16331772]Uusi-RasiK , SemanickLM , ZanchettaJR , BogadoCE , EriksenEF , SatoM , et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone2005;36(6):948-58. [MEDLINE: 15878318]WattsNB , MillerPD , KohlmeierLA , SebbaA , ChenP , WongM , et al. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. Journal of Bone &amp; Mineral Research2009;24(6):1125-31. [MEDLINE: 19113918]">FTP 2001</a>; <a href="./references#CD013424-bbs2-0005" title="HaghverdiF , FarbodaraT , MortajiS , SoltaniP , SaidiN . Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5 [Erratum in: Iran J Kidney Dis. 2015 Jan;9(1):76; PMID: 25599744]. Iranian Journal of Kidney Diseases2014;8(6):461-6. [MEDLINE: 25362221]">Haghverdi 2014</a>; <a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a>). </p> </li> <li> <p>BMD was assessed in all studies.</p> <ul id="CD013424-list-0016"> <li> <p>BMD at femoral neck: <a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a>; <a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>; <a href="./references#CD013424-bbs2-0005" title="HaghverdiF , FarbodaraT , MortajiS , SoltaniP , SaidiN . Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5 [Erratum in: Iran J Kidney Dis. 2015 Jan;9(1):76; PMID: 25599744]. Iranian Journal of Kidney Diseases2014;8(6):461-6. [MEDLINE: 25362221]">Haghverdi 2014</a>; <a href="./references#CD013424-bbs2-0006" title="HeilbergIP , HernandezE , AlonzoE , ValeraR , FerreiraLG , GomesSA , et al. Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. Renal Failure2005;27(2):155-61. [MEDLINE: 15807179]HernandezE , ValeraR , AlonzoE , Bajares-LilueM , CarliniR , CaprilesF , et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney International2003;63(6):2269-74. [MEDLINE: 12753317]HernandezE , ValeraR , TeranJ , Bajares-LilueM , CapriilesF , AlonzoE , et al. The effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone resorption markers and serum lipids in postmenopausal women on chronic hemodialysis (HD) [abstract no: A2974]. Journal of the American Society of Nephrology2000;11(Sept):563-4A. [CENTRAL: CN-00550530] HernandezE , ValeraR , TeranJ , Bajares-LilueM , CaprilesF , AlonzoE , et al. One year controlled study on the effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone metabolism and serum lipids on postmenopausal women on chronic hemodialysis (HD) [abstract no: A3879]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):743A. [CENTRAL: CN-00550533] Weisinger, JR, HeilbergIP , HernandezE , CarliniR , Bellorin-FontE . Selective estrogen receptor modulators in chronic renal failure. Kidney International - Supplement2003;63(85):S62-5. [MEDLINE: 12753268]">Hernandez 2003</a>; <a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a> </p> </li> <li> <p>BMD at lumbar spine: <a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a>; <a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>; <a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a>; <a href="./references#CD013424-bbs2-0004" title="BoonenS , MarinF , MellstromD , XieL , DesaiahD , KregeJH , et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Journal of the American Geriatrics Society2006;54(5):782-9. [MEDLINE: 16696744]ChenP , MillerPD , DelmasPD , MisurskiDA , KregeJH . Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. Journal of Bone &amp; Mineral Research2006;21(11):1785-90. [MEDLINE: 17002571]CransGG , SilvermanSL , GenantHK , GlassEV , KregeJH . Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. Arthritis &amp; Rheumatism2004;50(12):4028-34. [MEDLINE: 15593198]Dawson-HughesB , ChenP , KregeJH . Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. Journal of Clinical Endocrinology &amp; Metabolism2007;92(12):4630-6. [MEDLINE: 17911178]DelmasPD , LicataAA , ReginsterJY , CransGG , ChenP , MisurskiDA , et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone2006;39(2):237-43. [MEDLINE: 16563890]GallagherJC , GenantHK , CransGG , VargasSJ , KregeJH . Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1583-7. [MEDLINE: 15613428]GenantHK , HalseJ , BrineyWG , XieL , GlassEV , KregeJH . The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Current Medical Research &amp; Opinion2005;21(7):1027-34. [MEDLINE: 16004669]GenantHK , SirisE , CransGG , DesaiahD , KregeJH . Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone2005;37(2):170-4. [MEDLINE: 15961357]JiangY , ZhaoJJ , MitlakBH , WangO , GenantHK , EriksenEF . Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. Journal of Bone &amp; Mineral Research2003;18(11):1932-41. [MEDLINE: 14606504]KregeJH , WanX . Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone2012;50(1):161-4. [MEDLINE: 22036910]MillerPD , SchwartzEN , ChenP , MisurskiDA , KregeJH . Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis International2007;18(1):59-68. [MEDLINE: 17013567]NeerRM , ArnaudCD , ZanchettaJR , PrinceR , GaichGA , ReginsterJY , et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal Medicine2001;344(19):1434-41. [MEDLINE: 11346808]PaschalisEP , GlassEV , DonleyDW , EriksenEF . Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial. Journal of Clinical Endocrinology &amp; Metabolism2005;90(8):4644-9. [MEDLINE: 15914535]SatterwhiteJ , HeathmanM , MillerPD , MarinF , GlassEV , DobnigH . Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcified Tissue International2010;87(6):485-92. [MEDLINE: 20953593]SilvermanSL , PiziakVK , ChenP , MisurskiDA , WagmanRB . Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. Journal of Rheumatology2005;32(12):2405-9. [MEDLINE: 16331772]Uusi-RasiK , SemanickLM , ZanchettaJR , BogadoCE , EriksenEF , SatoM , et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone2005;36(6):948-58. [MEDLINE: 15878318]WattsNB , MillerPD , KohlmeierLA , SebbaA , ChenP , WongM , et al. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. Journal of Bone &amp; Mineral Research2009;24(6):1125-31. [MEDLINE: 19113918]">FTP 2001</a>; <a href="./references#CD013424-bbs2-0005" title="HaghverdiF , FarbodaraT , MortajiS , SoltaniP , SaidiN . Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5 [Erratum in: Iran J Kidney Dis. 2015 Jan;9(1):76; PMID: 25599744]. Iranian Journal of Kidney Diseases2014;8(6):461-6. [MEDLINE: 25362221]">Haghverdi 2014</a>; <a href="./references#CD013424-bbs2-0006" title="HeilbergIP , HernandezE , AlonzoE , ValeraR , FerreiraLG , GomesSA , et al. Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. Renal Failure2005;27(2):155-61. [MEDLINE: 15807179]HernandezE , ValeraR , AlonzoE , Bajares-LilueM , CarliniR , CaprilesF , et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney International2003;63(6):2269-74. [MEDLINE: 12753317]HernandezE , ValeraR , TeranJ , Bajares-LilueM , CapriilesF , AlonzoE , et al. The effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone resorption markers and serum lipids in postmenopausal women on chronic hemodialysis (HD) [abstract no: A2974]. Journal of the American Society of Nephrology2000;11(Sept):563-4A. [CENTRAL: CN-00550530] HernandezE , ValeraR , TeranJ , Bajares-LilueM , CaprilesF , AlonzoE , et al. One year controlled study on the effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone metabolism and serum lipids on postmenopausal women on chronic hemodialysis (HD) [abstract no: A3879]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):743A. [CENTRAL: CN-00550533] Weisinger, JR, HeilbergIP , HernandezE , CarliniR , Bellorin-FontE . Selective estrogen receptor modulators in chronic renal failure. Kidney International - Supplement2003;63(85):S62-5. [MEDLINE: 12753268]">Hernandez 2003</a>; <a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a> </p> </li> <li> <p>BMD at total hip: <a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a>; <a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>; <a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a> </p> </li> </ul> </li> <li> <p>Adverse events were reported in all studies</p> </li> <li> <p>SONG outcomes</p> <ul id="CD013424-list-0017"> <li> <p>Death was reported in four studies (5,664 participants) (<a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>; <a href="./references#CD013424-bbs2-0005" title="HaghverdiF , FarbodaraT , MortajiS , SoltaniP , SaidiN . Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5 [Erratum in: Iran J Kidney Dis. 2015 Jan;9(1):76; PMID: 25599744]. Iranian Journal of Kidney Diseases2014;8(6):461-6. [MEDLINE: 25362221]">Haghverdi 2014</a>; <a href="./references#CD013424-bbs2-0006" title="HeilbergIP , HernandezE , AlonzoE , ValeraR , FerreiraLG , GomesSA , et al. Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. Renal Failure2005;27(2):155-61. [MEDLINE: 15807179]HernandezE , ValeraR , AlonzoE , Bajares-LilueM , CarliniR , CaprilesF , et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney International2003;63(6):2269-74. [MEDLINE: 12753317]HernandezE , ValeraR , TeranJ , Bajares-LilueM , CapriilesF , AlonzoE , et al. The effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone resorption markers and serum lipids in postmenopausal women on chronic hemodialysis (HD) [abstract no: A2974]. Journal of the American Society of Nephrology2000;11(Sept):563-4A. [CENTRAL: CN-00550530] HernandezE , ValeraR , TeranJ , Bajares-LilueM , CaprilesF , AlonzoE , et al. One year controlled study on the effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone metabolism and serum lipids on postmenopausal women on chronic hemodialysis (HD) [abstract no: A3879]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):743A. [CENTRAL: CN-00550533] Weisinger, JR, HeilbergIP , HernandezE , CarliniR , Bellorin-FontE . Selective estrogen receptor modulators in chronic renal failure. Kidney International - Supplement2003;63(85):S62-5. [MEDLINE: 12753268]">Hernandez 2003</a>; <a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a>) </p> </li> <li> <p>Cardiovascular and cerebrovascular morbidity were reported in two studies (3,471 participants) reported (<a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>; <a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a>) </p> </li> <li> <p>Life participation was not reported</p> </li> <li> <p>Fatigue score was not reported</p> </li> <li> <p>Vascular access failure was reported in two studies (110 participants) (<a href="./references#CD013424-bbs2-0005" title="HaghverdiF , FarbodaraT , MortajiS , SoltaniP , SaidiN . Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5 [Erratum in: Iran J Kidney Dis. 2015 Jan;9(1):76; PMID: 25599744]. Iranian Journal of Kidney Diseases2014;8(6):461-6. [MEDLINE: 25362221]">Haghverdi 2014</a>; <a href="./references#CD013424-bbs2-0006" title="HeilbergIP , HernandezE , AlonzoE , ValeraR , FerreiraLG , GomesSA , et al. Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. Renal Failure2005;27(2):155-61. [MEDLINE: 15807179]HernandezE , ValeraR , AlonzoE , Bajares-LilueM , CarliniR , CaprilesF , et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney International2003;63(6):2269-74. [MEDLINE: 12753317]HernandezE , ValeraR , TeranJ , Bajares-LilueM , CapriilesF , AlonzoE , et al. The effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone resorption markers and serum lipids in postmenopausal women on chronic hemodialysis (HD) [abstract no: A2974]. Journal of the American Society of Nephrology2000;11(Sept):563-4A. [CENTRAL: CN-00550530] HernandezE , ValeraR , TeranJ , Bajares-LilueM , CaprilesF , AlonzoE , et al. One year controlled study on the effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone metabolism and serum lipids on postmenopausal women on chronic hemodialysis (HD) [abstract no: A3879]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):743A. [CENTRAL: CN-00550533] Weisinger, JR, HeilbergIP , HernandezE , CarliniR , Bellorin-FontE . Selective estrogen receptor modulators in chronic renal failure. Kidney International - Supplement2003;63(85):S62-5. [MEDLINE: 12753268]">Hernandez 2003</a>) </p> </li> <li> <p>PD‐related infections were not reported</p> </li> <li> <p>PD failure was not reported</p> </li> <li> <p>QoL was not reported</p> </li> </ul> </li> <li> <p>Serum levels of intact PTH, calcium, phosphorus, and alkaline phosphatase (total) were reported by one study (60 participants) (<a href="./references#CD013424-bbs2-0005" title="HaghverdiF , FarbodaraT , MortajiS , SoltaniP , SaidiN . Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5 [Erratum in: Iran J Kidney Dis. 2015 Jan;9(1):76; PMID: 25599744]. Iranian Journal of Kidney Diseases2014;8(6):461-6. [MEDLINE: 25362221]">Haghverdi 2014</a>). </p> </li> </ul> </p> </section> </section> <section id="CD013424-sec-0056"> <h4 class="title">Excluded studies</h4> <p>The characteristics of the excluded studies based on full‐text assessment are shown in the <a href="./references#CD013424-sec-0127" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD013424-sec-0057"> <h3 class="title">Risk of bias in included studies</h3> <p>The results of risk of bias assessment of the seven included studies are summarised in <a href="#CD013424-fig-0002">Figure 2</a> and <a href="#CD013424-fig-0003">Figure 3</a>. Two authors independently assessed the included studies for each checklist item as having a high, low, or unclear risk of bias. </p> <div class="figure" id="CD013424-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013424-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD013424-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013424-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD013424-sec-0058"> <h4 class="title">Allocation</h4> <section id="CD013424-sec-0059"> <h5 class="title">Random sequence generation</h5> <p>Two studies (<a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a>; <a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>) used a computer‐generated random sequence. The remaining five studies (<a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a>; <a href="./references#CD013424-bbs2-0004" title="BoonenS , MarinF , MellstromD , XieL , DesaiahD , KregeJH , et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Journal of the American Geriatrics Society2006;54(5):782-9. [MEDLINE: 16696744]ChenP , MillerPD , DelmasPD , MisurskiDA , KregeJH . Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. Journal of Bone &amp; Mineral Research2006;21(11):1785-90. [MEDLINE: 17002571]CransGG , SilvermanSL , GenantHK , GlassEV , KregeJH . Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. Arthritis &amp; Rheumatism2004;50(12):4028-34. [MEDLINE: 15593198]Dawson-HughesB , ChenP , KregeJH . Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. Journal of Clinical Endocrinology &amp; Metabolism2007;92(12):4630-6. [MEDLINE: 17911178]DelmasPD , LicataAA , ReginsterJY , CransGG , ChenP , MisurskiDA , et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone2006;39(2):237-43. [MEDLINE: 16563890]GallagherJC , GenantHK , CransGG , VargasSJ , KregeJH . Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1583-7. [MEDLINE: 15613428]GenantHK , HalseJ , BrineyWG , XieL , GlassEV , KregeJH . The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Current Medical Research &amp; Opinion2005;21(7):1027-34. [MEDLINE: 16004669]GenantHK , SirisE , CransGG , DesaiahD , KregeJH . Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone2005;37(2):170-4. [MEDLINE: 15961357]JiangY , ZhaoJJ , MitlakBH , WangO , GenantHK , EriksenEF . Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. Journal of Bone &amp; Mineral Research2003;18(11):1932-41. [MEDLINE: 14606504]KregeJH , WanX . Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone2012;50(1):161-4. [MEDLINE: 22036910]MillerPD , SchwartzEN , ChenP , MisurskiDA , KregeJH . Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis International2007;18(1):59-68. [MEDLINE: 17013567]NeerRM , ArnaudCD , ZanchettaJR , PrinceR , GaichGA , ReginsterJY , et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal Medicine2001;344(19):1434-41. [MEDLINE: 11346808]PaschalisEP , GlassEV , DonleyDW , EriksenEF . Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial. Journal of Clinical Endocrinology &amp; Metabolism2005;90(8):4644-9. [MEDLINE: 15914535]SatterwhiteJ , HeathmanM , MillerPD , MarinF , GlassEV , DobnigH . Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcified Tissue International2010;87(6):485-92. [MEDLINE: 20953593]SilvermanSL , PiziakVK , ChenP , MisurskiDA , WagmanRB . Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. Journal of Rheumatology2005;32(12):2405-9. [MEDLINE: 16331772]Uusi-RasiK , SemanickLM , ZanchettaJR , BogadoCE , EriksenEF , SatoM , et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone2005;36(6):948-58. [MEDLINE: 15878318]WattsNB , MillerPD , KohlmeierLA , SebbaA , ChenP , WongM , et al. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. Journal of Bone &amp; Mineral Research2009;24(6):1125-31. [MEDLINE: 19113918]">FTP 2001</a>; <a href="./references#CD013424-bbs2-0005" title="HaghverdiF , FarbodaraT , MortajiS , SoltaniP , SaidiN . Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5 [Erratum in: Iran J Kidney Dis. 2015 Jan;9(1):76; PMID: 25599744]. Iranian Journal of Kidney Diseases2014;8(6):461-6. [MEDLINE: 25362221]">Haghverdi 2014</a>; <a href="./references#CD013424-bbs2-0006" title="HeilbergIP , HernandezE , AlonzoE , ValeraR , FerreiraLG , GomesSA , et al. Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. Renal Failure2005;27(2):155-61. [MEDLINE: 15807179]HernandezE , ValeraR , AlonzoE , Bajares-LilueM , CarliniR , CaprilesF , et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney International2003;63(6):2269-74. [MEDLINE: 12753317]HernandezE , ValeraR , TeranJ , Bajares-LilueM , CapriilesF , AlonzoE , et al. The effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone resorption markers and serum lipids in postmenopausal women on chronic hemodialysis (HD) [abstract no: A2974]. Journal of the American Society of Nephrology2000;11(Sept):563-4A. [CENTRAL: CN-00550530] HernandezE , ValeraR , TeranJ , Bajares-LilueM , CaprilesF , AlonzoE , et al. One year controlled study on the effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone metabolism and serum lipids on postmenopausal women on chronic hemodialysis (HD) [abstract no: A3879]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):743A. [CENTRAL: CN-00550533] Weisinger, JR, HeilbergIP , HernandezE , CarliniR , Bellorin-FontE . Selective estrogen receptor modulators in chronic renal failure. Kidney International - Supplement2003;63(85):S62-5. [MEDLINE: 12753268]">Hernandez 2003</a>; <a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a>) did not indicate the randomisation methods and were therefore categorised as unclear. </p> <p>We used a subset of data from these five studies (<a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a>; <a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>; <a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a>; <a href="./references#CD013424-bbs2-0004" title="BoonenS , MarinF , MellstromD , XieL , DesaiahD , KregeJH , et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Journal of the American Geriatrics Society2006;54(5):782-9. [MEDLINE: 16696744]ChenP , MillerPD , DelmasPD , MisurskiDA , KregeJH . Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. Journal of Bone &amp; Mineral Research2006;21(11):1785-90. [MEDLINE: 17002571]CransGG , SilvermanSL , GenantHK , GlassEV , KregeJH . Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. Arthritis &amp; Rheumatism2004;50(12):4028-34. [MEDLINE: 15593198]Dawson-HughesB , ChenP , KregeJH . Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. Journal of Clinical Endocrinology &amp; Metabolism2007;92(12):4630-6. [MEDLINE: 17911178]DelmasPD , LicataAA , ReginsterJY , CransGG , ChenP , MisurskiDA , et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone2006;39(2):237-43. [MEDLINE: 16563890]GallagherJC , GenantHK , CransGG , VargasSJ , KregeJH . Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1583-7. [MEDLINE: 15613428]GenantHK , HalseJ , BrineyWG , XieL , GlassEV , KregeJH . The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Current Medical Research &amp; Opinion2005;21(7):1027-34. [MEDLINE: 16004669]GenantHK , SirisE , CransGG , DesaiahD , KregeJH . Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone2005;37(2):170-4. [MEDLINE: 15961357]JiangY , ZhaoJJ , MitlakBH , WangO , GenantHK , EriksenEF . Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. Journal of Bone &amp; Mineral Research2003;18(11):1932-41. [MEDLINE: 14606504]KregeJH , WanX . Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone2012;50(1):161-4. [MEDLINE: 22036910]MillerPD , SchwartzEN , ChenP , MisurskiDA , KregeJH . Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis International2007;18(1):59-68. [MEDLINE: 17013567]NeerRM , ArnaudCD , ZanchettaJR , PrinceR , GaichGA , ReginsterJY , et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal Medicine2001;344(19):1434-41. [MEDLINE: 11346808]PaschalisEP , GlassEV , DonleyDW , EriksenEF . Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial. Journal of Clinical Endocrinology &amp; Metabolism2005;90(8):4644-9. [MEDLINE: 15914535]SatterwhiteJ , HeathmanM , MillerPD , MarinF , GlassEV , DobnigH . Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcified Tissue International2010;87(6):485-92. [MEDLINE: 20953593]SilvermanSL , PiziakVK , ChenP , MisurskiDA , WagmanRB . Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. Journal of Rheumatology2005;32(12):2405-9. [MEDLINE: 16331772]Uusi-RasiK , SemanickLM , ZanchettaJR , BogadoCE , EriksenEF , SatoM , et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone2005;36(6):948-58. [MEDLINE: 15878318]WattsNB , MillerPD , KohlmeierLA , SebbaA , ChenP , WongM , et al. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. Journal of Bone &amp; Mineral Research2009;24(6):1125-31. [MEDLINE: 19113918]">FTP 2001</a>; <a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a>), which also enrolled postmenopausal women with normal kidney function. The number of patients with CKD in each study was as follows. </p> <p> <ul id="CD013424-list-0018"> <li> <p><a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a>: 527/2,463 (21.4%) </p> </li> <li> <p><a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>: 581/2,027 (28.7%) </p> </li> <li> <p><a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a>: 2,890/7,868 (36.7%) </p> </li> <li> <p><a href="./references#CD013424-bbs2-0004" title="BoonenS , MarinF , MellstromD , XieL , DesaiahD , KregeJH , et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Journal of the American Geriatrics Society2006;54(5):782-9. [MEDLINE: 16696744]ChenP , MillerPD , DelmasPD , MisurskiDA , KregeJH . Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. Journal of Bone &amp; Mineral Research2006;21(11):1785-90. [MEDLINE: 17002571]CransGG , SilvermanSL , GenantHK , GlassEV , KregeJH . Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. Arthritis &amp; Rheumatism2004;50(12):4028-34. [MEDLINE: 15593198]Dawson-HughesB , ChenP , KregeJH . Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. Journal of Clinical Endocrinology &amp; Metabolism2007;92(12):4630-6. [MEDLINE: 17911178]DelmasPD , LicataAA , ReginsterJY , CransGG , ChenP , MisurskiDA , et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone2006;39(2):237-43. [MEDLINE: 16563890]GallagherJC , GenantHK , CransGG , VargasSJ , KregeJH . Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1583-7. [MEDLINE: 15613428]GenantHK , HalseJ , BrineyWG , XieL , GlassEV , KregeJH . The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Current Medical Research &amp; Opinion2005;21(7):1027-34. [MEDLINE: 16004669]GenantHK , SirisE , CransGG , DesaiahD , KregeJH . Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone2005;37(2):170-4. [MEDLINE: 15961357]JiangY , ZhaoJJ , MitlakBH , WangO , GenantHK , EriksenEF . Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. Journal of Bone &amp; Mineral Research2003;18(11):1932-41. [MEDLINE: 14606504]KregeJH , WanX . Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone2012;50(1):161-4. [MEDLINE: 22036910]MillerPD , SchwartzEN , ChenP , MisurskiDA , KregeJH . Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis International2007;18(1):59-68. [MEDLINE: 17013567]NeerRM , ArnaudCD , ZanchettaJR , PrinceR , GaichGA , ReginsterJY , et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal Medicine2001;344(19):1434-41. [MEDLINE: 11346808]PaschalisEP , GlassEV , DonleyDW , EriksenEF . Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial. Journal of Clinical Endocrinology &amp; Metabolism2005;90(8):4644-9. [MEDLINE: 15914535]SatterwhiteJ , HeathmanM , MillerPD , MarinF , GlassEV , DobnigH . Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcified Tissue International2010;87(6):485-92. [MEDLINE: 20953593]SilvermanSL , PiziakVK , ChenP , MisurskiDA , WagmanRB . Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. Journal of Rheumatology2005;32(12):2405-9. [MEDLINE: 16331772]Uusi-RasiK , SemanickLM , ZanchettaJR , BogadoCE , EriksenEF , SatoM , et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone2005;36(6):948-58. [MEDLINE: 15878318]WattsNB , MillerPD , KohlmeierLA , SebbaA , ChenP , WongM , et al. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. Journal of Bone &amp; Mineral Research2009;24(6):1125-31. [MEDLINE: 19113918]">FTP 2001</a>: 83/1,637 (5.1%) </p> </li> <li> <p><a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a>: 4,973/7,705 (64.5%). </p> </li> </ul> </p> <p><a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a> and <a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a> determined that the balance of the allocated groups was maintained because the number of extracted participants from each study was acceptable. </p> </section> <section id="CD013424-sec-0060"> <h5 class="title">Allocation concealment</h5> <p>Two studies (<a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a>; <a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>) used central randomisation, whereas no information was included in the other five studies, which were categorised as unclear. </p> </section> </section> <section id="CD013424-sec-0061"> <h4 class="title">Blinding</h4> <section id="CD013424-sec-0062"> <h5 class="title">Performance bias</h5> <p>All studies reported adequate double‐blinding procedures (<a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a>; <a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>; <a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a>; <a href="./references#CD013424-bbs2-0004" title="BoonenS , MarinF , MellstromD , XieL , DesaiahD , KregeJH , et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Journal of the American Geriatrics Society2006;54(5):782-9. [MEDLINE: 16696744]ChenP , MillerPD , DelmasPD , MisurskiDA , KregeJH . Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. Journal of Bone &amp; Mineral Research2006;21(11):1785-90. [MEDLINE: 17002571]CransGG , SilvermanSL , GenantHK , GlassEV , KregeJH . Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. Arthritis &amp; Rheumatism2004;50(12):4028-34. [MEDLINE: 15593198]Dawson-HughesB , ChenP , KregeJH . Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. Journal of Clinical Endocrinology &amp; Metabolism2007;92(12):4630-6. [MEDLINE: 17911178]DelmasPD , LicataAA , ReginsterJY , CransGG , ChenP , MisurskiDA , et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone2006;39(2):237-43. [MEDLINE: 16563890]GallagherJC , GenantHK , CransGG , VargasSJ , KregeJH . Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1583-7. [MEDLINE: 15613428]GenantHK , HalseJ , BrineyWG , XieL , GlassEV , KregeJH . The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Current Medical Research &amp; Opinion2005;21(7):1027-34. [MEDLINE: 16004669]GenantHK , SirisE , CransGG , DesaiahD , KregeJH . Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone2005;37(2):170-4. [MEDLINE: 15961357]JiangY , ZhaoJJ , MitlakBH , WangO , GenantHK , EriksenEF . Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. Journal of Bone &amp; Mineral Research2003;18(11):1932-41. [MEDLINE: 14606504]KregeJH , WanX . Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone2012;50(1):161-4. [MEDLINE: 22036910]MillerPD , SchwartzEN , ChenP , MisurskiDA , KregeJH . Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis International2007;18(1):59-68. [MEDLINE: 17013567]NeerRM , ArnaudCD , ZanchettaJR , PrinceR , GaichGA , ReginsterJY , et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal Medicine2001;344(19):1434-41. [MEDLINE: 11346808]PaschalisEP , GlassEV , DonleyDW , EriksenEF . Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial. Journal of Clinical Endocrinology &amp; Metabolism2005;90(8):4644-9. [MEDLINE: 15914535]SatterwhiteJ , HeathmanM , MillerPD , MarinF , GlassEV , DobnigH . Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcified Tissue International2010;87(6):485-92. [MEDLINE: 20953593]SilvermanSL , PiziakVK , ChenP , MisurskiDA , WagmanRB . Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. Journal of Rheumatology2005;32(12):2405-9. [MEDLINE: 16331772]Uusi-RasiK , SemanickLM , ZanchettaJR , BogadoCE , EriksenEF , SatoM , et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone2005;36(6):948-58. [MEDLINE: 15878318]WattsNB , MillerPD , KohlmeierLA , SebbaA , ChenP , WongM , et al. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. Journal of Bone &amp; Mineral Research2009;24(6):1125-31. [MEDLINE: 19113918]">FTP 2001</a>; <a href="./references#CD013424-bbs2-0005" title="HaghverdiF , FarbodaraT , MortajiS , SoltaniP , SaidiN . Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5 [Erratum in: Iran J Kidney Dis. 2015 Jan;9(1):76; PMID: 25599744]. Iranian Journal of Kidney Diseases2014;8(6):461-6. [MEDLINE: 25362221]">Haghverdi 2014</a>; <a href="./references#CD013424-bbs2-0006" title="HeilbergIP , HernandezE , AlonzoE , ValeraR , FerreiraLG , GomesSA , et al. Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. Renal Failure2005;27(2):155-61. [MEDLINE: 15807179]HernandezE , ValeraR , AlonzoE , Bajares-LilueM , CarliniR , CaprilesF , et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney International2003;63(6):2269-74. [MEDLINE: 12753317]HernandezE , ValeraR , TeranJ , Bajares-LilueM , CapriilesF , AlonzoE , et al. The effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone resorption markers and serum lipids in postmenopausal women on chronic hemodialysis (HD) [abstract no: A2974]. Journal of the American Society of Nephrology2000;11(Sept):563-4A. [CENTRAL: CN-00550530] HernandezE , ValeraR , TeranJ , Bajares-LilueM , CaprilesF , AlonzoE , et al. One year controlled study on the effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone metabolism and serum lipids on postmenopausal women on chronic hemodialysis (HD) [abstract no: A3879]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):743A. [CENTRAL: CN-00550533] Weisinger, JR, HeilbergIP , HernandezE , CarliniR , Bellorin-FontE . Selective estrogen receptor modulators in chronic renal failure. Kidney International - Supplement2003;63(85):S62-5. [MEDLINE: 12753268]">Hernandez 2003</a>; <a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a>). </p> </section> <section id="CD013424-sec-0063"> <h5 class="title">Detection bias</h5> <p>Outcome assessors were blinded in five studies (<a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a>; <a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>; <a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a>; <a href="./references#CD013424-bbs2-0004" title="BoonenS , MarinF , MellstromD , XieL , DesaiahD , KregeJH , et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Journal of the American Geriatrics Society2006;54(5):782-9. [MEDLINE: 16696744]ChenP , MillerPD , DelmasPD , MisurskiDA , KregeJH . Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. Journal of Bone &amp; Mineral Research2006;21(11):1785-90. [MEDLINE: 17002571]CransGG , SilvermanSL , GenantHK , GlassEV , KregeJH . Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. Arthritis &amp; Rheumatism2004;50(12):4028-34. [MEDLINE: 15593198]Dawson-HughesB , ChenP , KregeJH . Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. Journal of Clinical Endocrinology &amp; Metabolism2007;92(12):4630-6. [MEDLINE: 17911178]DelmasPD , LicataAA , ReginsterJY , CransGG , ChenP , MisurskiDA , et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone2006;39(2):237-43. [MEDLINE: 16563890]GallagherJC , GenantHK , CransGG , VargasSJ , KregeJH . Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1583-7. [MEDLINE: 15613428]GenantHK , HalseJ , BrineyWG , XieL , GlassEV , KregeJH . The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Current Medical Research &amp; Opinion2005;21(7):1027-34. [MEDLINE: 16004669]GenantHK , SirisE , CransGG , DesaiahD , KregeJH . Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone2005;37(2):170-4. [MEDLINE: 15961357]JiangY , ZhaoJJ , MitlakBH , WangO , GenantHK , EriksenEF . Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. Journal of Bone &amp; Mineral Research2003;18(11):1932-41. [MEDLINE: 14606504]KregeJH , WanX . Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone2012;50(1):161-4. [MEDLINE: 22036910]MillerPD , SchwartzEN , ChenP , MisurskiDA , KregeJH . Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis International2007;18(1):59-68. [MEDLINE: 17013567]NeerRM , ArnaudCD , ZanchettaJR , PrinceR , GaichGA , ReginsterJY , et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal Medicine2001;344(19):1434-41. [MEDLINE: 11346808]PaschalisEP , GlassEV , DonleyDW , EriksenEF . Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial. Journal of Clinical Endocrinology &amp; Metabolism2005;90(8):4644-9. [MEDLINE: 15914535]SatterwhiteJ , HeathmanM , MillerPD , MarinF , GlassEV , DobnigH . Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcified Tissue International2010;87(6):485-92. [MEDLINE: 20953593]SilvermanSL , PiziakVK , ChenP , MisurskiDA , WagmanRB . Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. Journal of Rheumatology2005;32(12):2405-9. [MEDLINE: 16331772]Uusi-RasiK , SemanickLM , ZanchettaJR , BogadoCE , EriksenEF , SatoM , et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone2005;36(6):948-58. [MEDLINE: 15878318]WattsNB , MillerPD , KohlmeierLA , SebbaA , ChenP , WongM , et al. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. Journal of Bone &amp; Mineral Research2009;24(6):1125-31. [MEDLINE: 19113918]">FTP 2001</a>; <a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a>). Other studies (<a href="./references#CD013424-bbs2-0005" title="HaghverdiF , FarbodaraT , MortajiS , SoltaniP , SaidiN . Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5 [Erratum in: Iran J Kidney Dis. 2015 Jan;9(1):76; PMID: 25599744]. Iranian Journal of Kidney Diseases2014;8(6):461-6. [MEDLINE: 25362221]">Haghverdi 2014</a>; <a href="./references#CD013424-bbs2-0006" title="HeilbergIP , HernandezE , AlonzoE , ValeraR , FerreiraLG , GomesSA , et al. Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. Renal Failure2005;27(2):155-61. [MEDLINE: 15807179]HernandezE , ValeraR , AlonzoE , Bajares-LilueM , CarliniR , CaprilesF , et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney International2003;63(6):2269-74. [MEDLINE: 12753317]HernandezE , ValeraR , TeranJ , Bajares-LilueM , CapriilesF , AlonzoE , et al. The effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone resorption markers and serum lipids in postmenopausal women on chronic hemodialysis (HD) [abstract no: A2974]. Journal of the American Society of Nephrology2000;11(Sept):563-4A. [CENTRAL: CN-00550530] HernandezE , ValeraR , TeranJ , Bajares-LilueM , CaprilesF , AlonzoE , et al. One year controlled study on the effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone metabolism and serum lipids on postmenopausal women on chronic hemodialysis (HD) [abstract no: A3879]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):743A. [CENTRAL: CN-00550533] Weisinger, JR, HeilbergIP , HernandezE , CarliniR , Bellorin-FontE . Selective estrogen receptor modulators in chronic renal failure. Kidney International - Supplement2003;63(85):S62-5. [MEDLINE: 12753268]">Hernandez 2003</a>) included no description and were categorised as unclear. </p> </section> </section> <section id="CD013424-sec-0064"> <h4 class="title">Incomplete outcome data</h4> <p>For the primary efficacy outcome of fracture events, four studies (<a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a>; <a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>; <a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a>; <a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a>) reported results of the ITT analyses. Two studies (<a href="./references#CD013424-bbs2-0004" title="BoonenS , MarinF , MellstromD , XieL , DesaiahD , KregeJH , et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Journal of the American Geriatrics Society2006;54(5):782-9. [MEDLINE: 16696744]ChenP , MillerPD , DelmasPD , MisurskiDA , KregeJH . Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. Journal of Bone &amp; Mineral Research2006;21(11):1785-90. [MEDLINE: 17002571]CransGG , SilvermanSL , GenantHK , GlassEV , KregeJH . Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. Arthritis &amp; Rheumatism2004;50(12):4028-34. [MEDLINE: 15593198]Dawson-HughesB , ChenP , KregeJH . Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. Journal of Clinical Endocrinology &amp; Metabolism2007;92(12):4630-6. [MEDLINE: 17911178]DelmasPD , LicataAA , ReginsterJY , CransGG , ChenP , MisurskiDA , et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone2006;39(2):237-43. [MEDLINE: 16563890]GallagherJC , GenantHK , CransGG , VargasSJ , KregeJH . Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1583-7. [MEDLINE: 15613428]GenantHK , HalseJ , BrineyWG , XieL , GlassEV , KregeJH . The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Current Medical Research &amp; Opinion2005;21(7):1027-34. [MEDLINE: 16004669]GenantHK , SirisE , CransGG , DesaiahD , KregeJH . Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone2005;37(2):170-4. [MEDLINE: 15961357]JiangY , ZhaoJJ , MitlakBH , WangO , GenantHK , EriksenEF . Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. Journal of Bone &amp; Mineral Research2003;18(11):1932-41. [MEDLINE: 14606504]KregeJH , WanX . Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone2012;50(1):161-4. [MEDLINE: 22036910]MillerPD , SchwartzEN , ChenP , MisurskiDA , KregeJH . Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis International2007;18(1):59-68. [MEDLINE: 17013567]NeerRM , ArnaudCD , ZanchettaJR , PrinceR , GaichGA , ReginsterJY , et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal Medicine2001;344(19):1434-41. [MEDLINE: 11346808]PaschalisEP , GlassEV , DonleyDW , EriksenEF . Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial. Journal of Clinical Endocrinology &amp; Metabolism2005;90(8):4644-9. [MEDLINE: 15914535]SatterwhiteJ , HeathmanM , MillerPD , MarinF , GlassEV , DobnigH . Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcified Tissue International2010;87(6):485-92. [MEDLINE: 20953593]SilvermanSL , PiziakVK , ChenP , MisurskiDA , WagmanRB . Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. Journal of Rheumatology2005;32(12):2405-9. [MEDLINE: 16331772]Uusi-RasiK , SemanickLM , ZanchettaJR , BogadoCE , EriksenEF , SatoM , et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone2005;36(6):948-58. [MEDLINE: 15878318]WattsNB , MillerPD , KohlmeierLA , SebbaA , ChenP , WongM , et al. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. Journal of Bone &amp; Mineral Research2009;24(6):1125-31. [MEDLINE: 19113918]">FTP 2001</a>; <a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a>) were classified as high risk because missing outcome data did not balance the numbers across intervention groups, and these studies excluded more than 10% of participants from the final analysis. The other five studies (<a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a>; <a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>; <a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a>; <a href="./references#CD013424-bbs2-0005" title="HaghverdiF , FarbodaraT , MortajiS , SoltaniP , SaidiN . Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5 [Erratum in: Iran J Kidney Dis. 2015 Jan;9(1):76; PMID: 25599744]. Iranian Journal of Kidney Diseases2014;8(6):461-6. [MEDLINE: 25362221]">Haghverdi 2014</a>; <a href="./references#CD013424-bbs2-0006" title="HeilbergIP , HernandezE , AlonzoE , ValeraR , FerreiraLG , GomesSA , et al. Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. Renal Failure2005;27(2):155-61. [MEDLINE: 15807179]HernandezE , ValeraR , AlonzoE , Bajares-LilueM , CarliniR , CaprilesF , et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney International2003;63(6):2269-74. [MEDLINE: 12753317]HernandezE , ValeraR , TeranJ , Bajares-LilueM , CapriilesF , AlonzoE , et al. The effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone resorption markers and serum lipids in postmenopausal women on chronic hemodialysis (HD) [abstract no: A2974]. Journal of the American Society of Nephrology2000;11(Sept):563-4A. [CENTRAL: CN-00550530] HernandezE , ValeraR , TeranJ , Bajares-LilueM , CaprilesF , AlonzoE , et al. One year controlled study on the effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone metabolism and serum lipids on postmenopausal women on chronic hemodialysis (HD) [abstract no: A3879]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):743A. [CENTRAL: CN-00550533] Weisinger, JR, HeilbergIP , HernandezE , CarliniR , Bellorin-FontE . Selective estrogen receptor modulators in chronic renal failure. Kidney International - Supplement2003;63(85):S62-5. [MEDLINE: 12753268]">Hernandez 2003</a>) were classified as unclear because there was insufficient information for judgement. </p> </section> <section id="CD013424-sec-0065"> <h4 class="title">Selective reporting</h4> <p>Two studies (<a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a>; <a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>) defined the primary efficacy and safety outcomes in the protocols associated with the published manuscripts. Protocols were not available for the other five studies (<a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a>; <a href="./references#CD013424-bbs2-0004" title="BoonenS , MarinF , MellstromD , XieL , DesaiahD , KregeJH , et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Journal of the American Geriatrics Society2006;54(5):782-9. [MEDLINE: 16696744]ChenP , MillerPD , DelmasPD , MisurskiDA , KregeJH . Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. Journal of Bone &amp; Mineral Research2006;21(11):1785-90. [MEDLINE: 17002571]CransGG , SilvermanSL , GenantHK , GlassEV , KregeJH . Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. Arthritis &amp; Rheumatism2004;50(12):4028-34. [MEDLINE: 15593198]Dawson-HughesB , ChenP , KregeJH . Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. Journal of Clinical Endocrinology &amp; Metabolism2007;92(12):4630-6. [MEDLINE: 17911178]DelmasPD , LicataAA , ReginsterJY , CransGG , ChenP , MisurskiDA , et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone2006;39(2):237-43. [MEDLINE: 16563890]GallagherJC , GenantHK , CransGG , VargasSJ , KregeJH . Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1583-7. [MEDLINE: 15613428]GenantHK , HalseJ , BrineyWG , XieL , GlassEV , KregeJH . The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Current Medical Research &amp; Opinion2005;21(7):1027-34. [MEDLINE: 16004669]GenantHK , SirisE , CransGG , DesaiahD , KregeJH . Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone2005;37(2):170-4. [MEDLINE: 15961357]JiangY , ZhaoJJ , MitlakBH , WangO , GenantHK , EriksenEF . Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. Journal of Bone &amp; Mineral Research2003;18(11):1932-41. [MEDLINE: 14606504]KregeJH , WanX . Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone2012;50(1):161-4. [MEDLINE: 22036910]MillerPD , SchwartzEN , ChenP , MisurskiDA , KregeJH . Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis International2007;18(1):59-68. [MEDLINE: 17013567]NeerRM , ArnaudCD , ZanchettaJR , PrinceR , GaichGA , ReginsterJY , et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal Medicine2001;344(19):1434-41. [MEDLINE: 11346808]PaschalisEP , GlassEV , DonleyDW , EriksenEF . Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial. Journal of Clinical Endocrinology &amp; Metabolism2005;90(8):4644-9. [MEDLINE: 15914535]SatterwhiteJ , HeathmanM , MillerPD , MarinF , GlassEV , DobnigH . Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcified Tissue International2010;87(6):485-92. [MEDLINE: 20953593]SilvermanSL , PiziakVK , ChenP , MisurskiDA , WagmanRB . Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. Journal of Rheumatology2005;32(12):2405-9. [MEDLINE: 16331772]Uusi-RasiK , SemanickLM , ZanchettaJR , BogadoCE , EriksenEF , SatoM , et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone2005;36(6):948-58. [MEDLINE: 15878318]WattsNB , MillerPD , KohlmeierLA , SebbaA , ChenP , WongM , et al. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. Journal of Bone &amp; Mineral Research2009;24(6):1125-31. [MEDLINE: 19113918]">FTP 2001</a>; <a href="./references#CD013424-bbs2-0005" title="HaghverdiF , FarbodaraT , MortajiS , SoltaniP , SaidiN . Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5 [Erratum in: Iran J Kidney Dis. 2015 Jan;9(1):76; PMID: 25599744]. Iranian Journal of Kidney Diseases2014;8(6):461-6. [MEDLINE: 25362221]">Haghverdi 2014</a>; <a href="./references#CD013424-bbs2-0006" title="HeilbergIP , HernandezE , AlonzoE , ValeraR , FerreiraLG , GomesSA , et al. Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. Renal Failure2005;27(2):155-61. [MEDLINE: 15807179]HernandezE , ValeraR , AlonzoE , Bajares-LilueM , CarliniR , CaprilesF , et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney International2003;63(6):2269-74. [MEDLINE: 12753317]HernandezE , ValeraR , TeranJ , Bajares-LilueM , CapriilesF , AlonzoE , et al. The effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone resorption markers and serum lipids in postmenopausal women on chronic hemodialysis (HD) [abstract no: A2974]. Journal of the American Society of Nephrology2000;11(Sept):563-4A. [CENTRAL: CN-00550530] HernandezE , ValeraR , TeranJ , Bajares-LilueM , CaprilesF , AlonzoE , et al. One year controlled study on the effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone metabolism and serum lipids on postmenopausal women on chronic hemodialysis (HD) [abstract no: A3879]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):743A. [CENTRAL: CN-00550533] Weisinger, JR, HeilbergIP , HernandezE , CarliniR , Bellorin-FontE . Selective estrogen receptor modulators in chronic renal failure. Kidney International - Supplement2003;63(85):S62-5. [MEDLINE: 12753268]">Hernandez 2003</a>; <a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a>). Only the percent improvement in the treatment groups (no control group data) were reported in four studies for death (<a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>; <a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a>) and BMD (<a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a>; <a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>; <a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a>) Four studies were judged to be at high risk of reporting bias (<a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a>; <a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>; <a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a>; <a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a>) and three studies were judged to have unclear risk of bias (<a href="./references#CD013424-bbs2-0004" title="BoonenS , MarinF , MellstromD , XieL , DesaiahD , KregeJH , et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Journal of the American Geriatrics Society2006;54(5):782-9. [MEDLINE: 16696744]ChenP , MillerPD , DelmasPD , MisurskiDA , KregeJH . Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. Journal of Bone &amp; Mineral Research2006;21(11):1785-90. [MEDLINE: 17002571]CransGG , SilvermanSL , GenantHK , GlassEV , KregeJH . Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. Arthritis &amp; Rheumatism2004;50(12):4028-34. [MEDLINE: 15593198]Dawson-HughesB , ChenP , KregeJH . Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. Journal of Clinical Endocrinology &amp; Metabolism2007;92(12):4630-6. [MEDLINE: 17911178]DelmasPD , LicataAA , ReginsterJY , CransGG , ChenP , MisurskiDA , et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone2006;39(2):237-43. [MEDLINE: 16563890]GallagherJC , GenantHK , CransGG , VargasSJ , KregeJH . Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1583-7. [MEDLINE: 15613428]GenantHK , HalseJ , BrineyWG , XieL , GlassEV , KregeJH . The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Current Medical Research &amp; Opinion2005;21(7):1027-34. [MEDLINE: 16004669]GenantHK , SirisE , CransGG , DesaiahD , KregeJH . Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone2005;37(2):170-4. [MEDLINE: 15961357]JiangY , ZhaoJJ , MitlakBH , WangO , GenantHK , EriksenEF . Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. Journal of Bone &amp; Mineral Research2003;18(11):1932-41. [MEDLINE: 14606504]KregeJH , WanX . Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone2012;50(1):161-4. [MEDLINE: 22036910]MillerPD , SchwartzEN , ChenP , MisurskiDA , KregeJH . Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis International2007;18(1):59-68. [MEDLINE: 17013567]NeerRM , ArnaudCD , ZanchettaJR , PrinceR , GaichGA , ReginsterJY , et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal Medicine2001;344(19):1434-41. [MEDLINE: 11346808]PaschalisEP , GlassEV , DonleyDW , EriksenEF . Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial. Journal of Clinical Endocrinology &amp; Metabolism2005;90(8):4644-9. [MEDLINE: 15914535]SatterwhiteJ , HeathmanM , MillerPD , MarinF , GlassEV , DobnigH . Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcified Tissue International2010;87(6):485-92. [MEDLINE: 20953593]SilvermanSL , PiziakVK , ChenP , MisurskiDA , WagmanRB . Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. Journal of Rheumatology2005;32(12):2405-9. [MEDLINE: 16331772]Uusi-RasiK , SemanickLM , ZanchettaJR , BogadoCE , EriksenEF , SatoM , et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone2005;36(6):948-58. [MEDLINE: 15878318]WattsNB , MillerPD , KohlmeierLA , SebbaA , ChenP , WongM , et al. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. Journal of Bone &amp; Mineral Research2009;24(6):1125-31. [MEDLINE: 19113918]">FTP 2001</a>; <a href="./references#CD013424-bbs2-0005" title="HaghverdiF , FarbodaraT , MortajiS , SoltaniP , SaidiN . Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5 [Erratum in: Iran J Kidney Dis. 2015 Jan;9(1):76; PMID: 25599744]. Iranian Journal of Kidney Diseases2014;8(6):461-6. [MEDLINE: 25362221]">Haghverdi 2014</a>; <a href="./references#CD013424-bbs2-0006" title="HeilbergIP , HernandezE , AlonzoE , ValeraR , FerreiraLG , GomesSA , et al. Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. Renal Failure2005;27(2):155-61. [MEDLINE: 15807179]HernandezE , ValeraR , AlonzoE , Bajares-LilueM , CarliniR , CaprilesF , et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney International2003;63(6):2269-74. [MEDLINE: 12753317]HernandezE , ValeraR , TeranJ , Bajares-LilueM , CapriilesF , AlonzoE , et al. The effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone resorption markers and serum lipids in postmenopausal women on chronic hemodialysis (HD) [abstract no: A2974]. Journal of the American Society of Nephrology2000;11(Sept):563-4A. [CENTRAL: CN-00550530] HernandezE , ValeraR , TeranJ , Bajares-LilueM , CaprilesF , AlonzoE , et al. One year controlled study on the effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone metabolism and serum lipids on postmenopausal women on chronic hemodialysis (HD) [abstract no: A3879]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):743A. [CENTRAL: CN-00550533] Weisinger, JR, HeilbergIP , HernandezE , CarliniR , Bellorin-FontE . Selective estrogen receptor modulators in chronic renal failure. Kidney International - Supplement2003;63(85):S62-5. [MEDLINE: 12753268]">Hernandez 2003</a>). </p> </section> <section id="CD013424-sec-0066"> <h4 class="title">Other potential sources of bias</h4> <p>Six studies were sponsored by pharmaceutical companies (<a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a>; <a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>; <a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a>; <a href="./references#CD013424-bbs2-0004" title="BoonenS , MarinF , MellstromD , XieL , DesaiahD , KregeJH , et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Journal of the American Geriatrics Society2006;54(5):782-9. [MEDLINE: 16696744]ChenP , MillerPD , DelmasPD , MisurskiDA , KregeJH . Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. Journal of Bone &amp; Mineral Research2006;21(11):1785-90. [MEDLINE: 17002571]CransGG , SilvermanSL , GenantHK , GlassEV , KregeJH . Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. Arthritis &amp; Rheumatism2004;50(12):4028-34. [MEDLINE: 15593198]Dawson-HughesB , ChenP , KregeJH . Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. Journal of Clinical Endocrinology &amp; Metabolism2007;92(12):4630-6. [MEDLINE: 17911178]DelmasPD , LicataAA , ReginsterJY , CransGG , ChenP , MisurskiDA , et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone2006;39(2):237-43. [MEDLINE: 16563890]GallagherJC , GenantHK , CransGG , VargasSJ , KregeJH . Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1583-7. [MEDLINE: 15613428]GenantHK , HalseJ , BrineyWG , XieL , GlassEV , KregeJH . The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Current Medical Research &amp; Opinion2005;21(7):1027-34. [MEDLINE: 16004669]GenantHK , SirisE , CransGG , DesaiahD , KregeJH . Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone2005;37(2):170-4. [MEDLINE: 15961357]JiangY , ZhaoJJ , MitlakBH , WangO , GenantHK , EriksenEF . Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. Journal of Bone &amp; Mineral Research2003;18(11):1932-41. [MEDLINE: 14606504]KregeJH , WanX . Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone2012;50(1):161-4. [MEDLINE: 22036910]MillerPD , SchwartzEN , ChenP , MisurskiDA , KregeJH . Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis International2007;18(1):59-68. [MEDLINE: 17013567]NeerRM , ArnaudCD , ZanchettaJR , PrinceR , GaichGA , ReginsterJY , et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal Medicine2001;344(19):1434-41. [MEDLINE: 11346808]PaschalisEP , GlassEV , DonleyDW , EriksenEF . Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial. Journal of Clinical Endocrinology &amp; Metabolism2005;90(8):4644-9. [MEDLINE: 15914535]SatterwhiteJ , HeathmanM , MillerPD , MarinF , GlassEV , DobnigH . Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcified Tissue International2010;87(6):485-92. [MEDLINE: 20953593]SilvermanSL , PiziakVK , ChenP , MisurskiDA , WagmanRB . Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. Journal of Rheumatology2005;32(12):2405-9. [MEDLINE: 16331772]Uusi-RasiK , SemanickLM , ZanchettaJR , BogadoCE , EriksenEF , SatoM , et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone2005;36(6):948-58. [MEDLINE: 15878318]WattsNB , MillerPD , KohlmeierLA , SebbaA , ChenP , WongM , et al. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. Journal of Bone &amp; Mineral Research2009;24(6):1125-31. [MEDLINE: 19113918]">FTP 2001</a>; <a href="./references#CD013424-bbs2-0006" title="HeilbergIP , HernandezE , AlonzoE , ValeraR , FerreiraLG , GomesSA , et al. Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. Renal Failure2005;27(2):155-61. [MEDLINE: 15807179]HernandezE , ValeraR , AlonzoE , Bajares-LilueM , CarliniR , CaprilesF , et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney International2003;63(6):2269-74. [MEDLINE: 12753317]HernandezE , ValeraR , TeranJ , Bajares-LilueM , CapriilesF , AlonzoE , et al. The effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone resorption markers and serum lipids in postmenopausal women on chronic hemodialysis (HD) [abstract no: A2974]. Journal of the American Society of Nephrology2000;11(Sept):563-4A. [CENTRAL: CN-00550530] HernandezE , ValeraR , TeranJ , Bajares-LilueM , CaprilesF , AlonzoE , et al. One year controlled study on the effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone metabolism and serum lipids on postmenopausal women on chronic hemodialysis (HD) [abstract no: A3879]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):743A. [CENTRAL: CN-00550533] Weisinger, JR, HeilbergIP , HernandezE , CarliniR , Bellorin-FontE . Selective estrogen receptor modulators in chronic renal failure. Kidney International - Supplement2003;63(85):S62-5. [MEDLINE: 12753268]">Hernandez 2003</a>; <a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a>). </p> </section> </section> <section id="CD013424-sec-0067"> <h3 class="title" id="CD013424-sec-0067">Effects of interventions</h3> <p>See: <a href="./full#CD013424-tbl-0001"><b>Summary of findings 1</b> Any anti‐osteoporotic drugs versus placebo in postmenopausal women with osteoporosis and CKD stages 3‐4</a>; <a href="./full#CD013424-tbl-0002"><b>Summary of findings 2</b> Raloxifene versus placebo for postmenopausal women with osteoporosis and CKD stages 5 and 5D</a> </p> <p>We were unable to perform the qualitative analysis as planned for the following reasons:</p> <p> <ul id="CD013424-list-0019"> <li> <p>We could not obtain sufficient information on each CKD stage, despite contacting the corresponding authors. </p> </li> <li> <p>Most of the studies reported both vertebral and non‐vertebral or clinical fracture.</p> </li> </ul> </p> <p>These were handled as follows:</p> <p> <ul id="CD013424-list-0020"> <li> <p>Stage of CKD was divided into 2 groups: 1) stages 3‐4, and 2) stages 5 and 5D, based on the study's description/definition. </p> <ul id="CD013424-list-0021"> <li> <p><a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a> reported data separately for stages 3 and 4 </p> </li> <li> <p><a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a> reported data separately for stages 3a and 3b‐4. </p> </li> </ul> </li> <li> <p>We divided “the Fracture at any sites” into “Vertebral fracture by radiography” and “Clinical fracture”. Clinical fracture was defined as any site fractures with fracture‐related symptoms( <a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>). </p> </li> </ul> </p> <p>See: <a href="./full#CD013424-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD013424-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD013424-sec-0068"> <h4 class="title">1. Patients with osteoporosis and CKD stages 3‐4</h4> <p>Five studies were eligible (<a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a>; <a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>; <a href="./references#CD013424-bbs2-0004" title="BoonenS , MarinF , MellstromD , XieL , DesaiahD , KregeJH , et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Journal of the American Geriatrics Society2006;54(5):782-9. [MEDLINE: 16696744]ChenP , MillerPD , DelmasPD , MisurskiDA , KregeJH . Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. Journal of Bone &amp; Mineral Research2006;21(11):1785-90. [MEDLINE: 17002571]CransGG , SilvermanSL , GenantHK , GlassEV , KregeJH . Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. Arthritis &amp; Rheumatism2004;50(12):4028-34. [MEDLINE: 15593198]Dawson-HughesB , ChenP , KregeJH . Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. Journal of Clinical Endocrinology &amp; Metabolism2007;92(12):4630-6. [MEDLINE: 17911178]DelmasPD , LicataAA , ReginsterJY , CransGG , ChenP , MisurskiDA , et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone2006;39(2):237-43. [MEDLINE: 16563890]GallagherJC , GenantHK , CransGG , VargasSJ , KregeJH . Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1583-7. [MEDLINE: 15613428]GenantHK , HalseJ , BrineyWG , XieL , GlassEV , KregeJH . The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Current Medical Research &amp; Opinion2005;21(7):1027-34. [MEDLINE: 16004669]GenantHK , SirisE , CransGG , DesaiahD , KregeJH . Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone2005;37(2):170-4. [MEDLINE: 15961357]JiangY , ZhaoJJ , MitlakBH , WangO , GenantHK , EriksenEF . Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. Journal of Bone &amp; Mineral Research2003;18(11):1932-41. [MEDLINE: 14606504]KregeJH , WanX . Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone2012;50(1):161-4. [MEDLINE: 22036910]MillerPD , SchwartzEN , ChenP , MisurskiDA , KregeJH . Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis International2007;18(1):59-68. [MEDLINE: 17013567]NeerRM , ArnaudCD , ZanchettaJR , PrinceR , GaichGA , ReginsterJY , et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal Medicine2001;344(19):1434-41. [MEDLINE: 11346808]PaschalisEP , GlassEV , DonleyDW , EriksenEF . Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial. Journal of Clinical Endocrinology &amp; Metabolism2005;90(8):4644-9. [MEDLINE: 15914535]SatterwhiteJ , HeathmanM , MillerPD , MarinF , GlassEV , DobnigH . Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcified Tissue International2010;87(6):485-92. [MEDLINE: 20953593]SilvermanSL , PiziakVK , ChenP , MisurskiDA , WagmanRB . Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. Journal of Rheumatology2005;32(12):2405-9. [MEDLINE: 16331772]Uusi-RasiK , SemanickLM , ZanchettaJR , BogadoCE , EriksenEF , SatoM , et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone2005;36(6):948-58. [MEDLINE: 15878318]WattsNB , MillerPD , KohlmeierLA , SebbaA , ChenP , WongM , et al. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. Journal of Bone &amp; Mineral Research2009;24(6):1125-31. [MEDLINE: 19113918]">FTP 2001</a>; <a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a>; <a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a>). The anti‐osteoporotic drugs included were abaloparatide, alendronate, denosumab, teriparatide, and raloxifene. </p> <section id="CD013424-sec-0069"> <h5 class="title">Fracture: vertebral fracture by radiography</h5> <p>In the meta‐analysis using the inverse variance random‐effects model, anti‐osteoporotic drugs may reduce the risk of vertebral fracture (<a href="./references#CD013424-fig-0004" title="">Analysis 1.1</a> (5 studies): RR 0.52, 95% CI 0.39 to 0.69; low certainty evidence). Heterogeneity was moderate (I² = 40%). </p> </section> <section id="CD013424-sec-0070"> <h5 class="title">Fracture<i>:</i> clinical fracture </h5> <p>In the meta‐analysis using the inverse variance random‐effects model, anti‐osteoporotic drugs probably makes little or no difference to the risk of clinical fracture (<a href="./references#CD013424-fig-0005" title="">Analysis 1.2</a> (4 studies): RR 0.91, 95% CI 0.79 to 1.05; moderate certainty evidence). However, we could not incorporate the study of <a href="./references#CD013424-bbs2-0004" title="BoonenS , MarinF , MellstromD , XieL , DesaiahD , KregeJH , et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Journal of the American Geriatrics Society2006;54(5):782-9. [MEDLINE: 16696744]ChenP , MillerPD , DelmasPD , MisurskiDA , KregeJH . Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. Journal of Bone &amp; Mineral Research2006;21(11):1785-90. [MEDLINE: 17002571]CransGG , SilvermanSL , GenantHK , GlassEV , KregeJH . Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. Arthritis &amp; Rheumatism2004;50(12):4028-34. [MEDLINE: 15593198]Dawson-HughesB , ChenP , KregeJH . Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. Journal of Clinical Endocrinology &amp; Metabolism2007;92(12):4630-6. [MEDLINE: 17911178]DelmasPD , LicataAA , ReginsterJY , CransGG , ChenP , MisurskiDA , et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone2006;39(2):237-43. [MEDLINE: 16563890]GallagherJC , GenantHK , CransGG , VargasSJ , KregeJH . Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1583-7. [MEDLINE: 15613428]GenantHK , HalseJ , BrineyWG , XieL , GlassEV , KregeJH . The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Current Medical Research &amp; Opinion2005;21(7):1027-34. [MEDLINE: 16004669]GenantHK , SirisE , CransGG , DesaiahD , KregeJH . Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone2005;37(2):170-4. [MEDLINE: 15961357]JiangY , ZhaoJJ , MitlakBH , WangO , GenantHK , EriksenEF . Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. Journal of Bone &amp; Mineral Research2003;18(11):1932-41. [MEDLINE: 14606504]KregeJH , WanX . Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone2012;50(1):161-4. [MEDLINE: 22036910]MillerPD , SchwartzEN , ChenP , MisurskiDA , KregeJH . Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis International2007;18(1):59-68. [MEDLINE: 17013567]NeerRM , ArnaudCD , ZanchettaJR , PrinceR , GaichGA , ReginsterJY , et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal Medicine2001;344(19):1434-41. [MEDLINE: 11346808]PaschalisEP , GlassEV , DonleyDW , EriksenEF . Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial. Journal of Clinical Endocrinology &amp; Metabolism2005;90(8):4644-9. [MEDLINE: 15914535]SatterwhiteJ , HeathmanM , MillerPD , MarinF , GlassEV , DobnigH . Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcified Tissue International2010;87(6):485-92. [MEDLINE: 20953593]SilvermanSL , PiziakVK , ChenP , MisurskiDA , WagmanRB . Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. Journal of Rheumatology2005;32(12):2405-9. [MEDLINE: 16331772]Uusi-RasiK , SemanickLM , ZanchettaJR , BogadoCE , EriksenEF , SatoM , et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone2005;36(6):948-58. [MEDLINE: 15878318]WattsNB , MillerPD , KohlmeierLA , SebbaA , ChenP , WongM , et al. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. Journal of Bone &amp; Mineral Research2009;24(6):1125-31. [MEDLINE: 19113918]">FTP 2001</a> into the meta‐analysis because no clinical fractures occurred in either the treatment and placebo groups. Heterogeneity was low (I² = 0%). </p> </section> <section id="CD013424-sec-0071"> <h5 class="title">Mean change in BMD</h5> <section id="CD013424-sec-0072"> <h6 class="title">Femoral neck</h6> <p>Three studies (<a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a>; <a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>; <a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a>) (6,081 patients) described the assessment of the BMD at the femoral neck. However, we were unable to incorporate these studies into the meta‐analysis because only the percentage change in the BMD in the treatment group was reported. In the three studies the mean change in BMD of the femoral neck was reported to improve by approximately 0.5% to 5% in the intervention group. The certainty of evidence was very low. </p> </section> <section id="CD013424-sec-0073"> <h6 class="title">Lumbar spine</h6> <p>All five studies (9,054 patients) described the assessment of the BMD at the lumbar spine. However, we were unable to incorporate these studies into the meta‐analysis because only the percentage change in the BMD in the treatment group was reported. In the five studies the mean change in BMD of the lumbar spine was reported to improve by approximately 1% to 15% in the intervention group. The certainty of evidence was very low. </p> </section> <section id="CD013424-sec-0074"> <h6 class="title">Total hip</h6> <p>Three studies (<a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a>; <a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>; <a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a>) (3,998 patients) described the assessment of the BMD at the total hip. However, these studies could not be incorporated into the meta‐analysis because only the percentage change in the BMD in the treatment group was reported. In the three studies the mean change in BMD of the total hip was reported to improve by approximately 5% to 6% in the intervention group. The certainty of evidence was very low. </p> </section> <section id="CD013424-sec-0075"> <h6 class="title">Radius</h6> <p>This outcome was not reported by the included studies.</p> </section> </section> <section id="CD013424-sec-0076"> <h5 class="title">Adverse events</h5> <p>In the meta‐analysis using the inverse variance random‐effects model, the use of anti‐osteoporotic drug probably makes little or no difference to adverse events (<a href="./references#CD013424-fig-0006" title="">Analysis 1.3</a> (4 studies): RR 0.99, 95% CI 0.98 to 1.00; moderate certainty evidence). Heterogeneity was low (I² = 2%). <a href="./references#CD013424-bbs2-0004" title="BoonenS , MarinF , MellstromD , XieL , DesaiahD , KregeJH , et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Journal of the American Geriatrics Society2006;54(5):782-9. [MEDLINE: 16696744]ChenP , MillerPD , DelmasPD , MisurskiDA , KregeJH . Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. Journal of Bone &amp; Mineral Research2006;21(11):1785-90. [MEDLINE: 17002571]CransGG , SilvermanSL , GenantHK , GlassEV , KregeJH . Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. Arthritis &amp; Rheumatism2004;50(12):4028-34. [MEDLINE: 15593198]Dawson-HughesB , ChenP , KregeJH . Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. Journal of Clinical Endocrinology &amp; Metabolism2007;92(12):4630-6. [MEDLINE: 17911178]DelmasPD , LicataAA , ReginsterJY , CransGG , ChenP , MisurskiDA , et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone2006;39(2):237-43. [MEDLINE: 16563890]GallagherJC , GenantHK , CransGG , VargasSJ , KregeJH . Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1583-7. [MEDLINE: 15613428]GenantHK , HalseJ , BrineyWG , XieL , GlassEV , KregeJH . The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Current Medical Research &amp; Opinion2005;21(7):1027-34. [MEDLINE: 16004669]GenantHK , SirisE , CransGG , DesaiahD , KregeJH . Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone2005;37(2):170-4. [MEDLINE: 15961357]JiangY , ZhaoJJ , MitlakBH , WangO , GenantHK , EriksenEF . Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. Journal of Bone &amp; Mineral Research2003;18(11):1932-41. [MEDLINE: 14606504]KregeJH , WanX . Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone2012;50(1):161-4. [MEDLINE: 22036910]MillerPD , SchwartzEN , ChenP , MisurskiDA , KregeJH . Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis International2007;18(1):59-68. [MEDLINE: 17013567]NeerRM , ArnaudCD , ZanchettaJR , PrinceR , GaichGA , ReginsterJY , et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal Medicine2001;344(19):1434-41. [MEDLINE: 11346808]PaschalisEP , GlassEV , DonleyDW , EriksenEF . Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial. Journal of Clinical Endocrinology &amp; Metabolism2005;90(8):4644-9. [MEDLINE: 15914535]SatterwhiteJ , HeathmanM , MillerPD , MarinF , GlassEV , DobnigH . Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcified Tissue International2010;87(6):485-92. [MEDLINE: 20953593]SilvermanSL , PiziakVK , ChenP , MisurskiDA , WagmanRB . Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. Journal of Rheumatology2005;32(12):2405-9. [MEDLINE: 16331772]Uusi-RasiK , SemanickLM , ZanchettaJR , BogadoCE , EriksenEF , SatoM , et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone2005;36(6):948-58. [MEDLINE: 15878318]WattsNB , MillerPD , KohlmeierLA , SebbaA , ChenP , WongM , et al. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. Journal of Bone &amp; Mineral Research2009;24(6):1125-31. [MEDLINE: 19113918]">FTP 2001</a> could not be incorporated into the meta‐analysis but reported adverse events were observed in 99.1% of all study patients (576/581). </p> </section> <section id="CD013424-sec-0077"> <h5 class="title">Death (any cause)</h5> <p><a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a> and <a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a> (5,554 patients) reported death, however they could not be incorporated into the meta‐analysis because only the total number of deaths was reported. The death in these studies ranged from 0.7% to 1.6%. The certainty of evidence was low. </p> </section> <section id="CD013424-sec-0078"> <h5 class="title">Cardiovascular and cerebrovascular morbidity</h5> <p><a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a> and <a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a> (3,471 patients) assessed cardiovascular and cerebrovascular morbidity. However, <a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a> could not be incorporated into the meta‐analysis because it only reported total cardiovascular or cerebrovascular events (cardiovascular events 2.6% and cerebrovascular events 2.2%). Denosumab probably makes little or no difference to cardiovascular and cerebrovascular morbidity (<a href="./references#CD013424-fig-0007" title="">Analysis 1.4</a> (1 study, 8,281 participants): RR 1.00, 95% CI 0.75 to 1.32; moderate certainty evidence). </p> </section> <section id="CD013424-sec-0079"> <h5 class="title">Quality of life</h5> <p>QoL was not reported by the included studies.</p> </section> <section id="CD013424-sec-0080"> <h5 class="title">Bone markers</h5> <p>Bone markers were not reported by the included studies.</p> </section> </section> <section id="CD013424-sec-0081"> <h4 class="title">2. Patients with osteoporosis and CKD stages 5 and 5D</h4> <p>Two eligible studies were identified (<a href="./references#CD013424-bbs2-0005" title="HaghverdiF , FarbodaraT , MortajiS , SoltaniP , SaidiN . Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5 [Erratum in: Iran J Kidney Dis. 2015 Jan;9(1):76; PMID: 25599744]. Iranian Journal of Kidney Diseases2014;8(6):461-6. [MEDLINE: 25362221]">Haghverdi 2014</a>; <a href="./references#CD013424-bbs2-0006" title="HeilbergIP , HernandezE , AlonzoE , ValeraR , FerreiraLG , GomesSA , et al. Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. Renal Failure2005;27(2):155-61. [MEDLINE: 15807179]HernandezE , ValeraR , AlonzoE , Bajares-LilueM , CarliniR , CaprilesF , et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney International2003;63(6):2269-74. [MEDLINE: 12753317]HernandezE , ValeraR , TeranJ , Bajares-LilueM , CapriilesF , AlonzoE , et al. The effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone resorption markers and serum lipids in postmenopausal women on chronic hemodialysis (HD) [abstract no: A2974]. Journal of the American Society of Nephrology2000;11(Sept):563-4A. [CENTRAL: CN-00550530] HernandezE , ValeraR , TeranJ , Bajares-LilueM , CaprilesF , AlonzoE , et al. One year controlled study on the effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone metabolism and serum lipids on postmenopausal women on chronic hemodialysis (HD) [abstract no: A3879]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):743A. [CENTRAL: CN-00550533] Weisinger, JR, HeilbergIP , HernandezE , CarliniR , Bellorin-FontE . Selective estrogen receptor modulators in chronic renal failure. Kidney International - Supplement2003;63(85):S62-5. [MEDLINE: 12753268]">Hernandez 2003</a>), both evaluated raloxifene. </p> <section id="CD013424-sec-0082"> <h5 class="title">Fracture<i>:</i> vertebral fracture evidenced by radiography </h5> <p>Vertebral fracture identified by radiography was not reported by the included studies.</p> </section> <section id="CD013424-sec-0083"> <h5 class="title">Fracture: clinical fracture</h5> <p><a href="./references#CD013424-bbs2-0005" title="HaghverdiF , FarbodaraT , MortajiS , SoltaniP , SaidiN . Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5 [Erratum in: Iran J Kidney Dis. 2015 Jan;9(1):76; PMID: 25599744]. Iranian Journal of Kidney Diseases2014;8(6):461-6. [MEDLINE: 25362221]">Haghverdi 2014</a> reported it is uncertain whether raloxifene reduces the risk of clinical fracture (<a href="./references#CD013424-fig-0008" title="">Analysis 2.1</a>: RR 0.33, 95% CI 0.01 to 7.87; very low certainty evidence). </p> </section> <section id="CD013424-sec-0084"> <h5 class="title">Mean change in the BMD</h5> <section id="CD013424-sec-0085"> <h6 class="title">Femoral neck</h6> <p>It is uncertain whether raloxifene improves the BMD at the femoral neck (<a href="./references#CD013424-fig-0009" title="">Analysis 2.2</a> (2 studies, 110 participants): MD 0.01, 95% CI 0.00 to 0.02; very low certainty evidence). Heterogeneity was high (I² = 91%). </p> </section> <section id="CD013424-sec-0086"> <h6 class="title">Lumbar spine</h6> <p>Raloxifene may increase the BMD at the lumbar spine (<a href="./references#CD013424-fig-0010" title="">Analysis 2.3</a> (2 studies, 110 participants): MD 0.03, 95% CI 0.03 to 0.04; low certainty evidence). Heterogeneity was low (I² = 0%). </p> </section> <section id="CD013424-sec-0087"> <h6 class="title">Total hip</h6> <p>BMD in the total hip was not reported by the included studies.</p> </section> <section id="CD013424-sec-0088"> <h6 class="title">Radius</h6> <p>BMD in the radius was not reported by the included studies.</p> </section> </section> <section id="CD013424-sec-0089"> <h5 class="title">Adverse events</h5> <p>Both studies (<a href="./references#CD013424-bbs2-0005" title="HaghverdiF , FarbodaraT , MortajiS , SoltaniP , SaidiN . Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5 [Erratum in: Iran J Kidney Dis. 2015 Jan;9(1):76; PMID: 25599744]. Iranian Journal of Kidney Diseases2014;8(6):461-6. [MEDLINE: 25362221]">Haghverdi 2014</a>; <a href="./references#CD013424-bbs2-0006" title="HeilbergIP , HernandezE , AlonzoE , ValeraR , FerreiraLG , GomesSA , et al. Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. Renal Failure2005;27(2):155-61. [MEDLINE: 15807179]HernandezE , ValeraR , AlonzoE , Bajares-LilueM , CarliniR , CaprilesF , et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney International2003;63(6):2269-74. [MEDLINE: 12753317]HernandezE , ValeraR , TeranJ , Bajares-LilueM , CapriilesF , AlonzoE , et al. The effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone resorption markers and serum lipids in postmenopausal women on chronic hemodialysis (HD) [abstract no: A2974]. Journal of the American Society of Nephrology2000;11(Sept):563-4A. [CENTRAL: CN-00550530] HernandezE , ValeraR , TeranJ , Bajares-LilueM , CaprilesF , AlonzoE , et al. One year controlled study on the effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone metabolism and serum lipids on postmenopausal women on chronic hemodialysis (HD) [abstract no: A3879]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):743A. [CENTRAL: CN-00550533] Weisinger, JR, HeilbergIP , HernandezE , CarliniR , Bellorin-FontE . Selective estrogen receptor modulators in chronic renal failure. Kidney International - Supplement2003;63(85):S62-5. [MEDLINE: 12753268]">Hernandez 2003</a>) reported no adverse events. The certainty of evidence was very low. </p> </section> <section id="CD013424-sec-0090"> <h5 class="title">Death</h5> <p>It is uncertain whether raloxifene reduces the risk of death (<a href="./references#CD013424-fig-0012" title="">Analysis 2.5</a> (2 studies, 110 participants): RR 1.00, 95% CI 0.22 to 4.56; very low certainty evidence). </p> </section> <section id="CD013424-sec-0091"> <h5 class="title">Vascular access failure</h5> <p>Vascular access failure was not reported by the included studies.</p> </section> <section id="CD013424-sec-0092"> <h5 class="title">Life participation, fatigue score, PD‐related infections, or PD failure</h5> <p>Life participation, fatigue scores, PD‐related infections, or PD failure were not by the included studies. </p> </section> <section id="CD013424-sec-0093"> <h5 class="title">Quality of life</h5> <p>QoL was not reported by the included studies.</p> </section> <section id="CD013424-sec-0094"> <h5 class="title">Bone markers</h5> <p><a href="./references#CD013424-bbs2-0005" title="HaghverdiF , FarbodaraT , MortajiS , SoltaniP , SaidiN . Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5 [Erratum in: Iran J Kidney Dis. 2015 Jan;9(1):76; PMID: 25599744]. Iranian Journal of Kidney Diseases2014;8(6):461-6. [MEDLINE: 25362221]">Haghverdi 2014</a> reported some differences in bone markers between raloxifene and placebo (<a href="./references#CD013424-fig-0014" title="">Analysis 2.7</a>; <a href="./references#CD013424-fig-0015" title="">Analysis 2.8</a>; <a href="./references#CD013424-fig-0016" title="">Analysis 2.9</a>; <a href="./references#CD013424-fig-0017" title="">Analysis 2.10</a>). However, the baseline data were not balanced, and no marked changes were observed between the treatment and placebo groups. </p> </section> </section> <section id="CD013424-sec-0095"> <h4 class="title">Subgroup analyses</h4> <p>Subgroup analyses based on age (&lt; 18 years and ≥ 18 years) and sex were not possible as all patients were postmenopausal women. </p> <section id="CD013424-sec-0096"> <h5 class="title">Types of interventions</h5> <p>Five drugs were identified (abaloparatide, alendronate, denosumab, teriparatide, and raloxifene). Meta‐analysis could be only conducted about teriparatide. The results are provided below. </p> <section id="CD013424-sec-0097"> <h6 class="title">Abaloparatide</h6> <p><a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a> reported it is uncertain whether abaloparatide reduces the risk of vertebral fracture because the certainty of this evidence is very low (<a href="./references#CD013424-fig-0018" title="">Analysis 3.1</a>: RR 0.25, 95% CI 0.03 to 2.20) and abaloparatide probably makes little or no difference to adverse events (<a href="./references#CD013424-fig-0022" title="">Analysis 3.5</a>: RR 1.01, 95% CI 0.94 to 1.10; moderate certainty evidence). </p> </section> <section id="CD013424-sec-0098"> <h6 class="title">Alendronate</h6> <p><a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a> reported alendronate may make little or no difference to the risk of vertebral fracture (<a href="./references#CD013424-fig-0023" title="">Analysis 4.1</a>: RR 0.74, 95% CI 0.33 to 1.66; low certainty evidence) and the risk of clinical fracture (<a href="./references#CD013424-fig-0024" title="">Analysis 4.2</a>: RR 0.79, 0.52 to 1.20; low certainty evidence). </p> </section> <section id="CD013424-sec-0099"> <h6 class="title">Denosumab</h6> <p><a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a> reported denosumab probably reduces the risk of vertebral fracture (<a href="./references#CD013424-fig-0025" title="">Analysis 5.1</a>: RR 0.41, 95% CI 0.28 to 0.58; moderate certainty evidence), may make little or no difference to the risk of clinical fracture (<a href="./references#CD013424-fig-0026" title="">Analysis 5.2</a>: RR 0.86, 95%CI 0.66 to 1.12; low certainty evidence), and probably makes little or no difference to adverse events (<a href="./references#CD013424-fig-0030" title="">Analysis 5.6</a>: RR 0.99, 95% CI 0.97 to 1.01; moderate certainty evidence), and cardiovascular and cerebrovascular morbidity (<a href="./references#CD013424-fig-0031" title="">Analysis 5.7</a>: RR 1.00, 95% CI 0.75 to 1.32; moderate certainty evidence). </p> <p><b>Teriparatide</b> </p> <p>Teriparatide probably reduces the risk of vertebral fracture (<a href="./references#CD013424-fig-0032" title="">Analysis 6.1</a>: RR 0.31, 95% CI 0.10 to 0.90; moderate certainty evidence). Heterogeneity was low (I² = 0%). Teriparatide may make little or no difference to adverse events (<a href="./references#CD013424-fig-0036" title="">Analysis 6.5</a>: RR 0.95, 95% CI 0.74 to 1.14; low certainty evidence). Heterogeneity was high (I² = 79%). </p> <p><b>Raloxifene</b> </p> <p><a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a> reported that raloxifene probably reduces the risk of vertebral fracture (<a href="./references#CD013424-fig-0037" title="">Analysis 7.1</a>: RR 0.60, 95% CI 0.36 to 1.00; moderate certainty evidence), may make little or no difference to the risk of clinical fracture (<a href="./references#CD013424-fig-0038" title="">Analysis 7.2</a>: RR 0.96, 95% CI 0.80 to 1.16; low certainty evidence) and probably makes little or no difference to adverse events (<a href="./references#CD013424-fig-0041" title="">Analysis 7.5</a>: RR 0.99, 95% CI 0.98 to 1.00; moderate certainty evidence). </p> </section> </section> <section id="CD013424-sec-0100"> <h5 class="title">Intact PTH level (&lt; 50, 50‐300, and &gt; 300 pg/mL)</h5> <p>Most eligible patients were likely to have stable intact PTH levels. We contacted the relevant study authors to request further details; however, they were unable to provide further information. </p> </section> <section id="CD013424-sec-0101"> <h5 class="title">Concomitant use of vitamin D</h5> <p>Most eligible patients were likely to use vitamin D. We contacted the relevant study authors to request further details; however, they were unable to provide further information. </p> </section> </section> <section id="CD013424-sec-0102"> <h4 class="title">Sensitivity analyses</h4> <p>All eligible studies were considered to be at a high risk for bias. In the sensitivity analysis, we excluded studies judged to be at a high risk of bias for at least one of the overall risk of bias domains. <a href="./references#CD013424-bbs2-0004" title="BoonenS , MarinF , MellstromD , XieL , DesaiahD , KregeJH , et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Journal of the American Geriatrics Society2006;54(5):782-9. [MEDLINE: 16696744]ChenP , MillerPD , DelmasPD , MisurskiDA , KregeJH . Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. Journal of Bone &amp; Mineral Research2006;21(11):1785-90. [MEDLINE: 17002571]CransGG , SilvermanSL , GenantHK , GlassEV , KregeJH . Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. Arthritis &amp; Rheumatism2004;50(12):4028-34. [MEDLINE: 15593198]Dawson-HughesB , ChenP , KregeJH . Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. Journal of Clinical Endocrinology &amp; Metabolism2007;92(12):4630-6. [MEDLINE: 17911178]DelmasPD , LicataAA , ReginsterJY , CransGG , ChenP , MisurskiDA , et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone2006;39(2):237-43. [MEDLINE: 16563890]GallagherJC , GenantHK , CransGG , VargasSJ , KregeJH . Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1583-7. [MEDLINE: 15613428]GenantHK , HalseJ , BrineyWG , XieL , GlassEV , KregeJH . The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Current Medical Research &amp; Opinion2005;21(7):1027-34. [MEDLINE: 16004669]GenantHK , SirisE , CransGG , DesaiahD , KregeJH . Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone2005;37(2):170-4. [MEDLINE: 15961357]JiangY , ZhaoJJ , MitlakBH , WangO , GenantHK , EriksenEF . Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. Journal of Bone &amp; Mineral Research2003;18(11):1932-41. [MEDLINE: 14606504]KregeJH , WanX . Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone2012;50(1):161-4. [MEDLINE: 22036910]MillerPD , SchwartzEN , ChenP , MisurskiDA , KregeJH . Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis International2007;18(1):59-68. [MEDLINE: 17013567]NeerRM , ArnaudCD , ZanchettaJR , PrinceR , GaichGA , ReginsterJY , et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal Medicine2001;344(19):1434-41. [MEDLINE: 11346808]PaschalisEP , GlassEV , DonleyDW , EriksenEF . Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial. Journal of Clinical Endocrinology &amp; Metabolism2005;90(8):4644-9. [MEDLINE: 15914535]SatterwhiteJ , HeathmanM , MillerPD , MarinF , GlassEV , DobnigH . Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcified Tissue International2010;87(6):485-92. [MEDLINE: 20953593]SilvermanSL , PiziakVK , ChenP , MisurskiDA , WagmanRB . Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. Journal of Rheumatology2005;32(12):2405-9. [MEDLINE: 16331772]Uusi-RasiK , SemanickLM , ZanchettaJR , BogadoCE , EriksenEF , SatoM , et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone2005;36(6):948-58. [MEDLINE: 15878318]WattsNB , MillerPD , KohlmeierLA , SebbaA , ChenP , WongM , et al. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. Journal of Bone &amp; Mineral Research2009;24(6):1125-31. [MEDLINE: 19113918]">FTP 2001</a> and <a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a> were excluded from this analysis (<a href="./references#CD013424-fig-0042" title="">Analysis 8.1</a>; <a href="./references#CD013424-fig-0043" title="">Analysis 8.2</a>; <a href="./references#CD013424-fig-0044" title="">Analysis 8.3</a>). The results were similar to <a href="./references#CD013424-fig-0004" title="">Analysis 1.1</a>, <a href="./references#CD013424-fig-0005" title="">Analysis 1.2</a>, and <a href="./references#CD013424-fig-0006" title="">Analysis 1.3</a>. </p> </section> <section id="CD013424-sec-0103"> <h4 class="title">Funnel plots</h4> <p>No funnel plots were generated to evaluate potential publication bias because less than 10 eligible RCTs were available for each pooled analysis. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013424-sec-0104" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013424-sec-0104"></div> <section id="CD013424-sec-0105"> <h3 class="title" id="CD013424-sec-0105">Summary of main results</h3> <p>Seven studies randomising 9,164 patients were included in our meta‐analyses of the main outcomes. All participants were postmenopausal women. Five studies included patients with CKD stages 3‐4, and two studies included patients with CKD stages 5 or 5D. Five anti‐osteoporotic agents were identified: abaloparatide, alendronate, denosumab, raloxifene, and teriparatide. </p> <p>Among patients with CKD stages 3‐4, anti‐osteoporotic drugs may reduce the risk of vertebral fracture. Anti‐osteoporotic drugs probably makes little or no difference to the risk of clinical fracture or adverse events. The efficacy and safety of anti‐osteoporotic drugs were similar during sensitivity analysis, which excluded studies with a high risk of bias for at least one of the overall risk of bias domains. </p> <p>Among patients with CKD stages 5 and 5D, it is uncertain whether raloxifene reduces the risk of clinical fracture and death. Raloxifene may slightly improve the BMD at the lumbar spine, and uncertain effects on BMD at the femoral neck. </p> <p>We could not perform a meta‐analysis of each type of intervention because each drug was assessed in individual studies. </p> </section> <section id="CD013424-sec-0106"> <h3 class="title" id="CD013424-sec-0106">Overall completeness and applicability of evidence</h3> <p>Both published and unpublished data were included in this review. We contacted the relevant corresponding authors to acquire the data that were not reported in the published articles. However, the information obtained was insufficient. All study participants were postmenopausal women; therefore, the evidence obtained cannot be directly applied to men and paediatric patients. Importantly, the CKD‐BMD of all study participants was stable at baseline; therefore, the evidence cannot be applied to patients with insufficient control of CKD‐BMD. </p> </section> <section id="CD013424-sec-0107"> <h3 class="title" id="CD013424-sec-0107">Quality of the evidence</h3> <p>The certainty of the evidence was graded using the GRADE approach (<a href="./references#CD013424-bbs2-0056" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6. [MEDLINE: 18436948]">GRADE 2008</a>). As shown in the <a href="./full#CD013424-tbl-0001">summary of findings Table 1</a>, among patients with CKD stages 3‐4, vertebral fracture was assessed to be of low certainty owing to concerns of serious risks of bias and inconsistency. We assessed clinical fracture and adverse events to be of moderate certainty owing to concerns of serious risks of bias. </p> <p>As shown in the <a href="./full#CD013424-tbl-0002">summary of findings Table 2</a>, among patients with CKD stages 5 and 5D, we assessed clinical fracture and death to be of very low certainty owing to concerns of serious risks of bias and serious imprecision. We assessed the mean change in the BMD at the lumbar spine to be of low certainty owing to concerns of serious risks of bias and indirectness. </p> <p>We assessed the mean change in the BMD at the femoral neck to be of very low certainty owing to concerns of serious risks of bias, inconsistency, and indirectness. </p> </section> <section id="CD013424-sec-0108"> <h3 class="title" id="CD013424-sec-0108">Potential biases in the review process</h3> <p>We performed a comprehensive search using several different databases; however, we cannot rule out the possibility that smaller studies were missed. In addition, although we contacted the corresponding authors and conducted web searches to collect additional data, we were unable to obtain sufficient information. There might be a potential bias due to data availability or publication status. </p> </section> <section id="CD013424-sec-0109"> <h3 class="title" id="CD013424-sec-0109">Agreements and disagreements with other studies or reviews</h3> <p>This review differed from the review by <a href="./references#CD013424-bbs2-0103" title="WilsonLM , RebholzCM , JirruE , LiuMC , ZhangA , GayleardJ , et al. Benefits and harms of osteoporosis medications in patients with chronic kidney disease. Annals of Internal Medicine2017;166(9):649-58. [PMID: 28395318]">Wilson 2017</a> in several aspects. <a href="./references#CD013424-bbs2-0026" title="ToussaintND , LauKK , PolkinghorneKR , KerrPG . Randomised placebo-controlled trial of alendronate on vascular calcification in patients with chronic kidney disease [abstract no: 008]. Nephrology2009;14(Suppl 1):A2-3. [CENTRAL: CN-00775976] ToussaintND , LauKK , PolkinghorneKR , KerrPG . Randomised placebo-controlled trial of alendronate on vascular calcification in patients with chronic kidney disease [abstract no: SA-FC345]. Journal of the American Society of Nephrology2009;20(Abstract Suppl):81A. ToussaintND , LauKK , StraussBJ , PolkinghorneKR , KerrPG . Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. American Journal of Kidney Diseases2010;56(1):57-68. [MEDLINE: 20347511]">Toussaint 2010</a> was excluded because most of the patients did not have osteoporosis, and the <a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a> study was newly included. In addition, this review demonstrated an effect that included all drug subtypes. The primary results of this review were consistent with those of <a href="./references#CD013424-bbs2-0103" title="WilsonLM , RebholzCM , JirruE , LiuMC , ZhangA , GayleardJ , et al. Benefits and harms of osteoporosis medications in patients with chronic kidney disease. Annals of Internal Medicine2017;166(9):649-58. [PMID: 28395318]">Wilson 2017</a>. However, the evidence is limited to patients with CKD stages 3‐5D. </p> <p>The effects of each drug were consistent with findings in the general population (<a href="./references#CD013424-bbs2-0046" title="CrandallCJ , NewberrySJ , DiamantA , LimYW , GelladWF , BoothMJ , et al. Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Annals of Internal Medicine2014;161(10):711-23. [MEDLINE: 25199883]">Crandall 2014</a>; <a href="./references#CD013424-bbs2-0091" title="ReginsterJY , BianicF , CampbellR , MartinM , WilliamsSA , FitzpatrickLA . Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Osteoporosis International2019;30(7):1465-73. [MEDLINE: 30953114]">Reginster 2019</a>). Regarding the five large studies identified (<a href="./references#CD013424-bbs2-0001" title="BilezikianJP , FitzpatrickLA , WilliamsGC , HuMY , HattersleyG , RizzoliR . Bone mineral density and bone turnover marker changes with sequential abaloparatide/alendronate: Results of ACTIVExtend [abstract no: MO0655]. Journal of Bone &amp; Mineral Research2017;32(1):S377. [EMBASE: 620203679]BilezikianJP , HattersleyG , MitlakBH , HuMY , FitzpatrickLA , DabrowskiC , et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. Current Medical Research &amp; Opinion2019;35(12):2097-102. [MEDLINE: 31418585]BilezikianJP , HattersleyG , WilliamsG , HuMY , FitzpatrickLA , PapapoulosS . Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]. Journal of Bone &amp; Mineral Research2016;31(Suppl 1):S264. [EMBASE: 620694016]CosmanF , HattersleyG , HuMY , WilliamsGC , FitzpatrickLA , BlackDM . Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. Journal of Bone &amp; Mineral Research2017;32(1):17-23. [MEDLINE: 27612281]MillerPD , HattersleyG , RiisBJ , WilliamsGC , LauE , RussoLA , et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]. JAMA2016;316(7):722-33. [MEDLINE: 27533157]MoreiraCA , FitzpatrickLA , WangY , ReckerRR . Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone2017;97:314-9. [MEDLINE: 27826127]">ACTIVE 2016</a>; <a href="./references#CD013424-bbs2-0002" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet1996;348(9041):1535-41. [MEDLINE: 8950879]BlackDM , ReissTF , NevittMC , CauleyJ , KarpfD , CummingsSR . Design of the Fracture Intervention Trial. Osteoporosis International1993;3 Suppl 3:S29-39. [MEDLINE: 8298200]CummingsSR , BlackDM , ThompsonDE , ApplegateWB , Barrett-ConnorE , MuslinerTA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA1998;280(24):2077-82. [MEDLINE: 9875874]EnsrudKE , Barrett-ConnorEL , SchwartzA , SantoraAC , BauerDC , SuryawanshiS , et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Journal of Bone &amp; Mineral Research2004;19(8):1259-69. [MEDLINE: 15231012]JamalSA , BauerDC , EnsrudKE , CauleyJA , HochbergM , IshaniA , et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone &amp; Mineral Research2007;22(4):503-8. [MEDLINE: 17243862]">FIT 1993</a>; <a href="./references#CD013424-bbs2-0003" title="BroadwellA , EbelingPR , FranekE , GoemaereS , WagmanRB , YinX , et al. Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]. Arthritis &amp; Rheumatology2017;69:Suppl 10. [EMBASE: 618911821]CummingsSR , San MartinJ , McClungMR , SirisES , EastellR , ReidIR , et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]. New England Journal of Medicine2009;361(8):756-65. [MEDLINE: 19671655]EgbunaOI , CheungAM , SiddhantiS , WangA , DaizadehN , AnthonyM , et al. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]. Journal of the American Society of Nephrology2010;21(Abstract Suppl):640A. JamalSA , LjunggrenO , Stehman-Breen, C, CummingsS , McClungM , GoemaereS , et al. The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]. Bone2010;47(Suppl 1):S207-8. [EMBASE: 71732799]JamalSA , LjunggrenO , Stehman-BreenC , CummingsSR , McClungMR , GoemaereS , et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone &amp; Mineral Research2011;26(8):1829-35. [MEDLINE: 21491487]">FREEDOM 2009</a>; <a href="./references#CD013424-bbs2-0004" title="BoonenS , MarinF , MellstromD , XieL , DesaiahD , KregeJH , et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Journal of the American Geriatrics Society2006;54(5):782-9. [MEDLINE: 16696744]ChenP , MillerPD , DelmasPD , MisurskiDA , KregeJH . Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. Journal of Bone &amp; Mineral Research2006;21(11):1785-90. [MEDLINE: 17002571]CransGG , SilvermanSL , GenantHK , GlassEV , KregeJH . Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. Arthritis &amp; Rheumatism2004;50(12):4028-34. [MEDLINE: 15593198]Dawson-HughesB , ChenP , KregeJH . Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. Journal of Clinical Endocrinology &amp; Metabolism2007;92(12):4630-6. [MEDLINE: 17911178]DelmasPD , LicataAA , ReginsterJY , CransGG , ChenP , MisurskiDA , et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone2006;39(2):237-43. [MEDLINE: 16563890]GallagherJC , GenantHK , CransGG , VargasSJ , KregeJH . Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. Journal of Clinical Endocrinology &amp; Metabolism2005;90(3):1583-7. [MEDLINE: 15613428]GenantHK , HalseJ , BrineyWG , XieL , GlassEV , KregeJH . The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Current Medical Research &amp; Opinion2005;21(7):1027-34. [MEDLINE: 16004669]GenantHK , SirisE , CransGG , DesaiahD , KregeJH . Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone2005;37(2):170-4. [MEDLINE: 15961357]JiangY , ZhaoJJ , MitlakBH , WangO , GenantHK , EriksenEF . Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. Journal of Bone &amp; Mineral Research2003;18(11):1932-41. [MEDLINE: 14606504]KregeJH , WanX . Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone2012;50(1):161-4. [MEDLINE: 22036910]MillerPD , SchwartzEN , ChenP , MisurskiDA , KregeJH . Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis International2007;18(1):59-68. [MEDLINE: 17013567]NeerRM , ArnaudCD , ZanchettaJR , PrinceR , GaichGA , ReginsterJY , et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal Medicine2001;344(19):1434-41. [MEDLINE: 11346808]PaschalisEP , GlassEV , DonleyDW , EriksenEF . Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial. Journal of Clinical Endocrinology &amp; Metabolism2005;90(8):4644-9. [MEDLINE: 15914535]SatterwhiteJ , HeathmanM , MillerPD , MarinF , GlassEV , DobnigH . Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcified Tissue International2010;87(6):485-92. [MEDLINE: 20953593]SilvermanSL , PiziakVK , ChenP , MisurskiDA , WagmanRB . Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. Journal of Rheumatology2005;32(12):2405-9. [MEDLINE: 16331772]Uusi-RasiK , SemanickLM , ZanchettaJR , BogadoCE , EriksenEF , SatoM , et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone2005;36(6):948-58. [MEDLINE: 15878318]WattsNB , MillerPD , KohlmeierLA , SebbaA , ChenP , WongM , et al. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. Journal of Bone &amp; Mineral Research2009;24(6):1125-31. [MEDLINE: 19113918]">FTP 2001</a>; <a href="./references#CD013424-bbs2-0007" title="BorgstromF , JohnellO , KanisJA , OdenA , SykesD , JonssonB . Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics2004;22(17):1153-65. [MEDLINE: 15612833]EttingerB , BlackDM , MitlakBH , KnickerbockerRK , NickelsenT , GenantHK , et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]. JAMA1999;282(7):637-45. [MEDLINE: 10517716]IshaniA , BlackwellT , JamalSA , CummingsSR , EnsrudKE , MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. Journal of the American Society of Nephrology2008;19(7):1430-8. [MEDLINE: 18400939]JohnellO , KanisJA , BlackDM , BaloghA , PoorG , SarkarS , et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. Journal of Bone &amp; Mineral Research2004;19(5):764-72. [MEDLINE: 15068500]KanisJA , BorgstromF , JohnellO , OdenA , SykesD , JonssonB . Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International2005;16(1):15-25. [MEDLINE: 15672210]MelamedM , NeugartenJ , BlackwellT , ArnstenJ , EnsrudK , IshaniA , et al. The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]. Journal of the American Society of Nephrology2007;18(Abstracts):544A. SilvermanSL , ShenW , MinshallME , XieS , MosesKH . Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. Journal of Rheumatology2007;34(1):140-4. [MEDLINE: 17216681]SirisE , AdachiJD , LuY , FuerstT , CransGG , WongM , et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporosis International2002;13(11):907-13. [MEDLINE: 12415439]Uusi-RasiK , BeckTJ , SemanickLM , DaphtaryMM , CransGG , DesaiahD , et al. Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial. Osteoporosis International2006;17(4):575-86. [MEDLINE: 16392026]">MORE 1999</a>), we used a subset of data from these five studies in our meta‐analysis. The each subset result was consistent with the overall results of each study. However, the 95% CIs for the estimates were wide owing to the smaller sample sizes. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013424-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Flow diagram." data-id="CD013424-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/full#CD013424-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013424-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/full#CD013424-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013424-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/full#CD013424-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Any anti‐osteoporotic drug versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 1: Vertebral fracture by radiography" data-id="CD013424-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Any anti‐osteoporotic drug versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 1: Vertebral fracture by radiography </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Any anti‐osteoporotic drug versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 2: Clinical fracture" data-id="CD013424-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Any anti‐osteoporotic drug versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 2: Clinical fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Any anti‐osteoporotic drug versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 3: Adverse events" data-id="CD013424-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Any anti‐osteoporotic drug versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 3: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Any anti‐osteoporotic drug versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 4: Cardiovascular and cerebrovascular morbidity" data-id="CD013424-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Any anti‐osteoporotic drug versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 4: Cardiovascular and cerebrovascular morbidity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Raloxifene versus placebo for patients with osteoporosis and CKD stage 5D, Outcome 1: Clinical fracture" data-id="CD013424-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Raloxifene versus placebo for patients with osteoporosis and CKD stage 5D, Outcome 1: Clinical fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Raloxifene versus placebo for patients with osteoporosis and CKD stage 5D, Outcome 2: Mean change in femoral neck BMD (DXA)" data-id="CD013424-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Raloxifene versus placebo for patients with osteoporosis and CKD stage 5D, Outcome 2: Mean change in femoral neck BMD (DXA) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Raloxifene versus placebo for patients with osteoporosis and CKD stage 5D, Outcome 3: Mean change in lumbar spine BMD (DXA)" data-id="CD013424-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Raloxifene versus placebo for patients with osteoporosis and CKD stage 5D, Outcome 3: Mean change in lumbar spine BMD (DXA) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Raloxifene versus placebo for patients with osteoporosis and CKD stage 5D, Outcome 4: Adverse events" data-id="CD013424-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Raloxifene versus placebo for patients with osteoporosis and CKD stage 5D, Outcome 4: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Raloxifene versus placebo for patients with osteoporosis and CKD stage 5D, Outcome 5: Death" data-id="CD013424-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Raloxifene versus placebo for patients with osteoporosis and CKD stage 5D, Outcome 5: Death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Raloxifene versus placebo for patients with osteoporosis and CKD stage 5D, Outcome 6: Vascular access failure" data-id="CD013424-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Raloxifene versus placebo for patients with osteoporosis and CKD stage 5D, Outcome 6: Vascular access failure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Raloxifene versus placebo for patients with osteoporosis and CKD stage 5D, Outcome 7: Serum intact PTH" data-id="CD013424-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Raloxifene versus placebo for patients with osteoporosis and CKD stage 5D, Outcome 7: Serum intact PTH </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Raloxifene versus placebo for patients with osteoporosis and CKD stage 5D, Outcome 8: Serum calcium" data-id="CD013424-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Raloxifene versus placebo for patients with osteoporosis and CKD stage 5D, Outcome 8: Serum calcium </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Raloxifene versus placebo for patients with osteoporosis and CKD stage 5D, Outcome 9: Serum phosphorus" data-id="CD013424-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Raloxifene versus placebo for patients with osteoporosis and CKD stage 5D, Outcome 9: Serum phosphorus </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Raloxifene versus placebo for patients with osteoporosis and CKD stage 5D, Outcome 10: Serum alkaline phosphatase (total)" data-id="CD013424-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Raloxifene versus placebo for patients with osteoporosis and CKD stage 5D, Outcome 10: Serum alkaline phosphatase (total) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Abaloparatide versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 1: Vertebral fracture by radiography" data-id="CD013424-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Abaloparatide versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 1: Vertebral fracture by radiography </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Abaloparatide versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 2: Mean change in femoral neck BMD (DXA)" data-id="CD013424-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Abaloparatide versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 2: Mean change in femoral neck BMD (DXA) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Abaloparatide versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 3: Mean change in lumbar spine BMD (DXA)" data-id="CD013424-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Abaloparatide versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 3: Mean change in lumbar spine BMD (DXA) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Abaloparatide versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 4: Mean change in total hip BMD (DXA)" data-id="CD013424-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Abaloparatide versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 4: Mean change in total hip BMD (DXA) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Abaloparatide versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 5: Adverse events" data-id="CD013424-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Abaloparatide versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 5: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Alendronate versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 1: Vertebral fracture by radiography" data-id="CD013424-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Alendronate versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 1: Vertebral fracture by radiography </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Alendronate versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 2: Clinical fracture" data-id="CD013424-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Alendronate versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 2: Clinical fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Denosumab versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 1: Vertebral fracture by radiography" data-id="CD013424-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Denosumab versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 1: Vertebral fracture by radiography </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Denosumab versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 2: Clinical fracture" data-id="CD013424-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Denosumab versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 2: Clinical fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Denosumab versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 3: Mean change in femoral neck BMD (DXA)" data-id="CD013424-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Denosumab versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 3: Mean change in femoral neck BMD (DXA) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Denosumab versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 4: Mean change in lumbar spine BMD (DXA)" data-id="CD013424-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Denosumab versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 4: Mean change in lumbar spine BMD (DXA) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Denosumab versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 5: Mean change in total hip BMD (DXA)" data-id="CD013424-fig-0029" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Denosumab versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 5: Mean change in total hip BMD (DXA) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Denosumab versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 6: Adverse events" data-id="CD013424-fig-0030" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Denosumab versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 6: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Denosumab versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 7: Cardiovascular and cerebrovascular morbidity" data-id="CD013424-fig-0031" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Denosumab versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 7: Cardiovascular and cerebrovascular morbidity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Teriparatide versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 1: Vertebral fracture by radiography" data-id="CD013424-fig-0032" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Teriparatide versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 1: Vertebral fracture by radiography </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Teriparatide versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 2: Clinical fracture" data-id="CD013424-fig-0033" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Teriparatide versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 2: Clinical fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Teriparatide versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 3: Mean change in femoral neck BMD (DXA)" data-id="CD013424-fig-0034" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Teriparatide versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 3: Mean change in femoral neck BMD (DXA) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Teriparatide versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 4: Mean change in lumbar spine BMD (DXA)" data-id="CD013424-fig-0035" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Teriparatide versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 4: Mean change in lumbar spine BMD (DXA) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Teriparatide versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 5: Adverse events" data-id="CD013424-fig-0036" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Teriparatide versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 5: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Raloxifene versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 1: Vertebral fracture by radiography" data-id="CD013424-fig-0037" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Raloxifene versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 1: Vertebral fracture by radiography </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Raloxifene versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 2: Clinical fracture" data-id="CD013424-fig-0038" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Raloxifene versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 2: Clinical fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Raloxifene versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 3: Mean change in femoral neck BMD (DXA)" data-id="CD013424-fig-0039" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Raloxifene versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 3: Mean change in femoral neck BMD (DXA) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Raloxifene versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 4: Mean change in lumbar spine BMD (DXA)" data-id="CD013424-fig-0040" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Raloxifene versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 4: Mean change in lumbar spine BMD (DXA) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Raloxifene versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 5: Adverse events" data-id="CD013424-fig-0041" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: Raloxifene versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 5: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Sensitivity analysis: any anti‐osteoporotic drugs versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 1: Vertebral fracture by radiography" data-id="CD013424-fig-0042" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Sensitivity analysis: any anti‐osteoporotic drugs versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 1: Vertebral fracture by radiography </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Sensitivity analysis: any anti‐osteoporotic drugs versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 2: Clinical fracture" data-id="CD013424-fig-0043" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Sensitivity analysis: any anti‐osteoporotic drugs versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 2: Clinical fracture </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013424-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/urn:x-wiley:14651858:media:CD013424:CD013424-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Sensitivity analysis: any anti‐osteoporotic drugs versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 3: Adverse events" data-id="CD013424-fig-0044" src="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_t/tCD013424-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Sensitivity analysis: any anti‐osteoporotic drugs versus placebo for patients with osteoporosis and CKD stages 3‐4, Outcome 3: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/media/CDSR/CD013424/image_n/nCD013424-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013424-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Any anti‐osteoporotic drugs versus placebo in postmenopausal women with osteoporosis and CKD stages 3‐4</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Any anti‐osteoporotic drugs versus placebo in</b> postmenopausal women<b>with osteoporosis and CKD stages 3‐4</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> postmenopausal women with osteoporosis and CKD stages 3‐4 </p> <p><b>Settings:</b> multinational; outpatients </p> <p><b>Intervention:</b> any anti‐osteoporotic drugs (abaloparatide, alendronate, denosumab, raloxifene, teriparatide) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Any anti‐osteoporotic drugs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vertebral fracture by radiography</b> </p> <p>Follow up: range 19 to 54 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> <p>(28 to 50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.52</p> <p>(0.39 to 0.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9,054 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical fracture</b> </p> <p>Follow up: range 24 to 54 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 1000</p> <p>(43 to 57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.91</p> <p>(0.79 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5,827 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in BMD of the femoral neck</b> </p> <p>Follow up: range 19 to 54 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Included studies only reported the percentage change in the BMD in the intervention group. In the three studies the mean change in BMD of the femoral neck was reported to improve by approximately 0.5% to 5% in the intervention group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6,081 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in BMD of the lumbar spine</b> </p> <p>Follow up: range 19 to 54 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Included studies only reported the percentage change in the BMD in the intervention group. In the five studies the mean change in BMD of the lumbar spine was reported to improve by approximately 1% to 15% in the intervention group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9,054 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in BMD of the total hip</b> </p> <p>Follow up: range 19 to 54 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Included studies only reported the percentage change in the BMD in the intervention group. In the three studies the mean change in BMD of the total hip was reported to improve by approximately 5% to 6% in the intervention group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3,998 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in BMD of the distal radius</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow up: range 19 to 54 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>946 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>937 per 1000</p> <p>(927 to 946)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.99</p> <p>(0.98 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9,054 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b> </p> <p>Follow up: range 36 to 54 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Included studies only reported total death. Death ranged from 0.7% to 1.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4,973 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1, 3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CKD:</b> chronic kidney disease; <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; <b>BMD:</b> bone mineral density; <b>QoL</b>: quality of life </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/><b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to a serious risk of bias: all studies had a high overall risk of bias<br/><sup>2</sup> Downgraded one level due to inconsistency: there was substantial heterogeneity </p> <p><sup>3</sup>Downgraded one level due to a publication bias: there were high risk of reporting bias </p> <p><sup>4</sup>Downgraded one level due to indirectness: surrogate endpoint was evaluated </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Any anti‐osteoporotic drugs versus placebo in postmenopausal women with osteoporosis and CKD stages 3‐4</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/full#CD013424-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013424-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Raloxifene versus placebo for postmenopausal women with osteoporosis and CKD stages 5 and 5D</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Raloxifene versus placebo for postmenopausal women with osteoporosis and CKD stages 5 and 5D</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> postmenopausal women with osteoporosis and CKD stages 5 and 5D </p> <p><b>Settings:</b> Iran, Venezuela; in‐ and outpatients </p> <p><b>Intervention:</b> any anti‐osteoporotic drugs (raloxifene) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Raloxifene</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vertebral fracture by radiography</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical fracture</b> </p> <p>Follow up: 8 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> <p>(0 to 260)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.33</p> <p>(0.01 to 7.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in BMD of the femoral neck</b><br/>Follow up: range 8 to 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean change in BMD of the femoral neck was 0.01 g/cm² higher with raloxifene than placebo (95% CI 0.00 to 0.02) </p> <p>(mean change in BMD of the femoral neck in placebo group was ‐0.009 to ‐0.002 g/cm²)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.01</p> <p>(0.00 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1, 3, 4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in BMD of the lumbar spine</b><br/>Follow up: range 8 to 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean change in BMD of the lumbar spine was 0.03 g/cm² higher with raloxifene than placebo (95% CI 0.03 to 0.04) </p> <p>(mean change BMD of the lumbar in placebo group was ‐0.019 to ‐0.003 g/cm²)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.03</p> <p>(0.03 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1, 4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in BMD of the total hip</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in BMD of the distal radius</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p>Follow up: range 8 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No adverse events were observed in the included studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b> </p> <p>Follow up: range 8 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> <p>(11 to 228)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00</p> <p>(0.22 ‐ 4.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1, 2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CKD:</b> chronic kidney disease; <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; <b>MD:</b> Mean Difference; <b>BMD:</b> bone mineral density; <b>QoL:</b> quality of life </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level due to a serious risk of bias: all studies had a high overall risk of bias<br/><sup>2</sup>Downgraded two levels due to serious imprecision: there were very few/no events and the CIs encompass both considerable benefit and considerable harm<br/><sup>3</sup>Downgraded one level due to inconsistency: there was considerable heterogeneity<br/><sup>4</sup>Downgraded one level due to indirectness: surrogate endpoint was evaluated </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Raloxifene versus placebo for postmenopausal women with osteoporosis and CKD stages 5 and 5D</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/full#CD013424-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013424-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Any anti‐osteoporotic drug versus placebo for patients with osteoporosis and CKD stages 3‐4</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Vertebral fracture by radiography <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.39, 0.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Clinical fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.79, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.98, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Cardiovascular and cerebrovascular morbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.75, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Any anti‐osteoporotic drug versus placebo for patients with osteoporosis and CKD stages 3‐4</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013424-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Raloxifene versus placebo for patients with osteoporosis and CKD stage 5D</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Clinical fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Mean change in femoral neck BMD (DXA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [0.00, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Mean change in lumbar spine BMD (DXA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.03, 0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.22, 4.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Vascular access failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Serum intact PTH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>80.50 [‐82.73, 243.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Serum calcium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐0.81, ‐0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Serum phosphorus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.51, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Serum alkaline phosphatase (total) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>213.70 [‐170.98, 598.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Raloxifene versus placebo for patients with osteoporosis and CKD stage 5D</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013424-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Abaloparatide versus placebo for patients with osteoporosis and CKD stages 3‐4</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Vertebral fracture by radiography <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 2.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Mean change in femoral neck BMD (DXA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Mean change in lumbar spine BMD (DXA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Mean change in total hip BMD (DXA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.94, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Abaloparatide versus placebo for patients with osteoporosis and CKD stages 3‐4</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013424-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Alendronate versus placebo for patients with osteoporosis and CKD stages 3‐4</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Vertebral fracture by radiography <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.33, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Clinical fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.52, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Alendronate versus placebo for patients with osteoporosis and CKD stages 3‐4</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013424-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Denosumab versus placebo for patients with osteoporosis and CKD stages 3‐4</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Vertebral fracture by radiography <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.28, 0.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Clinical fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.66, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Mean change in femoral neck BMD (DXA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Mean change in lumbar spine BMD (DXA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Mean change in total hip BMD (DXA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.97, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Cardiovascular and cerebrovascular morbidity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.75, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Denosumab versus placebo for patients with osteoporosis and CKD stages 3‐4</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013424-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Teriparatide versus placebo for patients with osteoporosis and CKD stages 3‐4</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Vertebral fracture by radiography <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.10, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Clinical fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Mean change in femoral neck BMD (DXA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Mean change in lumbar spine BMD (DXA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.79, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Teriparatide versus placebo for patients with osteoporosis and CKD stages 3‐4</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013424-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Raloxifene versus placebo for patients with osteoporosis and CKD stages 3‐4</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Vertebral fracture by radiography <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.36, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Clinical fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.80, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Mean change in femoral neck BMD (DXA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Mean change in lumbar spine BMD (DXA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.98, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Raloxifene versus placebo for patients with osteoporosis and CKD stages 3‐4</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013424-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Sensitivity analysis: any anti‐osteoporotic drugs versus placebo for patients with osteoporosis and CKD stages 3‐4</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Vertebral fracture by radiography <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.32, 0.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Clinical fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.67, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.97, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Sensitivity analysis: any anti‐osteoporotic drugs versus placebo for patients with osteoporosis and CKD stages 3‐4</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013424.pub2/references#CD013424-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013424.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013424-note-0014">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013424-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013424-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013424-note-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD013424-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD013424-note-0013">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD013424-note-0008">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013424-note-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013424-note-0007">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013424\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013424\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013424\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013424\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013424\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013424\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013424\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013424\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013424\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013424\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013424\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013424\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013424\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013424\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013424\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013424\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013424\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013424\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uYcNEb5O&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013424.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013424.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013424.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013424.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013424.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726831713"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013424.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726831717"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013424.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e9d415990f480',t:'MTc0MDcyNjgzMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 